# **Psychoneuroendocrinology**

## **An International Journal**

**Editor-in-Chief** 

Robert T. Rubin

Harbor - U.C.L.A. Medical Center, Torrance, California **Associate Editor** 

Harvey H. Feder

Rutgers University, Newark, New Jersey

Ten Year Author and Key-Word-In-Context Indexes

Volumes 1 - 10, 1975 - 1985



### **Pergamon Press**

Oxford · New York · Beijing · Frankfurt · São Paulo Sydney · Tokyo · Toronto

## **Psychoneuroendocrinology**

#### An International Journal

Editor-in-Chief

ROBERT T. RUBIN, Harbor - U.C.L.A. Medical Center, Torrance, California

Associate Editor

HARVEY H. FEDER, Rutgers University, Newark, New Jersey

#### **Editorial Board**

P. J. V. Beumont (Sydney)

B. Bohus (Groningen)

G. M. Brown (Hamilton)

W. A. Brown (Providence)

B. J. Carroll (Durham)

A. Ehrhardt (New York)

G. Fink (Edinburgh)

A. A. Gerall (New Orleans)

F. Holsboer (Mainz)

I. Izquierdo (Port Alegre)

P. Loosen (Durham)

B. S. McEwen (New York)

J. Meites (East Lansing)

F. Naftolin (New Haven)

R. E. Poland (Torrance)

S. Reichlin (Boston)

J. Sutin (Atlanta)

S. Takahashi (Otsu)

P. P. Vitaliano (Seattle)

S. Watson (Ann Arbor)

#### Publishing and Advertising Offices

Pergamon Journals Ltd., Headington Hill Hall, Oxford OX3 0BW, U.K.

#### 1986 Annual Subscription Rates

For libraries, university departments, government laboratories, industrial and other multiple-reader institutions, U.S. \$135.00 per annum; two-year rate (1986-87) U.S. \$256.50 (including postage and insurance). For members of the International Society of Psychoneuroendocrinology, U.S. \$30.00 per annum.

In the interests of maximizing the dissemination of the research results published in this important international journal, we have established a two-tier price structure. Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of U.S. \$50.00 per annum. Subscription enquiries from customers in North America should be sent to: Pergamon Journals Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, U.S.A., and for the remainder of the world to: Pergamon Journals Ltd., Headington Hill Hall, Oxford OX3 0BW, I.K.

#### Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfilm os completion of the annual index at the end of the subscription year.

#### **Published Quarterly**

#### Copyright © 1986 Pergamon Journals Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organizations which do not permit such assignments. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature, and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

Photocopying information for users in the U.S.A. The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of \$3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970.

Permission for other we. The copyright owner's consent does not extend to copyring for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copyring.

The Item-Fee Code for this publication is: 0306-4530/86 \$3.00 + 0.00

#### PERGAMON JOURNALS

HEADINGTON HILL HALL OXFORD OX3 0BW U.K.

MAXWELL HOUSE FAIRVIEW PARK, ELMSFORD NY 10523, U.S.A.

#### PSYCHONEUROENDOCRINOLOGY TEN YEAR AUTHOR AND KWIC INDEXES VOLUMES 1 – 10, 1975 – 1985

Both the author and the Key-Word-In-Context (KWIC) indexes list the volume number and the first page for each citation. In the author index, authors of every article are listed. In the KWIC index, each significant word of every title is listed alphabetically, within the context of its title. (Each listing includes a portion of the title just preceding and just following the key word.) For example, to conduct a search for all citations on 'cortisol', one also should look under the alternate terms 'adrenocortical' and 'corticosteroids' to be certain all pertinent information is retrieved.

#### **AUTHOR INDEX**

Aakvang A, 6: 245
Anrabi B, 2: 365
Abou-Samra AB, 8: 321
Acker GR, 10: 445
Adinoff BA, 10: 367
Afrasiahi MA, 4: 145
Agnati L, 2: 203
Agren H, 7: 309,
9: 233
Akazawa S, 6: 171
Akerstedt T, 4: 219
Akesode A, 1: 419
al Satli M, 2: 399,
5: 319, 6: 121
Alaranta H, 8: 333
Alavez E, 8: 451
Albala AA, 9: 423
Allen JP, 4: 351
Altaher ARH, 9: 107
Alvarez MA, 8: 451
Amsterdam JD, 6: 359,
7: 177, 7: 239,
8: 351
Anapliotou M, 6: 341
Anda E, 2: 275
Andrews M, 2: 267
Annecillo C, 1: 427,
8: 309
Anon, 1: 2
Ansseau M, 0: 10: 215
Apud JA, 9: 125
Aran GW, 10: 49
Ardeleanu A, 3: 93
Arendt J, 8: 327
Arnold P, 1: 141
Aron C, 2: 399,
5: 319, 6: 121
Arthur RJ, 7: 97
Asnis GM, 5: 339,
6: 223, 6: 365,
7: 235, 7: 295
Aun F, 10: 303
Ayalon D, 5: 53

Backstrom T, 3: 103, 6: 245 Baduel A, 9: 319 Bajard L, 8: 321 Balass R, 1: 25 Baldessarini RJ, 4: 175, 10: 49 Baldrighi G, 6: 81 Balfe A, 6: 261 Balfour DJ, 4: 85 Balldin J, 5: 329 Banay-Schwartz M, 4: 207 Banks WA, 10: 385
Bannet J, 6: 177
Barchas JD, 1: 103
Barfield RJ, 9: 217
Barnet ER, 10: 345
Barnett DB, 9: 13
Barrett J, 7: 125
Bartholini G, 9: 135
Batrinos ML, 6: 341
Batta SK, 1: 115
Bauman J, 5: 225
Baumann P, 3: 245
Beach FA, 1: 3
Beck-Friis J, 9: 261, Beck-Priis J, 9: 261, 10: 173 Becker D, 1: 141, 7: 75 Beckmann H, 10: 187, 10: 351 Bedard PJ, 9: 375 Bell R, 4: 351 Bellodi L, 4: 329 Belmaker RH, 6: 177, 10: 273 Ben-David M, 6: 177 Benington F, 1: 123 Benkert O, 6: 231, 9: 147 Benwell ME, 4: 83 Beyer C, 4: 245 Bielert C, 5: 287, 7: 31 Bijlsma WA, 9: 199 Binkley SA, 6: 181 Biondi M, 10: 289 Birbaumer N, 6: 301, 6: 311 Bishop P. 4: 89 Bissette G, 2: 179. 3: 279 Bjorum N, 2: 131, 6: 253 Blackburn IM, 10: 461 Blackwood DHR, 10: 461 Blaschke D, 10: 83 Bloom FE, 2: 59, 9: 319 Bluet-Pajot MT, 5: 139
Bohn MC, 8: 381
Bohus B, 8: 411
Boll E, 9: 147
Bolle P, 5: 329
Bolwig TG, 7: 303
Bonnyns M, 4: 67
Bonsall RW, 1: 153
Borgaonkar D, 1: 165
Borgan RJ, 4: 173
Born J, 9: 285
Boucher R, 9: 375
Bowers MB, 8: 429

4: 173 Bradley RJ, 1: 199 Brambilla P, 4: 329, 6: 321 Branch BJ, 1: 291, 7: 49
Brauman H, 2: 303
Breene GR, 6: 331
Brenner IM, 10: 345
Brett LP, 4: 275
Bridges RS, 8: 109
Broekkamp CL, 2: 17
Brooksbank BW, 2: 159
Brown GM, 1: 231,
3: 131, 4: 13,
7: 69, 7: 163,
7: 347
Brown WA, 10: 211
Buckley M, 4: 363
Bullinger M, 10: 315
Bunnell BN, 8: 421
Burgus R, 2: 59
Busch D, 6: 17
Bush HL, 10: 305
Butt WR, 9: 141 7: 49 Cairneross KD, 4: 253 Callifronas M, 6: 341 Campbell EA, 9: 107 Campbell M, 3: 195 Campbell PG, 1: 45 Canonico FL, 10: 203 Cantalamessa L, 10: 481 10: 481 Cardinali DP, 8: 3 Carilli L, 10: 289 Carillon CH, 9: 415 Caroff SN, 6: 359, 7: 177, 7: 239 Carrageo MA, 7: 229, 9: 381 9: 381
Carroll BJ, 2: 321, 3: 171, 6: 81, 6: 103, 6: 355, 7: 91, 9: 29, 9: 45, 9: 423
Carter DA, 7: 201
Carter B, 4: 117
Casady RL, 1: 291
Casper RC, 2: 105, 7: 59
Catania A, 10: 481 Catania A, 10: 481 Cazzullo CL, 10: 481 Cerfontaine J-L, 10: 215 Cervantes M, 4: 245 Chambers JW, 3: 131 Chambers W, 4: 191 Chance WT, 4: 199

Boyd AE III, 3: 113,

Chang K, 10: 109
Chaptal C, 3: 155
Chase TN, 10: 203
Checkley SA, 6: 77,
9: 279
Cheikh IE, 6: 37
Cheng M-P, 1: 95
Cho D, 5: 225
Christensen LW, 4: 311
Chrousos GP, 10: 401
Ciaranello RD, 1: 103
Ciesielski L, 5: 319
Clark CR, 5: 39
Clarke A, 8: 343
Clopper RR, 2: 365
Cocchi D, 9: 125
Coe CL, 3: 221, 5: 181,
7: 209, 8: 401
Coen P, 7: 355
Cohn D, 2: 131
Cohn M, 2: 197
Cohlins-Rothe H,
9: 305 9: 305 Collu R, 8: 213 Colpaert PC, 3: 203 Cook N, 9: 13 Cooley-Matthews B, 7: 49 Cools AR, 2: 17 Cools AR, 2: 17
Copolov DL, 10: 461
Corbani M, 8: 251
Cordova T, 5: 53
Corn T, 9: 279
Corvilian J, 2: 303
Couch JR, 10: 103
Counis R, 8: 251
Cowley JJ, 2: 159
Cox B, 4: 253
Cox BM, 2: 11
Coy DH, 5: 47,
10: 367
Creutsfeldt OD, 1: 1 Creutsfeldt OD, 1: 141. Creutsfeldt OD, 1: 7: 75 Crews D, 7: 259 Crine AP, 8: 447 Cullen J, 4: 107 Culver B, 3: 47 Curtia GC, 7: 69 Cutler WB, 4: 297, 5: 89 D'Antona N, 6: 321 Daigle M, 9: 375, 9: 399 Daiguji M, 7: 223 Dantzer R, 9: 319 Darragh A, 4: 363 Davies RK, 5: 147 Davis BM, 7: 347, 8: 103 Davis JM, 2: 105 Davis KL, 7: 347, 8: 103 B: 105 de Buck R, 2: 303 De Guzman T, 4: 207 de Wied D, 1: 315, 2: 35, 2: 63, 3: 203, 8: 411, 10: 439

Deck J, 6: 239
Deitrich RA, 1: 325
Dekirmenjian H, 2: 105
Demey-Ponsart B,
10: 215 10: 215
Demoulin A, 1: 185
Denman D, 10: 203
Deyo S, 9: 319
di Paolo T, 9: 375,
9: 399
Dias RD, 7: 229,
8: 81, 9: 77,
9: 381, 10: 165
Dibble ED, 7: 163
Dimond RC, 5: 81,
5: 261 Dimond RG, 5: 81, 5: 261 Doerr RG, 9: 147 Dolphin C, 4: 107 Donabedian RK, 3: 187, Jonapedian RK, 3: 1 3: 253 Donhowe JM, 6: 269 Dorner G, 8: 205 Dorr HG, 7: 155, 7: 329 7: 329
Doumont A, 10: 215
Doyle MP, 1: 213
Drummer D, 10: 273
Dubovsky SL, 7: 355
Ducharme JR, 8: 213
Duhault J, 5: 139 Eberhardt NL, 1: 399 Ebert M, 7: 163 Ebstein RP, 6: 177 Eccles JC, 7: 271 Edelstein ED, 10: 273 Eden S, 5: 329, 7: 245 Egdahl RH, 10: 303 Ehrhardt AA, 2: 383, 2: 391 2: 391 2: 391 Bichler VB, 1: 265 Bichmeter A, 7: 135 Elbert T, 6: 301, 6: 311 Elias AN, 7: 15 Ellingboe J, 1: 359, 3: 231 Elsasser T, 6: 139 Endicott J, 7: 295, 10: 15 Endo M, 3: 211 Endrocsi E, 3: 271 Eneroth P, 2: 203 Eriksson E, 5: 329, Eriksson B, 5: 329, 7: 245 Ervin GN, 2: 179 Eskildsen PC, 6: 253 Estour B, 8: 321 Etgen AM, 9: 217 Ettenberg A, 9: 319 Ettigi PG, 3: 131 Extein I, 6: 159, 8: 459, 10: 281 Pabbri A, 10: 289 Paber J, 2: 131, 2: 413, 4: 227 Paber R, 8: 463 Pacchinetti P, 6: 321 Palck SC, 2: 359

Palek A, 1: 207
Pang VS, 5: 345,
6: 17
Peder HH, 2: 337,
5: 25, 10: 123
Pehm H-L, 6: 301,
6: 311, 9: 285
Pehm-Wolfsdorf G,
6: 311, 9: 285
Peinberg M, 6: 355
Pekete HHK, 6: 113
Pelber J-P, 3: 245
Feldmann J, 1: 231
Perria S, 3: 195
Pevre-Montange M,
8: 321 Fevre-Montange M, 8: 321

Pile SE, 8: 343

Pinch SJ, 5: 269

Pinder E, 8: 441

Finnie M, 4: 117

Pisch RO, 6: 269

Pitzgerald KM, 2: 73

Fleming J, 8: 459

Flomm M, 4: 145

Ford DH, 1: 389, 3: 65

Forster B, 8: 441

Forster C, 4: 253

Fraicil F, 10: 289

Francis PT, 9: 69

Francis PT, 9: 69

Francis PT, 9: 69

Francoeur D, 6: 239

Franks RD, 7: 355

Freeman CP, 10: 461

French ED, 3: 237

Friberg Y, 4: 219

Friedlander H, 4: 145 8: 321 Friberg Y, 4: 219
Friedlander H, 4: 145
Frienkel N, 3: telt
Friesen HG, 7: 347
Froberg JE, 4: 219
Frohman LA, 7: 59
Fujit T, 9: 391
Fujita M, 6: 347
Fuller R, 4: 107 Fuxe K, 2: 203 Gaffori 0, 10: 439
Galatzer A, 5: 235
Gandelman R, 6: 131
Garbutt JC, 9: 311
Garcia CR, 4: 297, 5: 89
Garcia JF, 3: 237
Garfinkel PE, 4: 13
Garver DL, 2: 105
Gattaz WP, 10: 187, 10: 351
Gwienowski AM, 1: 41 10: 351
Gawienowski AM, 1: 411
Geenen V, 10: 61,
10: 215
Gelfand MM, 10: 325
Genazzani AR, 6: 321
George JM, 10: 33
George R, 3: 237
Gerken A, 9: 147,
10: 261
Gerlach JL, 2: 249

Gerlach JL, 2: 249 Gerner RH, 8: 455 Gershon ES, 7: 163 Gibb W, 8: 213 Gieles LC, 2: 17 Gillham B, 9: 107 Gillin JC, 4: 341 Gispen WH, 2: 63, 9: 199, 10: 431 Gladwell RT, 9: 69 Glass JE, 9: 217 Glass AR, 5: 81, 5: 261 Glass JC, 8: 401 Glazer WM, 8: 429, 10: 345 Goffi 3, 10: 337 Gold MS, 3: 187, 3: 253, 5: 147, 6: 159, 8: 459, 10: 281 Gold PW, 7: 163, 10: 401 Goldstein A, 2: 11 10: 401 Goldstein A, 2: 11 Gomeni R, 9: 141 Gomez A, 8: 451 Gonzalez CA, 6: 53, 6: 65, 7: 209 Gonzalez CA, 6: 5! 6: 65, 7: 209 Goode DJ, 5: 345 Goodlin BL, 6: 65 Gororen LJG, 9: 249 Gordon HW, 5: 235 Gorski RA, 1: 371, 4: 311 4: 311 Gorzalka BB, 5: 157 Goy RW, 4: 1, 6: 105 Graham CA, 5: 245 Grant LD, 2: 179 Grasberger R, 10: 303 Gray DS, 5: 157 Gray GD, 2: 315 Greden JP, 6: 355 Green O, 3: 181 Green R, 5: 269 Greene LW, 3: 195 Gregoire F, 2: 303 Griffiths EC, 10: 225 Grisanti GC, 2: 383, 2: 391 2: 391
Grossman MK, 7: 15
Gualtieri CT, 6: 331
Guastalla A, 6: 321
Gudelaky GA, 6: 3
Guidotti A, 2: 227
Guillemin R, 2: 59
Gunnar MR, 6: 53,
6: 65, 6: 269
Gupta D, 9: 179
Guroff JJ, 7: 163
Gustafsson JA, 2: 203
Guyda H, 4: 79
Gwirtsman HE, 8: 455 2: 391

Haars H, 9: 179
Haberman M, 1: 207
Hadley JC, 2: 267
Hagen C, 2: 413
Hajos F, 1: 25
Halbreich U, 5: 339,
6: 223, 6: 365,
7: 235, 7: 295,
10: 15

Hall RP, 7: 101,
7: 113, 7: 125
Halpern PS, 3: 165,
4: 191, 5: 339,
6: 223, 6: 365,
7: 235
Hamburg DA, 1: 103
Hamilton BPM, 6: 37
Hammer M, 7: 303
Hannada K, 10: 193
Hannak D, 10: 351
Harmsen-Louman W,
9: 249 9: 249 Harrell LE, 2: 179 Harris RI, 7: 177 Haskett RF, 9: 29, Harris RI, 7: 177
Haskett RP, 9: 29,
9: 423
Hatotani N, 2: 115,
4: 47, 4: 155
Hattori H, 4: 47
Hauser K, 10: 421
Hausler A, 10: 421
Hawk B, 6: 331
Hays SE, 3: 1,
5: 121, 6: 45,
9: 29
Heilman RO, 9: 415
Heilhammer DH, 10: 77
Hellman RE, 1: 389
Hendler N, 1: 419
Hendricks SE, 9: 293
Herd JA, 7: 113
Hernandez DE, 10: 149
Hershman J, 8: 455
Herz M, 9: 173
Herzog F, 7: 217 Hershman J, 8: 455 Herz M, 9: 173 Herzog F, 7: 217 Higashimura T, 4: 47 Hirai K, 3: 211 Hosamatsu K, 4: 47 Hoffman RA, 1: 321 Hofschuster E, 6: 231 Hogland U, 10: 431 Hokfelt T, 2: 203 Holbrooke SE, 2: 287, 5: 13 Hollander CS, 3: 195 5: 13
Hollander CS, 3: 195
Hollingsworth P,
1: 207
Holman RB, 9: 69
Holsber P, 7: 155,
7: 329, 9: 147,
10: 261
Honer WG, 9: 279
Hooper J, 4: 117
Horvath J, 8: 195
Howard E, 6: 159
Howard JL, 9: 293
Howard JL, 9: 293 5: 287
Hraschek A, 3: 271
Hau TH, 6: 37
Hubert V, 10: 77
Hull EM, 5: 113
Hummer L, 4: 227
Hurlburt C, 10: 355
Hurme M, 8: 333

Hurst M, 7: 101, 7: 113, 7: 125 Hyyppa MT, 2: 349, 2: 359, 4: 29, 7: 195, 8: 333 7: 195, 8: 333

Ikeda H, 9: 391
Inoue K, 4: 155
Ioannou D, 6: 341
Isaia GC, 10: 337
Ivai A, 5: 203
Izquierdo I, 7: 91, 7: 229, 8: 81, 9: 77, 9: 381, 10: 159, 10: 165
Jacobs LS, 4: 341
Jaffee WL, 5: 35
James B, 5: 225
Janssen PA, 3: 203
Jansson JO, 7: 245
Jardanhazy T, 7: 185
Jarett IR, 9: 21
Jarett IB, 9: 301, 10: 71
Jekelis AW, 9: 161
Jenkins CD, 7: 101, 7: 113, 7: 125
Jennekens FGI, 9: 199
Jennings PE, 9: 13
Jimerson DC, 7: 163
Jimerson DC, 7: 163
Jimerson BS, 7: 163
Johnson AL, 2: 159
Johnson AL, 2: 159
Johnson AL, 2: 349, 4: 29
Jones MT, 9: 107
Jones RH, 10: 5
Jones RH, 10: 5
Jones RH, 8: 95
Jordan RM, 4: 351
Joseph MS, 8: 95
Jose A, 8: 185
Jozea R, 8: 195
Jutisz M, 8: 251

Kaiser M, 10: 275 Kaiser N, 10: 273 Kamiya S, 4: 47 Kanoy R, 6: 331 Kant GJ, 8: 421 Kantoy N, 6: 591
Kant GJ, 8: 421
Kanyicska B, 6: 113
Karcagi V, 2: 275
Kastin AJ, 5: 47,
7: 347, 10: 367,
10: 385
Kathol RG, 9: 57
Katsarkas A, 4: 79
Katz RJ, 6: 81
Kawakani M, 5: 203
Keil LC, 8: 95
Kelley JF, 8: 309
Kendall JW, 10: 33
Keasler IR, 7: 163
Keasler IR, 7: 163
Keasler S, 1: 103
Kester P, 5: 269
Keuhnle JC, 3: 231
Keyser A, 8: 157
Kimura P, 5: 203
Kirkegaard C, 2: 131,
2: 413, 4: 227,

6: 189, 6: 253, 7: 366 Kitayana I, 2: 115, 4: 155 Kjellman BP, 9: 261, 10: 173 10: 173 Klein HE, 6: 231 Koch B, 7: 217 Koinig G, 10: 61 Koob GP, 9: 319 Kopp HG, 2: 237 Koriath U, 6: 331 Korsvik 3, 6: 269 Kovacs GL, 1: 219, 8: 411 8: 411
Kowarski AA, 1: 419
Krantz DE, 10: 211
Kreger BE, 7: 125
Krieger AM, 4: 297
Krivoy WA, 2: 43, 10: 105
Kroeger DC, 2: 43
Krynock GM, 4: 179
Kula NS, 4: 173
Kupfer DJ, 8: 355
Kurcz M, 2: 275
Kuromaru S, 5: 253
Kurosawa A, 2: 227
Kutner M, 1: 153
Kytomaki O, 2: 349, 4: 29 8: 411 4: 29 4: 29

Laakmann G, 7: 135,
 7: 141, 10: 83

Labrie P, 9: 399

Laczi F, 7: 185

Ladisich W, 2: 257

Lahtela K, 8: 333

Lajtha A, 4: 207

Landau IT, 2: 337,
 5: 25

Lander N, 5: 53

Lane LA, 10: 461

Lang RE, 10: 187

Langer G, 2: 373,
 2: 379, 3: 165,
 10: 61

Langvik V-A, 2: 349,
 4: 29

Lara PP, 2: 137

Laszlo PA, 7: 185

Lauder JN, 8: 121

Lauridsen UB, 2: 131,
 2: 413 Lauridsen UB, 2: 131, 2: 413 Le Moal M, 9: 319 Lebrun C, 9: 319 Lebrun C, 9: 319 Legros J-J, 1: 185, 1: 203, 8: 447, 10: 61, 10: 215 Lehrman D, 1: 95 Leibowitz SP, 10: 109 Lemon M, 2: 267 Lenox RH, 8: 421 Leone RM, 4: 117 Lerer B, 6: 177 Leshrer AI, 1: 213 Lesser IM, 8: 441 Levin RM, 6: 359 Levine S, 3: 221, 4: 275, 5: 181, 6: 53, 6: 65, 7: 209, 8: 401, 10: 125 Levy MI, 8: 103 Lewis D, 9: 57 Lewis V, 7: 339 Lewis VG, 9: 405 Lichtensteiger W, 2: 237
Lieberburg I, 2: 249
Lienhart R, 2: 237
Lifachitz ML, 7: 755
Lifachitz ML, 7: 355
Lightman SL, 6: 213,
8: 435
Lira J, 4: 29,
7: 195
Lindner HR, 5: 53
Ling N, 2: 59
Linsell CR, 4: 117,
6: 213, 8: 435
Linton PH, 1: 199
Lipton MA, 3: 279
Lisk RD, 5: 191,
5: 305
Lissak K, 1: 219
Livingston L, 7: 101
Liunggren J-G, 9: 261,
10: 173 2: 237 10: 173 Lobl RT, 1: 131 Locatelli V, 9: 125 Lofstrom A, 2: 203, 3: 103, 4: 57, 4: 75 London DR, 9: 141 Loosen PT, 2: 137, 3: 279, 5: 63, 7: 147, 9: 311, 10: 237 Lorenz RJ, 1: 291 Louis F, 8: 447 Lowe EL, 3: 221, 5: 181 Lucki I, 7: 177, 8: 351 Luine VM, 2: 249 8: 351 Luine VN, 2: 249 Lumpkin MD, 8: 299 Lundqvist G, 9: 233 Lutzenberger W, 6: 301, 6: 311 6: 311

Mack G, 5: 319

MacKay DM, 7: 285

MacLusky NJ, 8: 429,
10: 345, 10: 355

Magrini G, 3: 245

Maguire J, 6: 261

Maickel RP, 6: 91

Maier W, 10: 261

Makkonen R, 7: 195

Malin DH, 2: 1

Manberg PJ, 3: 279

Mander AJ, 10: 461

Mangat H, 9: 97

Manowitz P, 9: 161

Marinari KT, 1: 213

Marrone BL, 2: 337

Martin DM, 5: 147, Martin DM, 5: 147, 6: 159
Martin JT, 3: 261
Martin-du Pan R, 3: 245
Martini L, 1: 115
Mason GA, 7: 147
Masotto C, 9: 125
Massars F, 10: 337
Mathe AA, 8: 103
Matte AC, 4: 21
Matussek N, 2: 379, 9: 173 9: 173 9: 173
McCann SM, 8: 299,
9: 97
McCarthy T, 9: 301,
10: 71
McCormack WM, 5: 33
McDonald SD, 4: 351
McEwen BS, 2: 249,
3: 155, 5: 1
McGarrick GM, 7: 201
McGivern RF, 10: 221,
10: 363
McGrew WC, 5: 245
McIntosh TK, 10: 303
McKenzie JM, 4: 67
McKeon P, 6: 213
McWilliam JR, 6: 77
McMchoulam R, 5: 53
Meeker JB, 10: 421
Megens A, 2: 17
Meisel RL, 4: 287
Melio NK, 1: 347,
3: 231
Meltzer HY, 5: 345, McCann SM, 8: 299, 9: 97 Meltzer HY, 5: 345, 6: 17 Mendelson JH, 1: 359, 3: 231 Mendelson WB, 4: 341 Mendoza SP, 3: 221 Menna-Perper M, 9: 161 Menna-Perper M, 9: 101 Menon VJ, 9: 141 Merali Z, 7: 361 Mess B, 8: 89, 8: 195 Meyer RE, 1: 359 Meyer W, 1: 165 Meyer WJ III, 2: 365 Meyer-Bahlburg HP, 2: 383, 2: 391 Meyerhoff JL, 8: 421 Meyerson BJ, 10: 135, 10: 431 Neyerson B3, 10: 139, 10: 431

Michael RP, 1: 1, 1: 153, 1: 207, 1: 303, 2: 99, 2: 287, 3: 109, 3: 217, 5: 13, 6: 145

Migeon C, 1: 165

Mihailovic V, 7: 239

Mikuni M, 9: 37

Milks LC, 3: 65

Miller AL, 3: 155

Miller AL, 3: 155

Miller M, 7: 347

Mirin SM, 1: 359

Misslin R, 7: 217

Misunuma H, 8: 299, 9: 97
Modigh K, 5: 329, 7: 245
Moha RC, 8: 103
Molinatti GM, 10: 337
Moller SE, 2: 413
Money J, 1: 165, 1: 427, 2: 149, 2: 365, 7: 257, 7: 339, 8: 309, 8: 391, 9: 405
Monteleone P, 10: 203, 10: 475
Moore DC, 8: 429
Moore RY, 1: 265
Moretti C, 10: 289
Moore RY, 1: 265
Morin LP, 2: 73
Morin LP, 2: 73
Morin RD, 1: 123
Morin RD, 1: 123
Morin RD, 1: 123
Morin RD, 1: 203
Morselli PL, 9: 141
Mortiaux HJ, 2: 17
Motta P, 10: 481
Mounier P, 5: 139
Mueller RA III, 6: 159
Mueller RA III, 6: 159
Mueller PS, 9: 161
Mullen FE, 4: 117, 6: 213
Muller EE, 9: 125
Muller DA, 9: 147
Mulvihill JJ, 2: 365
Haber D, 10: 315
Maftelin P, 2: 409, 187

Naber D, 10: 315
Naftolin F, 2: 409,
8: 429, 10: 221,
10: 345, 10: 355
Nagase M, 5: 203
Nagy I, 2: 275
Naik SR, 2: 227
Nance DM, 4: 311
Naruse H, 9: 37
Nathan RB, 6: 223,
6: 365, 7: 235,
7: 295, 9: 301,
10: 71
Navarro D, 8: 451
Negri F, 4: 329
Negro-Vilar A, 9: 97
Nemeroff CB, 2: 179,
3: 279, 10: 149
Nerup J, 2: 131
Nesse HM, 7: 69
Netto CA, 9: 381,
10: 159
Nicholson SA, 9: 107
Nidess R, 3: 47
Niemegers CJ, 3: 203
Niewoehner CB, 9: 415
Nir I, 5: 53, 10: 273
Nomura J, 2: 115,
4: 47, 4: 155
Nonaka C, 9: 391
Norton KRW, 7: 295

Novell NW, 5: 39 Nurnberger JI Jr, 7: 163

O'Kelly D, 4: 363 O'Malley BP, 9: 13 Ohara M, 3: 211 Ohura T, 9: 37 Okada P, 7: 223 Olson GA, 5: 47 Olson RD, 5: 47 Ondo JG, 6: 139 Oppenheimer RL, 10: 109 Orlando RC, 10: 149 Orsatti A, 10: 481 Orsulak PJ, 1: 411 Ostrow L, 7: 295 Otsuki Y, 6: 347

Palkovits M, 6: 113 Palter M, 10: 303 Panchieri P, 10: 289 Pandey GN, 2: 105 Panitsa-Paflia C,

Panitsa-Faflia C, 6: 341 Panksepp J, 4: 89 Parrini D, 6: 321 Parvizi N, 2: 409 Pasley JN, 3: 311 Patel AJ, 1: 25 Pattee CJ, 1: 57, 1: 243

1: 243 Patterson JM, 10: 125 Paykel ES, 7: 201 Peck EJ Jr, 3: 155 Pekary E, 8: 455 Pena LA, 7: 365 Pennington LL, 8: 421 Perel JM, 10: 71 Perrone G, 10: 289 Perry MLS, 7: 229, 9: 381

Persky H, 1: 37 Peterfy G, 1: 57, 1: 243 Petraglia F, 6: 321 Pettus C, 2: 137 Pevet P, 8: 61 Pevnick J, 5: 225 Pfaff DH, 1: 79 Philip A, 10: 355 Piasio M, 2: 365 Pinter EJ, 1: 57, 1: 243, 4: 79 Pitoulis S, 6: 341 Poland RE, 1: 281, 5: 209, 7: 49, 8: 441, 8: 467, 10: 461 Pollard 07, 9: 293

8: 441, 8: 467, 10: 461 Pollard 07, 9: 293 Pottash ALC, 5: 147, 6: 159, 8: 459, 10: 281 Powell D, 6: 261 Powell EV, 3: 311 Prange AJ Jr, 2: 137, 2: 179, 3: 279, 5: 63, 6: 331, 7: 147, 10: 149
Prasad AJ, 9: 315
Pratt JJ Jr, 1: 411
Prysor-Jones RA,
7: 201
Puder M, 5: 53
Puig-Antich J, 4: 191

Quadagno DM, 6: 239 Quirce CM, 6: 91

Racagni G, 9: 125
Rao BR, 9: 249
Rasmuseen DR, 9: 343
Ratner A, 10: 95
Redmond DE Jr, 3: 187, 3: 253
Reichlin S, 3: 113
Reilly KB. 6: 181
Retter RJ, 1: 255, 8: 31
Reker D, 5: 225
Rezek DL, 2: 173
Rhines RK, 1: 389
Rickels K, 7: 177
Ritchie JC, 9: 45
Rochford J, 9: 161
Rockstroh B, 6: 301, 6: 311
Rodgers CH, 4: 127, 4: 237
Rodriguez-Sierra, 9: 293
Rogowski P, 4: 227
Roland CR, 10: 109
Ronnekleiv OK, 1: 291
Ropartz P, 7: 217
Rose RM, 7: 101, 7: 113, 7: 125
Rosecrans JA, 4: 199
Rosendahl W, 9: 179
Rosenthal PD, 9: 13
Rossi J III, 4: 89
Rowbotham MC, 8: 95
Rubin RT, 1: 281, 5: 121, 5: 209, 6: 105, 6: 99, 6: 103, 6: 187, 6: 277, 7: 1, 7: 249, 8: 1, 8: 119, 8: 245, 8: 441, 9: 1, 9: 29, 10: 10: 461
Ruelas R, 4: 245
Russak B, 2: 73
Rush AJ Jr, 8: 355
Russell GP, 1: 45
Russak C, 8: 89
Ryan N, 5: 147

Saarijarvi S, 7: 195 Sacchetti B, 6: 321 Sachar EJ, 2: 373, 3: 165, 4: 191, 5: 339, 6: 223, 6: 365, 7: 235, 7: 295

Sachs BD, 4: 287 Sachs BD, 4: 287 Saint-Come C, 10: 445 Samson WK, 8: 299 Sandman CA, 10: 33 Sandow J, 8: 277 Santoro A, 10: 289 Sarantakis D, 2: 1 Sarkar DK, 8: 259 Saghidharan SP. Sashidharan SP, 10: 461
Savoie S, 8: 213
Scapagnini U, 10: 203
Scarone S, 6: 321
Schaaf M, 5: 81, 5: 261
Schaub C, 5: 139
Scheibel J, 6: 139
Schleber JA, 10: 469
Schlesser M, 9: 57
Schmauss M, 7: 135, 7: 141 Sashidharan SP, 7: 141 Schmitt E, 7: 141 Schneider VM, 4: 127, 4: 237 4: 237 Schoen HW, 10: 83 Schonbeck G, 10: 61 Schotman P, 9: 199 Schroeder S, 6: 331 Schurneyer T, 10: 77 Schwartz M, 9: 405 Schwibbe M, 7: 75 Segal D, 2: 59 Segalen A, 5: 139 Seggie JA, 3: 131, 4: 135 Seggie JA, 3: 131, 4: 135 Seibold C, 6: 231 Servais J, 1: 203 Setalo G, 8: 195 Sever PS, 6: 213 Shafer RB, 9: 415 Sherman BM, 9: 57, Sherman BN, 9: 57, 10: 469
Sherwin BB, 10: 325
Shimoda K, 10: 193
Sholl SA, 6: 105
Shubeita HE, 6: 239
Signoret J-P, 1: 179
Silman RE, 4: 117
Silva A, 10: 481
Simmons 3, 7: 163
Simon NG, 6: 131
Singhal RL, 7: 361
Sippell WG, 7: 155, 7: 329, 9: 147
Skett P, 2: 203
Skrabanek P, 6: 261
Slade PD, 1: 45
Smallridge RC, 5: 261
Slade PD, 1: 45
Smallridge RC, 5: 261
Smallridge RC, 5: 261
Smarts 3, 10: 61
Smythies JR, 1: 123, 1: 199, 1: 317, 2: 71, 4: 117, 5: 177, 5: 353
Snyder AM, 5: 113
Snyder P, 7: 177, 8: 351
Soelberg Sorensen, 10: 469

Soelberg Sorensen,

7: 303 Soulairac A, 3: 17 Soulairac ML, 3: 1' Sourkes TL, 1: 69 Soura DO, 7: 229, 9: 381 Spruijt BM, 10: 431 Stacewicz-Sapuntz, 1: 411 Stalla GK, 9: 147 Stancer HC, 4: 13 Stanton ME, 10: 125 Steardo L, 10: 203, 10: 475 Steiger A, 9: 147 Steiner M, 2: 321, 3: 171, 6: 81, 9: 29 Sterescu N, 3: 93 Sternbach HA, 8: 455, Sternbach ma, 6: 499, 8: 459
Stevens EA, 4: 351
Stewart JM, 10: 103
Storch FI, 7: 163
Strand FL, 10: 445
Subryan V, 7: 355
Sullivan P, 9: 305
Sulon J, 8: 447, 10: 215
Suwa S, 9: 37
Swartzburg M, 9: 161
Sweeney DR, 5: 147, 6: 159
Syvalahti E, 2: 349
Szasz A, 7: 185
Szekeres AV, 7: 5
Szentendrei T, 6: 113
Szilard J, 7: 185 8: 459 Tabrizi MA, 5: 339, 6: 365, 7: 235 Takahashi K, 8: 237, 10: 193 Takahashi 3, 6: 171, Takahashi 3, 6: 171, 10: 193
Takesada M, 9: 37
Tamminga CA, 10: 203
Tanimoto K, 5: 253
Tanizawa 0, 6: 347
Tappaz ML, 9: 85
Targum SD, 9: 305
Taylor AN, 1: 291, 7: 49
Telegdy G, 1: 219, 7: 185
Telner JI, 7: 361
Tenkku M, 7: 195
Terenius L, 2: 53, 2: 63 2: 63
Thiercelin JF, 9: 141
Thody A, 9: 107
Thompson C, 9: 279
Thoren M, 10: 173
Timiras PS, 1: 399
Tirsch W, 1: 141
Todd K, 6: 213
Tolis G, 4: 79
Torda C, 3: 85
Tormey W, 4: 363
Tourniaire J, 8: 321 2: 63

Treusch J, 7: 135, 7: 141 Treusch U, 7: 135, 7: 141 Tsuji M, 6: 171 Tsuruhara T, 9: Turner BB, 1: 291 Udvarhelyi GB, 2: 365 Uhlir I, 4: 135 Ungar AL, 2: 1 Ungar G, 2: 1 Vaitukaitis JL, 5: 33 Valcana T, 1: 399 Valenta LJ, 4: 145, 7: 15 7: 15
Valkusz ZS, 7: 185
van der Kooy D, 9: 319
van der Walt LA,
5: 287, 7: 31
van Kammen DP, 4: 37
van Kessel H, 9: 249
van Ree JM, 2: 35, 3: 203 van Wimersma Grei, 3: 261 3: 261
Vaughan GM, 4: 351
Vaughan GM, 4: 351
Veith JL, 10: 33
Vernadakis A, 3: 47
Vijayan E, 9: 97
Vitaliano PP, 7: 3
Vivien-Roels B, 8: 327
Vogt JL, 5: 181
Voigt K-H, 6: 301, 9: 285
Volawka J, 5: 225
Volkmer N, 9: 381
von Frenckell R, 10: 61 10: 61 Von Rosen D, 9: 261 von Rosen D, 10: 173 Wagner A, 7: 185 Wahby VS, 10: 221 Wahlster U, 7: 135 Walker P, 1: 165 Walker SH, 7: 355 Walker WA, 2: 337 Wallen K, 4: 1 Ward IL. 9: 3 Ward IL. 9: 3
Warsh JJ, 4: 13
Watta SM, 9: 107
Webb M, 6: 261
Weichsel ME Jr, 5: 209
Weinberg J, 4: 275
Weiss GK, 10: 95
Weller C, 2: 287
Wenger J, 9: 319
Wetterberg L, 4: 219, 6: 75, 9: 261, 10: 173
White ME, 9: 305
Whitehead SA, 7: 201
Whitehead SA, 7: 201
Whitehead SA, 7: 201
Whitehead SA, 7: 201
Whitehead SA, 7: 263
Wiegant VM, 2: 63
Wiegant VM, 2: 63
Wiener SG, 8: 401
Wiesel PA, 2: 203

#### **Author Index**

Wilber JP, 3: 181
Vilens TE, 9: 45,
10: 49
Willenbring ML, 9: 415
Willenbring ML, 9: 415
Wilson CA, 2: 267
Wilson IC, 2: 137,
3: 279
Winokur A, 6: 359,
7: 177, 7: 239,
8: 351
Winokur C, 9: 57
Winter K, 7: 329
Wiswell JG, 6: 37
Wittmann M, 10: 83

Wofehuk ST, 7: 229 Wren AF, 4: 253 Wuttke W, 1: 141, 7: 75 Wyatt RJ, 4: 341 Yamada N, 10: 193 Yamaguchi N, 5: 253

Yamada N, 10: 193 Yamaguchi N, 5: 253 Yamaguchi T, 2: 115 Yamaji K, 6: 347 Yamashita I, 7: 223 Yamasaki J, 8: 237 Yamasaki K, 9: 37 Yelvington DB, 10: 95 Yeo T, 2: 267 Yeston NS, 10: 303 Young JK, 6: 281 Youngblood V, 6: 331

Zadina JE, 10: 367
Zanchin G, 4: 207
Zanisi M, 1: 115
Zichella L, 10: 289
Zimmermann E, 2: 43
Zis AP, 9: 425
Zohar J, 10: 273
Zontini G, 10: 475
Zucker I, 2: 73
Zunpe D, 1: 303,
3: 217, 6: 145

#### KEY-WORD-IN-CONTEXT INDEX

				28-804-01-11-11-11-14-18-18-18-18-18-18-18-18-18-18-18-18-18-
ACTH analogues. Imprin ACTH and multisteroid r ACTH in patients with m ACTH levels to visual.	ACTH or epinephrine on ACTH peptides. Develop ACTH secretion: a revie ACTH staulation and de ACTH, beta- endorphin a ACTH, beta- endorphin a	ACTH, epinephrine, beta ACTH, epinephrine, Met- ACTH-11ke peptides and ACTH-12ke peptides and ACTH-10 with disoriain ACTH4-10 Social and e ACTH4-10. Social and e ACTH4-10. Social and e ACTH4-10. Social and e	notion and a hypothesis notion at the pituitary action of ACTH, beta- e action. Games aminobut actions of irbeta- earthous of irbeta- earthous of steroid hore	
of vasopressin and asone suppression. tonin, cortisol and nahip of endogenous sociated effects of		idation. Effect of freets of argument of a control of the CHS. I vet these. Effects of the interference of the of CRG2766 and diam. Effect of an diam.	tion of LHRH ti- mmestic ts. Site of an pituitary the feedback	
323	202	253 139 139 139 139 139 139	405 405 165 207 267	£ 2442664888826262525525
	200000	00-0 %-	55 N	4 20 8 8 8 8 8 8 8 8 8 4 4 5 5 6 8 8 5 5 5 5
10 with discriminative 10. Social and explora 11-deoxycortisous forting 7-beta upcake and meta	17beta in basal rat bra 17beta - estradiolbensoa 962 Miscellany. Molto 1963 Miscellany. Mito 1964 Miscellany. Mito	24 on male rat behavior 24-hour rhythm of grout 24-hr monitoring of the 25 does not inhibit the 3H-estrone in neural an 3H-uridine. Growth in	46,IX congenital virili 46,IX androgen-innensit 46,IX males with antiso 47,IXY karyotyps: a cas 47,IXY and 46,IX males 5HT) before ovulation i	A2. Prostaglanding and abnormal hormone responsablement projectin responsablement projectin responsablement projectin responsablement projectin in the acetate (MRA) in girls. Acetate (MRA). Premata acid (GABA), a medulate acid changes during strandid content of brain tacid content of brain acid in the timing of acids and nonesterified acids and nonesterified acids and nonesterified acids and nonesterified acids and subjects.
terference of ACTH4- f ORG2766 and ACTH4- sma corticonterone, exporticosterone, erone and estradiol-	1	atients or activities and manic patients. A nd-Swiss mice. WER-e and metabolism of and labelling with		le of phospholipaee ing hormone elicits nifers. Madocrine omegalic subjects. d respectively with in the syndrome of medroxyprogesterone gamma aminobutyric onal and free fatty costeroids on amino gamma-aminobutyric gamma-aminobutyric samma glucose, amino nonesterified fatty ophan in normal and free fatty ophan in normal and free fatty ophan in normal and free fatty ophan in normal and fatty ophan in normal

21000010110101010101010101000001010001010	25222222222222
WARDLRQREANNENGQAHRREANNENCH	
adulthood. Sexual beha adults and hyperactive affect in the surgical affective anomalies in affective disorders and affective disorders and affective disorders. But affective disorders. New affective disorders. New affective disorders. New affective with the In affective with the In- affective with the In- affective with the In- affective with the In- affective with the In- affection operations. In- traffic controllers at traffic controllers	alcoaterone and cortiso aldosterone and cortiso aldosterone response to allosterone response to alpha-sarenergic receplabha-sarenergic receplabha-sarenergic receplabha-sarenergic stimal tertions in the sech alterations of blochest Alterations of blochest Alterations of blochest Alterations of blochest and settless in affect and and perchonective and acid content of b
puberty and during (3d). Book Review:  Gar storoids and os of metabolic and olic, endocrine and olic, endocrine and olic, endocrine and olic, endocrine and anion test in arbidopa, primary rders and secondary arbidopa, in primary arbidopa, in primarion ogy. Editorial: Annual progesterone ogy. Editorial: Annual oyoles of the activity on motor activity on motor activity the activity in erone and intermale in Development and der a GAB receptor to of norad reservity in Development and docrine activity in for the study of wth hormone test on y in rest activity	chemical aspects of the concentration of a persaion. Blunted tacts, exercise and ne. Involvement of urther evidence for hormone response to a liuations in mace. Punctions ituations in mace. Pineal Physiology, Neuroendorine and fluence of biogenic corticosteroids on corticosteroids
	522 8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
8-400FW909809L48FF900-FW6-WWW90F	2-84-R2R528588684R
adaptation to repeated addiction. Animal mode addiction. Animal mode addiction of adaense: foll administration of adren administration of adea administration of adea administration of action adrenal aniocholice; practice changed renal hyperplasia. The adrenal hyperplasia. The adrenal response of administration action adrenal response of administration action adrenal atoroid interadistration adrenation receptor bload administration adrenergic receptor med adrenergic receptor med adrenergic etamilation etamila	Adrencertical reactivities adrencertical reactivities adrencertical rhythm is adrencertician suppress adrencertician compare adult and neonatal guin Adult for activation of adult male rquirrel mon adult males. Efferentia adult men. Differentia adult men. Differentia adult sexual competence
not physiological, he study of alcohole and 'female hormone' I tension after TRH c and intracerebral mulation after i.v. as assessed by the ref after septial fects of peripheral fects of subchronic eractivity in newly puberty; idlopathic pituitary-rythmic pituitary-rythmic pituitary-rythmic pituitary-rythmic pituitary-rythmic pituitary-rythmic pituitary-rythmic pituitary-rythmic pituitary-rotal and pituitary-oral and pituitary-oral and pituitary-oral and pituitary-oral and pituitary-luencing pituitary-oral and pituitary-oral and pituitary-luencing pituitary-oral and anticary-luencing pituitary-luencing pituitary-oral and anticary-luencing pituitary-luencing pituitary-oral and anticary-oral and pituitary-luencing pituitary-oral and anticary-response to alpha-or-cetion and anticary-	octated veriables.  al cycle status and nt of the circadian induced pituitary- ngenital virilizing of gonadectomized syndrome compared.  Fold treamment when a endorphin in the group formation in class mounting and adrenal response of

231	165	221	10		20	12	200				179	3	65	75	127	13	319	60	255	518	202	267	642	00	44	0	147	20	123	333	195	30	451	2	00	140	27.		210	244	75	212	613	*	287	
-9	-:			- 4	00		* 5																								7:								:-					7:	3	
antiandrogen therapy planticholinergic drug bi	antisocial and/or sex-o	Antoni F (Mds). Book H	anxiety does not affect	anxlety. Adrenocortion	anxiolytic drugs on the	apomorphine ellects in	apomorphine. Prolonged	application to the dexa	applications and limits	approach through the at	arcuate donamine neuron	arcuste nucleus during	arcuate nucleus in male	area. Effect of proges	area. Inhibitory and f	areas and on corticoste	arginine vasopressin: a	arginine- vasopressin o	aromatase activity duri	arousal during 54 hours	arousal: mediation by v	aspects of alcoholism.	Repects of catecholamin	aspects of development	aspects of senisophreni	napects of the conthest	sapects of the synthesis	passessment-of-paople te	Associate Editor. Edit		atrophy, memory defects	atropine on the diurnal	Attention disturbance 1	attentional functioning	Attractant ellect of le	Charles and a second and a second	succession nervous ayare	a to some persons and the second	avoidance behaviour. 5	avoidance conditioning	avoidance conditioning	exis in nearth, engoer.	EXIS IN the Bale tamp:	haboon (Panio urainua)	baboons (Papio ursinus)	
offending behavior: sol. Effect of the	nd 46, XY males with	esearch, Laszlo FA.	one in man. Phobic	rtical function and	stress. Effects of	naloxone to reverse	an ester prodrug or	I IN SMILVE SEG 118	artiga: mechaniams,	TOTAL STORY OF THE	ible involvement of	of the hypothalamic	s in neurons of the	system and preoptic	mus or the preoptic	s in brain cortical	l administration of	n and 1-deamino-8-D-	sex differences in	ture and subjective		. Blochemical		docrinology. Basic		grogen ilutamide on		n nearformence in an	Editorial: Prom the	fluid: sex-related	en central cerebral	ubjects. Effect of	n Graves' disease.	H levels to visual-	s on the Bale rat.	Tours Intractices on	rata. Mole of the	Parota tempo and mo	stinotion of notice	Attiction of active	statte snock and	programme derenat	pitattary- gonadal	ifica. Mala chacma	-	
161	76	15	516	5	4			200	170	163	355	237	139	199	301	311	261	287	~	503	243	r,	600	2	212	000	240	203	212	57	59	45	181	-!	01.	. 20	200	000	125	000	257	127	124	315	39	
56																						000										-	n	i.			+ 4			'n						
0	_	aminobutyric acid in pi		_	ammonia metabolism. Ho	Manestle setion of Acre	amnestic and anti- amne	MEDIC GIRCL OF GLEC	ARF and plasma protacti	omphotonine dis odurio	amphetamine on plasma c	amygdaloid regions. Pa	analgesis in the rat.	analgesia. Investigati	analog on human cortica	analog on human cortica	analogues. Imprinting	analysis of hypothalami	analysis of repeated me	analysis. Circadian pa	analysis. Functional a	analysis. Repeated mea	anatomical data. GABA	androgen on the sexual	androgen treated male r	androgen-insensitivity	Animal moders for the s	enimate and man: 10048	Annual cycles of series	anomalies in the lean a	anorexia nervosa follow	anorexia nervosa. Expe	anorexia nervosa. Stud	antagonist action: thei	antagonist) and simelid	ancagonia ta on growen n	anterior nypothalamus or	and the property and	anterior pitultary lunc	Sheer for prout cary dash	anterior pitultary norm	anterior pitultary. Fo	anti- amnestic action o	antiandrosen flutemide	antiandrogen flutamide	
of plasma glucose, sible role of gamma	tary action. Gamma	atory role of gamma-	serotonin and gamma-	one in acromegaly.	hepatic steroid and	amnestic and anti-	ic receptors in the	ation abolishes the	a: pituitary cyclic	ne: Dektro- and De	ton. The effect of	or the basolateral	roxybutyrate narco-	influences on auto-	ffect of an ACTH4-9	ffect of an ACTH4-9	asopressin and ACTH	etry and continuous	ametric statistical	y statistical power	my: an experimental	ons and time series	pituitary function:	ts of centrogen and	avior in castrated,	perplasia and 40, AI	Alconol Magiction.	factors influencing	To thems monkeys	bolic and affective	ayed TSH release in	logical disorder in	(PRL) secretion in	eptides with opiate	Ketanserin (5-HI-2		d by lesions of the	tan parterna or rac	of anoton role of	or a long of the or	DA), B modulator of	CAMP System in rac	in the amneatic and	tin offerts of the	f the non-steroidal	

279	,						-		-								321			-	-	-							220		-													16		
66	5	6	6	6	0	-	9:	*	8:	-	-	4:	2	5	10:	9	9	6		10:	6	10:	10:	10:	8	0	0	0	0 -	ō	9	10:	0	9						ď	-	-	-	9	10:	e
			behavioral response to	behavioral training and	benavioral, and oplate	Behavioral, blochemical	Behavioral, but not phy	behaviour in the female	behaviour in the rat af	behaviour responses of	behaviour. 5-Hydroxytr	behaviour: a review. 0	behavioural studies in	bengoate and testostero	bengtropine on the diur	beta uptake and metabol.	Beta- endorphin and bet	pue	endorphin and	Bud			-			endorphin,		beta- endorphin, CHF, o	hete endorphin, naloxo		beta- lipotropin plasma		beta- MSH). Modulation	beta-2 adrenergic atimu	beta-hydroxylase activi	Decameturgone-Induced b	or negree of the second	binding of therefore	biochestos and neuroes	blochesical and physical	Biochemical aspects of	Biochemical aspects of	biochemical maturation	biochemical parameters	Biochemistry, and Behav	The same of the sa
and a hypothesis.	derlying neural and		eptice. A dramatic	Effect of various	-1. Developmental,	bipolar patients.	d infant primates.	nfluences on mating	ial and exploratory	rogen on the sexual	of active avoidance	avatems, drugs and	disease: follow-up	nahips by estradiol	peridol. Effect of	ne and estradiol-17-	fective disorders.	tie action of ACTH,	n rats. Effects of	human labor. ACTH.	he possible role of	ethasone suppresses	ior and reaction to	Influence of early	tion of naloxone or	n, epinephrine, and	reliminary report.	enatal or postnatal	Mot onkerheline,	procedures on brain	Beta- endorphin and	tic transmission by	timulating hormone	Lack of effect of	sed rats. Dopumine-	tamine in the rat.	ocol troops to be a	on neural receptor	iente. Rehaviorel.	a of pineal origin:	a. Meeting Report:	cts of alcoholism.	ctors affecting the	ce. Alterations of	Review: The Brain.	1
185																					-												259												47	
- 6	8	10	7:	55	0	0	3	-	8:	7:	4:	7:	3:	4:	10:	9	5	4:	10:	2:	3	5	6	-	*	ö	N.	- 6			-	4:	7	9	5		, ,	,,	, u		0	2	5	6	5	
back mechanism of cestr	Barbeau A. Tolis G (Eds	barrier to neuropeptide			-				Basic aspects of develo	Basis of Behavior, Beck	basolateral amygdaloid	Beckman AL (Ed). Book	behavior and maze learn	behavior and plasma lev	pue	and	by	behavior frequency and	behavior in an explorat								behavior of male rate t	behavior of ring doves.	Mohawior, Hebie Br. (Ed.)				behavior. On the origi		_	Denavior: antiandrogen		Behavior: medroxyproges						-		
f patients with low	llu R, Ducharme JR.	of the blood-brain	sumption in rate on	of L- tryptophan on	ntheline bromide on	alproate, to reduce	estradio1-17beta in	lular and molecular	euroendocrinology.	Review: The Meural	the habenula or the	Basis of Behavior.	nditioned avoidance	Parallel changes in	in treatment on the	in rats. Motivated	ation of rotational	usal women. Sexual	CTH1-24 on male rat	n aspects of sexual	egulation of sexual	ntermale aggressive	nhibitory avoidance	ilitation of sexual		that mediate sexual	adulthood. Sexual	icity in the sexual	The meural passis of	ormones on conflict	sexually dimorphic	nce of consumnatory	he origin of sexual	serum cortisol and	ns in female sexual	nd/or sex-oliending	TORGES TENTING	To the man number	infant seneration.	t rheaus macaques.	hey induce profound	Postsurgical IQ and	ndocrinological and	on in children with	f oplate peptides.	

				- 4		-		_					_																																			
,	27	-			150									-		281	227	245	123	177	353	53	217	13	253	177	123	185	207	211	149	315	237	309	400	113	200	5		640	.04	200	-	245	17	257	381	47
,	-	N	V		α		10:	-	7:	7:	8	9	2	5			5:						3:	+	5.	3.		10:							ö					- 6				4:	2	2	8:	3:
	90	9	80	1	00	Len	8	191	ut	0	th		-	nt		U	te	ne	8	ne n	00	94	uo	18	E		an a		PI	-	90		lo	de		2	0 +		4 5			14		0	0			L
	now the self ac	Datota Tocaliz	Celluler rechord	effects of horse	embryological co	hormonal influen	sex differences	brain: uptake and bindi	brains: duality without	Brambilla F, Racagni G.	grow	n JM	bulb removal on sexual	butyrophenone treatmen		18.	CAMP system in rat ante	1 8y	the	cancer. Prostaglanding	tere	cannabinoids: structure	captive male rhesus mon	carbidops in primary af	carbonate. Growth horm	carboxymethylases and	900	case for penetration.	ler	case report. Paranoid-	Addie	castrated, androgen tre	roni	catchup associated resp	catechol estrogens on s	000	Content	100000000000000000000000000000000000000	catecholamine denletton	catecholaminem from the	catecholamines in the	catecholamines in the f	Depression by a	e fa	Site of action o	causal factor for mood	the	ate
4	943				106	181	ffer	pue .	ty w	Raca	981	ghor	on s	tre		ntan	n 78	trus	0	tagi	er 3	Btr	rhes	prim	rowt	8968	a pu	trat	Gen	Par	110	rog	o pu	ated	Gen	Bung	200	200	200		12	-	ton	eron	act	for	from	s or
-	10.	7			bryo	FRON	tp x	take	ual i		n ba	Cle	val.	none		caloric homeostasis.	1 10	campus. Menstrusi	cancer drugs.	Pros	urth	ida:	ale	In	0 .	thyl	18 8I	pene	rt.	:	Iven	and.	te a	Boci	BEL	Catecholanine	catecholanine	catecholamine			ines	inee	ress	Rest	e of	tor	Pea	Actions of
	-					1: ho	1: 86	in ::	P : 6	1118	de o	6	remo	ophe		1c h	syst		r dr		7: 1	pino	Ne m	dope	nate	Kyne	noge	for	repoi	re po	5	ted	Vent	ID BE	101	101		10	010	018	Olan	olan	Der	Pro	314	fac	deri	
	brain.		brain	rair	brain:	brain:	brain:	rain	rain	ranb	romi	LOAD	ulb	utyr		alor	AME	am pu	ance	ance	ance	anna	apti	arbi	arbo	RFDO	arcti	. 984	984	901		Btr		ten	000	1	100	tech	tech	tech	tech	tech	cate.	cate.	cats.	usal	118	9118
-			the																																					_	_	_	_	_				0
+			ad th	of th	f th	18 11	ig rat	tor interactions in	d our	neuroendocrinology	te of propentheline	neuroendocrinology	luence of olfactory	g phenothiazine and	-	at and i unction and	on a regulation of	Tons	Bens and some anti-	Propriestanding and	Dun a	procking errect of	ne 1	ocrine responses to	s receiving lithium	nia. Brain protein	r 00	neuropeptides: the	47 XYY Karyotype: 8	nt by methyldopa: a	Bever	sexual behavior in	owth hormone in the	rence: Inliure and	olvtic drugs on the	4	stradiol and brain	of progesterone on	osomatic aspects of	lease of endogenous	of the synthesis of	tra]	I nucleus of female	male	ance to morphine in	191	ansierase (FRET) in	1181
	Theta in basal	in pituitary	88 81	on c	d maturation of	opir	the developing	ctic	Ourselves and	ring	ante	LING	olfa	AEIn	-	0110	1987	1000	900	nd in	aul pur Tanglus	erre	sma testosterone	pone	8 11	n pr	e fo	ides	roty	1140	13	1841	16	1	200	endocrine glanda	pur	Seror	peci	doge	hee	cer	f fe	n fe	phir.	abolism: a possibl	HMA	10
	1	Diti	Bone	rati	rati	000	evel	rer	PINE	nd oc	pro	ndoc	OI	othi	-	un T	900	2000	110	9	9	1 118	8018	Ten.	IVID	Brai	ptor	pept	KBT	Heth	1168	De l	LEO		drug	· ·	101	Resi	C 86	f er	Bynt	t of	o en	ne 1	BOL		900	TO STOJ :SAN
9 10	Det	- Tu	hor	matt	matt	In d	ne d	1	Ours	ar o	TO	nroe	ence	phen	on to	+ 100	0 0			1000	2001	TOCK	92 8	Line	Lece		Lece	euro	XX.	60	Bra	X	ou us	9010	T. 10	doct	rad	pre	mati	186	the	emer	ucle	Inki	e to	118	E LOI	
ā	-	8	14	-	•	80	-	202			9 1	ě,	n i	80	-	1 .	= "		0	. 0	4 4	9		00	m 1	-	+	Ē	4.7	1	7			9	0		99	0	080	100	of	010	1	P	92	a Do	+	
-	*		-		_,	0.0	- 4	20		- #	<b>1</b>	011	٠.		h													_		-																		
																	0	25	246	32	16	36	200	2	no	7	77	747	404	200	A DE	O a	0	113	121	205	399	245	347	105	. !	195		207	25.7	220	100	1
6	-	10	00																																8	8	6	ö	9	9	20	0		4	5		ċ	í
0 8	gic	nce	dot	ry.	binolar nationts make	200	a pu			2 2	9	0	0 0	body temperature and su	hop	BC.B	1 8	140	- na							200		1		1	10	brain beta- endorphin-1	000	92	or	Hor	or	18	do	ne.	pi	8	0 0	10	5	0 6	Por	
biological influences o	Biological, psychologic	fice	gona	4114	goc1				+		101			-	DBYC	Mac	Ance	sed 1	In W	ntie	940	ida	100		9	Berg		1		, and	200	ah i	ne.	688	development. Hor		dopamine receptor	Neurotransmitters	606	or the male guine	peptides with opi	peptides. smerge	Tigone carboxyme	Ricchemictum		Effects of morn	Pu	
ntJu	payc	Igni	or	pit	0118	000	000	Dune	0	Bot	Parr	440		ture	pue	les	Adv	Bion	Bra	Pro	Horn	Opto	Pro	Pro	Day	1	1				to	ndor	lami	1 ar	ment	development.	e re	ansm		male	8 41		Car		TOLD		Jenetic and	
81 1	1	818	6818	HO H	and and		LOBB	Tat	dru		.in	140	ALL P.	Dera	ght	Sc age	.we.	iev:	:Ae	.Mel									4	Vdro	7.10	-	echo	tica	elop	elop	Am in	rotr	rata	eue	9012	9013	4100	9 4 5 5	a have	frec	enet	
ogic	0610	ed 1c	ynth.	1100	Jer C	101	9	pop	King	Kine	1-br	ted		tem	vei	at m	Rev	Rev	Rev	Rev	Rev	Rev	Rev	Rev	Rev	Rev	Rev		+	5-1	bar	bet	Cat	COL	dev	dev	gob;	Ne	10	10		200		2 2	3		-	
biol	Biol	Blomedical Significance	9108	Diperiden on pituitary	pi po	Pin	blin	blin	bloc	bloc	6100	Blun	Apoq	pody	pody	poune	Book	Book	Book	Book	Book	Book	Book	Book	Sook	Sook	Pook	orde	BAO	rain	rain	rain	rain	brain cortical areas an	brain	brain	Drain	brain	Drain	Lain	Presta	Rrain	hrain	Brain	brain	brain.	brain.	
pur							16-	in	or					9.	of	of				_			-	-	-	-	-	-			q -pu	d n	d b	u p			-								_		_	
A.1. 8	K. 1	DOOK Neview:	ticholineant Status.	tonality' in mice	ns and 'well-state'	Dola	menopause: a double	ocortical rhythm in	adrenergic receptor	lati	Permeability of the	genous depression.	onin in relation to	elatonin excretion,	onship to change of	Lon	(Bd)	(eps	(ap	Ed	de)	de)	(ap)	(ep	Ed)	Ed >	Ed)	tests in depressed	erosexual status in	cal suppression and	bility of the blood-	sting procedures on	1 an	18 1	noral influences on	normone-dependent	Eda Dook Design		DUN D	and dependence	f production of the	and schizophrenia.	ino seid content of	The		_		
Paychosocial	PAG BT WOFK.	DE N	200		-111	uni		rhy	Per :	ovu	tty (	presi	lat	ROL	char	Est	2		0	9	5		P G	E) Q	To	RL (	AL (	depr	stat	9810	the	npe	ad 10	leve	nenc	debe	Eda Jose Comized	the animal cond	d metaboltem in	Pag .		phre	onte	Book Review:	in it		ou of	
ycho	9 8 5	00	11.5			1 In	anne	[cal	rkie	The	b11	de!	n r	ıın e	20	gan!	har	ont	110	hule	8.0	F8 P	rof	1 ed	ra J	big	man	in	unl	ppre	of	proc	estr	(PI	Lul	- Suc	200	200	1	Ann	ot ti	ligo	do	Re's	test	noreactivity	rerentiation	
Pa	BAGIO	. (0)	1	na l	8.00	onse	nope	orti	rene	.80	rnes	non	in 1	aton	Bhip	1 or	380	Ant	. To	1 tec	Inir	Tye		A op	Rive	. Ha	Beck	esta	Seex	1 80	lity	lne.	Sms .	9 80	2	BLOT		an	et o	-	rodi	BC	801	Book	prof	esci	enti	
. ?	0 0	-		10	n n	8	n	00	99	11	Pe	8	00	6	0	1.0	¥.	4	<	4	E+	2	2		•	OF		4	er	0	01	8	18	t10	0		2	+ he	-	4	f a	and	ino		of	nor	for	

																								_				-			-	_		
237						-	-	-	75.																					191	150	419	461	271
***		60	500	33	-	8	=;	4	9	N 6		5	-	0	9	66		ä.	- 6	-	5		10:	6	<b>:</b> :	-	-	6		2	* 6	-	0	ör
chronic morphine effect chronic neuroleptic the chronic neuroleptic tre	chronic schizophrenia.	chronological organisat	circadian adrenocortica Circadian organization	Circadian patterns of r	circadian raying or uri	circulating estradiol t	Circulating hormones, E	olasp mounting and adul	Cleghorn JM, Grof P (Bd	Clinical and experiment	clinical and psychologi	clinical assessment and	Clinical correlates.	closipramine treatment.	clonidine after repeate	clonidine at different	Clonidine-induced incre	CMS. ACTH-11ke peptide	co- carcinogens and som	coding in the neural si	coeducational campus.	coeruleus and hypothals	Collier HoJ, Rance MJ.	Collu R. Ducharme JR. B	Combination of naloxone	comparative studies of	Comparison of growth ho	Comparison of plasma co	Comparison of stress re	Comparison of the regul	competence in maie rnes	concentration of aldost	concentrations in major	concentrations in senii
the cat. Acute and ndocrine effects of ase. The effect of	in plasma levels in lactin secretion in the hypothalamus of		development of the roductive rhythms.	al power analysis.	w: its ontokeny and	The relationship of	al contraceptives.		rinology, Brown GM.		£		nel insufficience	after recovery with	hormone response to	other responses to	mediated synapses.	at the level of the	re of receptors for	cross-fiber pattern	aduates living on a	tivity in the locus	d Puture, Hughes J.	tters and Hormones,	aloxone, and of the	holamine depletion:	taclazepan in man.	t for melancholia.	nd corticosterone.	mic oligopeptides.	feet of two odorous	e integrated plasma	e salivary cortisol	d cyclic nucleotide
315	237	225	47	200	391	195	235	187	333	287	427	261	124	367	79	145	287	75	-	447	253	530	15	309	243	101	59	4	365	5	25	185	225	43
- 5001	- 20	0		8	- 6	-	5.	101	8	- 5	-	10:	- d	100	4	9	60	7:		- 60	9	ii c	10	7:	- a	-	3	-	30	5	0.00	-	60	
Cellular and molecular cellular mechanisms und central catecholamines	central cerebral atroph central dopamine neuron central effects of vaso	central effects. Thyro	central hypothalamic nu	central nervous system:	central neural mechanis	cerebral atrophy, memor	Cerebral organization i	cerebrospinal fluid of	cerebrospinal fluid: se	chacma baboons (Papio ur	change following change	change of body weight a	change of mothers and 1	changes after prenatal	changes during strenuou	changes in aggression,	changes in female rate	Changes in physiologica	Changes in saliva testo	Changes in sexual poten	0.5	changes. Characterizat	changes. Inituence of	changes. Patterns of d	changes. Psychosomatic	Characterization of cor	Characterization of the	chemical stimuli. Theo	childhood craniopharyng	children with behaviors	children: a pilot study	chlorpromagine on the p	cholinergic activity an	chronic effects of onla
ones and the brain: at. Involvement of	<ul> <li>Relation between eptide hormones and n of peripheral and</li> </ul>	mone: endocrine and	olism. Role of the	integration in the	th to the twentieth		onadal dysgenesis.			neminal emission in	-		i change iollowing		_		of hypothelamic EEG			nt atress in rats.	pression. Parallel	profound behavioral	es of pre-menstrual	- adrenal endocrine	orine and affective	rollers at work. I.	ehavioral changes.	heromones and other	s with a history of	tultary function in	in young payenotic	man. Influence of	in dopaminergic and	luence of acute and

9			63				-		-	-	-			173		45												103							240												233	
ú				4	10	9	10:		00	7:	80	0	6	0	9	61			-	0	0	6		0	+ (	ö -	- 4		10:	9	7:	10:	0	0		4	7	-	60	6	No	00		-	10:	10:	6	
the to he down		COLUCAL SYONES DO SENIO		corticosteroids on amin				corticosterone in the d	corticosterone levels a	corticosterone, 11-deox	corticosterone. Compar	corticotropin releasing	corticotropin-releasing	Bug	Bud	Bud	Bud	Bud	and	pue			-			cortisol in cerebrospin	cortisol in manic parie				Cortisol responses unde		cortisol stimulation af	cortisol time-points an	cortisol, metaconin and			counseling. 47, XYY and	count. Editorial: Neat		crantopharyngioma. Pos	Creat: a review. Role		orona-fiber nattern cod	cross-over study. Sex	CSF cortisol levels aft	CSF mark depressive epi	
A.O. and and and and	A Company of the contract	4-9 analog on numan	e errects on prasma	4	c patients. Plasma	rtical areas and on	n rhythm of urinary	plasma cortisol and	ve neurophysins and	minations of plasma	growth hormone and	inical studies with	teroid responses to	n test. Melatonin,	reumeision on serum	omparison of plasma	, 11-deoxycortisol,	the rhesus monkey:	Characterization of	. Beta- endorphin,	sal growth hormone,	Morphine inhibits	amethasone salivary	corticosterone and	reliminary report.	ain. Prolactin and	or aldosterone and	precentine on presses	nia. Increased Cop	subjects. Diurnal	equirrel monkeys.	nces on conditioned	mone, prolactin and	ression. Number of	or growth normone,	uitary hormones and	tisol, cortisol and	drogen therapy plus	atness and spelling	holics: prevalence,	istory of childhood	of hotel ordership	Dogs THRH most the	al consideration of	se: a double-blind.	phrenia. Increased	matostatin in human	
36	28.0	100	602	257	239	75	293	207	33	339	405	66	275	9	2	301	275	64	239	22	202	207	57	287	5	141	101	121	89	299	115	113	13	361	7	113	125	139	187	391	287	40E	153	247	113	295	113	
;		- 6	-			8:	6	-	10:	7:	6		*		7:	9	*	7.	29	4		*	*	21		- 6	00	2	4:	60	-		6	1:			7:	9	10:	6	4				1	7:	.9	
as Londittone Association	conditioning in the she	conditioning in the rue	conditions in remaie sq	conditions on the devel	conditions on the menst	conditions. The relati	conflict behavior. Eff		congenital adrenal hype	congenital virilizing a	congenital virilising a	Congress of the Interna	consequence of consumms	consolidation. Effect	conspecifics. Male cha	constant foreperiod rea	consummatory behavior.	consumption in rate on	contacts, exercise and	content in parts of the	content in the diestrus	content of brain tissue	content of the rat medi	₩.		contraceptives. Circul	contributions to neuroe	control of estrons rece	control of feeding. No	control of FSH secretio	control of gonadotropin	control of prolactin se	control of TSH and prol	controllability and pla	controllers at work. E	controllers of work. II	controllers at work. II	controlling prolactin a	controls. Vasopressin-	convulsions on the secr	copulation in male rate	copulatory and socio-se	coputation response par	copulation, in numeri vag	correlates. Endocrine		-	
and separate Park Colons	about this and one	BROCK and avoldance	r different housing	others and lighting	d all-fenale living	ine and psychiatric	ovarian hormones on	t. Gender identity	ng in patients with	nt gynecomastia and	culinization: 46,XX	venth International	renal activity as a	inephrine on memory	al cues from female	ked potentials in a	as a consequence of	of maternal ethanol	ence of male social	ne on catecholamine	brain catecholamine	-		ale. Telemetry and	and following oral	th and without oral	rain: empryological	he serotonin in the	moral and endocrine	ential hypothalamic	ostaglanding in the	ion in man. Neural		in the rat. Stress	vity in air trailic	vity in air traffic	vity in air traffic	role for taurine in	patients and normal	enetetrazol-induced	penile reflexes and	in an exploratory,	atile fatte soids "	toots in the enine	chological and work	e illness: clinical	id) levels in brain	

305	14	13	355	200	5	200	200	227	281	253	461	155	131	355	189	159	463	329	261	147	173	233	16	295	147	211	200	200	220	391	83	141	359	209	329	66	355	467	157	445	569	n	347	11	287	301
566	9 69	5:	œ i			- 6		*	10	9	10:	4:	5	9	9		9:	-	10:	5	10:	6	*	7:	6				30	. 69	10:	7:	9	21	1		:01	60	8	0	5:		9	5	4:	à
depressed patients. Se	depression and the dexa	Depression by estrogen		L-	2	depression. Signified at			. Mumber of	depression. Parallel c	depression. Pre- and p	depression. Psychoendo			depression. The thyrot				depression: its relatio	depressions: possible u	depressive disorder and	depressive episodes. L	depressive illness: a p	depressive illness: oli	depressive illness: rel	45	depressives. Provocati	deprivation. nelatonin	Ass. Ter-Mat- orkents beior	descent of sexual paych	desimipranine in human	desimipramine, diazepam	desmethylimipramine and	determination of the ap	determinations of plass	developing rat brain: h	developing rat brain: 8	pue :	and		12	T.	Development of a radioi	of	of	
ne dexamethasone in	test. Situational	us of female cats.	Recommendations for	anges. Patterns or	parhophysiology or	nts with endogenous	the pathogenesis of	nts with endogenous	naitivity for major	raone in endogenous	entrations in major	cendocrine model of	test in endogenous	and non-endogenous	rmone in endogenous	of major and minor	suppression test in	nts with endogenous	ression response in	olar, and secondary	patients with major	n in husan CSP sark	tion in prepubertal	suppression test in	releasing factor in	state induced in a	esting in recovered	g of hours of steep	no Met Tereage in	The genealogical	. administration of	mulation induced by	on. The effects of	hormones in serum:	ogenous depression:	nd DWA synthesis in	on formation in the	Review: Hormones in	. Basic aspects of	of ACTH peptides.	on and psychosexual	s during post-natal	and brain of rate.		ale rats. Pubertal	
3: 203															3: 421				149		179	100			-	-		-		10: 303	-	-		329								-	12: 177		-	
cue. Selective interfe 3			current status. The pr			Cycle in rate. Motivat					cycle. Influence of ma 6			of aggression an	AMP and plasma p	female rat. Inv	female rat. Rol		cytoprotective effect o 10		Growth, endoor	twenty patients	0		day. Endocrine activit				Delawad Will malaged in			_		deoxycortisol, cortisol		dependence. Brain pept	dependence. Effect of	dependent brain develop	dependent growth hormon	dependent nature of the	depletion: comparative		patients and	in a	patients on m	B up paulorand
sed on the narcotic	on neural growth in	loric homeostasis.	al stress syndrome:	logy of depression.	ontwheeld menstrum.	lor and the entrous	-		-			netrual	_	us monkeys. Annual	ale rate: pituitary			CSF vasopressin and	rvous system in the		ate dopamine neuron	1 IQ and behavioral	unction: anatomical	ferent times of the	e levels during the	terior hypothalanic	- vasopressin and 1-	rai atrophy, memory	ing horson (*EW)	l and postoperative	masculinization and	ntrations in senile	corticosterone, 11-	ycorticosterone, 11-	natrual cycle. The	le in tolerance and	ormones on morphine	-	man subjects. Dose-	Studies on the age-	ts of catecholamine	ng hormone tests in	eleasing hormone in	ced hypoglycemia in	sine vasopressin in	11 11 11 11 11 11 11 11 11 11 11 11 11

6: 1:3	_	3. 203	-	8: 451	•	-			-		10: 193			6: 53	-	8: 451		-		-	6: 365				1: 427		6: 113		0. 170	2: 237					7: 223				2: 373	9: 311	'	10: 325		9: 173		4: 107	4: 10/
dihydroxyphenylacetic a	Diegot solicimannosono	discriminative respond	disease, and adrenal in	disease. Attention dis	-	disorder and healthy hu	disorder in anorexia ne	disorders and healthy s	disorders and secondary	disorders. Bets- endor					diamociation of periphe	disturbance in Graves'	Diurnal cortisol respon	Diurnal growth hormone			diurnal prolactin respo	diurnal prolactin respo	diurnal rhythm regulati	DNA synthesis in develo	domicile in the syndrom	domperidone. Effects 1	DOPAC (3.4-dihydroxyphe		done in no notice desired					dopamine receptors. Ef		dopamine. Dopaminergic	dopamine. Meural and n	dopaminergic and cholin	Dopaminergic factors in	dose neuroleptics. A d	Dose-dependent growth h	double-blind, cross-ove	doves. Conadal hormone	drinking habits and the	drinking in female cats	1	driving task. Endocrin
mine and DOPAC (3,4-	Pactice Atacades	Co of ACTHA-10 KILLS	pression. Cushing's	turbance in Graves	Juvenile Addison's	th major depressive	f the psychological	1th major affective	. primary affective	secondary affective	n test in affective	Ten with heheviorel	n bringry offertice	repaones to social	ther evidence for a	disease. Attention	n normal subjects.	tmenopausal women.	one in normal men.	of atropine on the		bengtropine on the	eural mechanisms in	nfluences. RNA and		d by haloperidol or	e catecholamine and	mai men. Ellect of	olvement of arousts	ormones and central	Tuberoinfundibular	-	phrenia. Hormones,	ectomised rat brain	old-stressed rats.	of neuroleptics and	ocrine functions of	Sex differences in	tion and dopamine.	raone following low-	in human subjects.	rgical menopause: a	al behavior of ring	one test on alcohol	in response to milk	stress responses of	heavy-goods vehicle
8: 237 8: 121	-		. 4.	155		-	**				3: 459			1: 147		193		-			5: 339		*	-	159		215	-		-														400		173	105
development of the circ f	Horacon	1. behavior		in female	in paychi			suppressi		suppressi	suppressi	aunu-auni	au paragai	nuppressi	Rubbreasi	auppressi	suppressi	suppressi	suppressi		_	_							discepted on protecting					condi		ses of the	diagnosis.	effects of	effects of	hypothalam	prolactin	0				dihydrotestosterone and	dihydrotestosterone and e
g conditions on the	one-dependent brain	CRF. OF TWT-MIP-1.	dosterone following	sterone response to	cortisol following	on. Pre- and post-	dorphin in humans.	sol and cortisons.	al correlates. The	depression and the	line patients. The	Thirty-four-hour	rticonterone in the	CTH stimulation and	the outcome of the		he thirty-four-hour	sekly monitoring of	sol time-points and	an growth hormone.	ormone responses to	rtisol responses to	thy individuals and	mplications for the	The TRH test in the	nt and differential	suppression test.	d by desimilar amine,	of phentolesine on	mine content in the	ping rat brain: sex		d female rats. Sex	sol responses under	s to LHRH given via	ses to clonidine at	ical assessment and	treated male rats.	g hormone in rate.	cretion: a review.	normal adult men.	epressed patients.	aloxone in humans.	estrogens on sexual	onal factors in sex	on of testosterone,	cs of testosterone,

		22222222222222	
	# a = k a o o e e k a a 4 k	40252550054-648	
Book Review: Nor Book Review: Opi Book Review: Pro Book Review: Pro and endorine profit and endorine profit in female r synchronization in aman performance in female result for the female result for the female result for the female result.	k file twent k med ave: k med ave: tivity in sive shock sive thera sive thera sive thera contribut contribut broduction bacun babo	ty' in mice.  bottowity in a metivity in a metivity in a metivity in a metivity in a met of central e and exercive and exercive and psychiatr changes. Pat control of fe factore influence. Pat profile. Set profile.	responses to raythms in man status on rate status on rate system. The testing in recognized and be ACTH levels and contectolasmin depression.
Ede). Book R Ede). Book R Ede). Book R Ede). Book R Ede) and endor ENG and paych ENG and paych ENG and peych ENG and peych on and peych	signteenth to the twent B (R), Book Review: electrics Book Review: electrics activity in electroconvulsive shock Electroconvulsive thera electroconvulsive thera electroconvulsive thera electroconvulsive treat embryologics, contribut mergence of production eminence following remo emission in chacks babo	emctionality in mice- Endocine abnormalitie Endocine activity in Endocine activity in Endocine activity in endocine and affective endocine and enterial endocine changes. Pa endocine changes of a endocine data propies endocine data propies endocine glands. Cat endocine glands. Cat endocine glands. Cat endocine glands. Cat endocine glands. Cat	
akis A, Timiras PS Rance MJ, Tyers MC laghors MW, Grof P cagni G, de Wied D ormone on the aleep s in physicilagical, sis of hypothalamic one facilitation of reulating hormones, health theory, the	health theory: the doctinology, Sachar octine responses to sion by estrogen of dine after repeated ammeetic effect of in or substance P. sein release during drate. Effects of ation of the brain: he brain pertides. to the rat median influencing seminal.	ty, aggression and solvent smiffers. twork. Editorial: ls during the day. d work correlates. histric morbidity. udies of metabolic. releasing hormone: nal axis it health pituitary—adrenal. Neurobusoral and Shviromeetal and ollowing removal of new the sheep ESG and ness the sheryous and	nd growth hormone. a between alegy and tions of stress and icle driving task. In heroin addicts on ven. Provocative on damage. Growth. The relationship of on the release of stimulation test in from patients with from patients with
2253	282 282 282 282 282 282 282 282 282 282	\$5555555555555555555555555555555555555	257 257 119 2221 245
20492ku-kt		0-04-44-04-04-088-	
drug biperiden on pitui drug, sodium velproate, drugs and behaviour: a drugs and behaviour: a drugs on the catecholam drugs on the prognosic drugs. On the prognosic drugs: mechanisms, appl	duality without dualism Ducharme JR. Barbeau A. dwarfism.; pilot invent dwarfism. Growth of in Dynamics of testosteron dysgenesis. Gerebral o dyskinesis in men and p dyskinesis in sonkeys. dyskinesis. Estrogen r dysphoria: review of th	early beta—endorphin tearly life. Protorns af early life. Protorns af early post-natal life. BCF   Increases plasma & BCF   Book Review: Front Ed. Book Review: Front Ed. Book Review: The Ed. Book Review: The Editor and Reply. Lett Editor and Reply. Lett Editor. Editorial: Fro Editor: Romendations Editorial.	Editorial: 1982 Miscell Editorial: 1985 Miscell Editorial: 1986 Miscell Editorial: 1985 Miscell Editorial: Endocrine ac Editorial: In affiliati Editorial: Lesbian liem Editorial: The next fiv Editorial: The next fiv Editorial: The role of Editorial: The role of Editorial: The role of Editorial: The role of Eds). Book Review: Eta.
the anticholinergic re of the GABAergic projection anguesms, and and the use of fecus of anxiolytic receptor blocking es and psychomative d some anti-cancer one to neuroleptic			1982 Miscellany. 1985 Miscellany. 1985 Miscellany. 11085 Miscellany. 11085 Miscellany. 11085 Miscellany. 12080 Miscellany.

and degeness degreession. 6 5 25 a voort-and life. Estrogen of electrical and and degenession degreession. 7 155 at the meantal and degenession degreession. 7 155 at the and degeness light of degrees of a state of degenession degreession. 7 155 at the and degrees of degrees	endogenous depression.
15.55 At a reaskablish battogen of section o	depression.
Tripy in transmeatuality. Satrogen preparement and the cartion by meonatal satrogen preparement and the sation of article desired and the carticle actrogens on sexual difference of article actrogens of article actroders actroders of article actroders actroders of actroders actroders of actroders actroders of actroders actroders actroders of actroders actroders actroders of actroders actroders actroders of actroders actroder	depression.
ris 229 ardive dyskinesia. Bstrogen replacement an 10: 85 ication by neoratal strongen prepared and feet sign of a fraction of category of strong in neural and p 5: 85 ed behavior and the terrone of certone on sexual diff 2: 89 in the tenthols of serious recepitivity in 6: 89 in the control of estrong recepitivity in 6: 89 in the control of estrong recepitivity. We 5: 10: 10: 10: 10: 10: 10: 10: 10: 10: 10	depression.
8: 86 Effects of cateford estrogen treatment. Sy 3: 65 Effects of cateford estrogens on sexual dif 2: 65 27 de behavior and the estrone in neural and p 5: 65 321 de behavior and the estrone croeptivity in 10: 289 min the timing of estrone receptivity in 5: 77 proptic leatons on estrone croeptivity in 10: 289 min the timing of estrone receptivity in 7: 29: 81 min the control of estrone receptivity in 7: 229 d. hair statistical events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate recept 3: 10: 155 m.related estressing events on opiate 1: 150 mary corticosterone events estressing in a 6: 10: 150 mary corticosterone events estressing fauldies on 1: 150 mary corticosterone events estressing estressing fauldies on 1: 150 mary corticosterone events estressing fauldies on 1: 150 m.related measures experimental studies estat 1: 150 m.related measures experimental studies estat 1: 150 m.related measures experimental studies on 1: 150 m.related measures experimental studies on 1: 150 m.related measures experimental measures experiments of 1: 150 m.related measures experimental measures experiments of 1: 150 m.relate	depression:
8:361 Meffects of categories on sexual diff 2:365 metabolism of 3H—cettone cycle in rate. 6:37:47 propici and the eartone cycle in rate. 6:37:47 propici and the taining of eattone receptivity in 6:37:41 metabolism of settone receptivity in 7:37:48:41 metabolism of settone receptivity in 7:37:41 metabolism of settone receptivity in 7:37:41 metabolism of eattone receptivity in 7:37:42 metabolism of eattone receptivity in 7:37:42 metabolism of eattone without an eattone of a solid metabolism of a solid control of a solid control of a solid control of a solid metabolism of a solid metabol	ligand syste
6:32; definition of estrons cycle in rate. 6:32; definition of estrons cycles and rece 9:34; din the timing of estrons receptivity, or 6:34; din the timing estrons receptivity, or 6:35; din the timing estrons receptivity, or 6:30; 28; din the timing estrons receptivity, or 6:30; 28; din the timing estrons receptivity, or 6:30; 28; din the control of estrons receptivity, or 6:30; 28; din the control of estrons receptivity, or 6:30; 28; din the control of estrons receptivity, or 6:30; distribute evidence for a role of 7:30; distribute evidence for a role of 6:30; distribute for a role of 6:30;	110
9: 77 prooptic lesions on estrous cycles and rece 9: 28: 28: 28: 28: 28: 28: 28: 28: 28: 28	110
8: 411 id in the timing of estrous receptivity in 5: 10: 289 in the control of estrous receptivity ov 6: 289 in the control of estrous receptivity, ov 6: 289 is pressent. Further evidence for alpha-2 ad their statistical events on opiate recept 3: 10: 155 n-related stressful events on opiate recept 3: 10: 357 n-related stressful events on opiate recept 3: 10: 355 yohimbine. Further evidence for alpha-2 ad 3: 10: 357 yohimbine. Further evidence for alpha-2 ad 3: 10: 357 yohimbine. Further evidence for alpha-2 ad 3: 10: 357 yohimbine. Further evidence for alpha-2 ad 3: 10: 357 yohimbine. Further evidence for alpha-2 ad 3: 10: 357 yohimbine. Further evidence for alpha-2 ad 3: 10: 357 yohimbine. Further evidence for alpha-2 ad 3: 10: 229 do human cortical eveked potentials in a 6: 22: 59 intercontactonial eveked potentials in a 6: 22: 59 intercontactonial eveked potentials in a 6: 22: 59 intercontactonial eveked potentials in a 6: 3: 11: 357 youriectonial and exprimental analysis. By overine contacton and all-female 4: 30: 10: 10: 10: 10: 10: 10: 10: 10: 10: 1	and epinephri
10: 259  10: 251  10: 251  10: 251  10: 251  10: 251  10: 251  10: 251  10: 251  10: 251  10: 251  10: 252  10: 252  10: 252  10: 253  10: 253  10: 253  10: 253  10: 254  10: 255  10:	W. C.
10: 211  Foliation are statistical evaluation. Synchronic 10: 155  10: 155  10: 155  10: 165	D I I
10: 155 d their statistical evaluation. Synchronie 1: 88 81 an-pelated stressful events on optace recept 5: 89 an evaluation. Burther evidence for a role of 5: 10: 355 declarable. Further evidence for a role of 5: 10: 356 declarable evidence for a role of 5: 10: 357 declarable evidence for a role of 5: 10: 358 declarable evidence for a role of 5: 10: 358 declarable eve. Effects of osstro 1: 359 declarable eve. Effects of osstro 1: 350 declarable ever. Effects of osstro 1: 350 declarable ever. Events affecting the billiant releasing factor 1: milliant releasing factor 1: milliant events 1: 350 declarable ever. Events affecting the billiant releasing factor 1: milliant releasing factor 1: milliant releasing factor 2: milliant releasing factor 1: milliant releasing factor 2: milliant releasing factor 2: milliant releasing factor 2: milliant declarable ever. Effects 2:	in humann. D
10: 155 n-celated efrestil events on opiate recept 5: 16: 165 messtals. Current evidence for a dissocia 10: 16: 30. yolimbile. Further evidence for a place of 6: 10: 305 yolimbile. Further evidence for a place of 6: 10: 305 yolimbile. Further evidence that they indu 2: 10: 305 yolimbile. Further evidence that they indu 2: 229 de on human cortical eve. Effects of cestro 1: 229 le social contacts. Effects of cestro 1: 229 le social contacts. Experimental analysis. Eff 10: 289 le rhesus monkeys. Experimental analysis. Eff 20: 20: 20: 20: 20: 20: 20: 20: 20: 20:	in the adult
8: 81 sopressin. Further evidence for a dissocia 10: 567 yohimbine. Further evidence for alpha-2 ad 3: 10: 567 yohimbine. Further evidence for alpha-2 ad 3: 10: 567 gon human cortical evoked potentials in a 6: 4: 81 de owninctentials in a 6: 4: 82 de on human cortical evoked potentials in a 6: 4: 82 de on human cortical evoked potentials in a 6: 4: 82 de owninctential evoked potentials in a 6: 4: 82 de owninctential evoked potentials in a 6: 4: 82 de owninctential evoked potentials in a 6: 4: 82 de owninctential evoked potentials in a 6: 4: 82 de owninctential evoked potentials in a 6: 4: 82 de owninctential evoked a 8: 32 de owninctential and all-female 6: 8: 8: 8: 8: 8: 8: 8: 8: 8: 8: 8: 8: 8:	treatment on
10: 305 mecatasas: Current evidence for a phase of 10: 367 late-like activity: evidence that they indu 2: 48 g on human cortical evoked potentials in a 6: 2: 229 the ovariectomised ewe. Effects of cestro 1: 229 late ovariectomised ewe. Effects of cestro 1: 229 late ovariectomy: a excretion, body tempera 4: 229 le rhesue monkeys. Exprinental availables by ovariectomy: a experimental availables of 2: 289 le rhesue monkeys. Exprimental availables of 2: 289 le rhesue monkeys. Exprimental availables of 3: 287 anorexis nervos. Experimental studies on 1: 289 le rhesue monkeys. Experimental studies on 2: 287 sion. Clinical and experimental studies on 2: 287 view. Clinical and experimental studies on 2: 287 view. Clinical and experimental studies on 2: 287 sion. Clinical and experimental studies on 2: 289 le rhesutal and contactly condition of 3: 229 ret behavior in a exploratory condition of 3: 229 ret behavior in a exploratory condition of 3: 229 ret behavior in a exploratory influences 4: 229 ale preputial gland extracts on the male ra 1: 229 lattes of hormonal facilitation of Eds syn 3: 375 lattes of hormonal facilitation of Eds syn 3: 375 lattes of hormonal facilitatory influences 2: 229 condition releasing factor for mood changes 2: 220 contact minimal reterminal factor for mood changes 2: 222 contact minimal reterminal factor for mood changes 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for mood shanges 2: 222 contact minimal reterminal factor for	OF
10: 367 jatesine critical evoked potentials in a 6: 8: 8: 8: 8: 9: 0n human cortical evoked potentials in a 6: 8: 8: 8: 9: 0n human cortical evoked potentials in a 6: 8: 3: 7: 229 the accidance excretion in rate. Eff 10: 22: 59 leadocial contacts. Experiential in rate. Eff 10: 22: 59 leadocial contacts. Experiential analysis. 10: 22: 9: 10: 22: 9: 10: 22: 9: 22: 22	In
8: 8! g on human cortical evoked potentials in a 6: 7: 229 the average of the continuous and the continuous	AP-
7: 229 g on human cortical evoked potentials in a 6: The ovariectomized eve. Effects of cestro 1: 1 nary corticosterone excretion in rate. Eff 10: 2: 59 le accial contacts, Exerction, body tempera 4: 7: 229 le rocial contacts, Exerciton, body tempera 6: 10: 289 le rocial contacts, Experimental analysis. 8: 37 anorexis mervosa. Experimental analysis. 9: 8: 37 anorexis mervosa. Experimental analysis. 9: 8: 287 view. Clinical and experimental atudies on 2: 1: 303 view. Clinical and experimental atudies on 2: 287 view. Clinical and experimental atudies on 2: 287 view. Clinical and experimental atudies on 2: 287 view. Clinical and experimental atudies on 2: 288 and alopesidol on experimental atudies on 2: 229 rat behavior in an exploratory, copulatory 0: 187 gluccorticoids in expersion and developm 7: 229 rate. Presental gland extracts on the male ra 1: 29 ale preputial gland extracts on the male ra 1: 405 de Research, Laszlo FA, Antoni F (Eds). Bo 10: 29: 295 mygdaloid regions. Facilitation of Excive and 2: 19: 429 is a possible causal facilitation for more 8: 19: 429 is a possible causal factor for mod changes 6: 105 icotropin-releasing factor in depressive il cotropin-releasing factor: Indepressive 1: 1: 13: 0thinamic releasing factor: Indepressive 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1:	naloxone, an
9:381 the countectomised eve. Effects of cestro 1: 2:59 lwation. Melatomin excretion in rats. Eff 40: 2:59 le social contacts. Experimental sumishers 6: 10:289 le rhesus mankeys. Experimental analydis. By ovarienteem annexels. Experimental analydis. By 527 anorexis nervoss. Experimental studies on 1: 8:327 sion. Clinical and experimental studies on 1: 8:328 sion. Clinical and experimental studies on 1: 8:329 ret behavior in an exploratory behaviour 1: 8:31 ret behavior in an exploratory conditatory 10: 8:329 in girls. Prenatal exposure to onedroxyprog 2: 8:405 de Research. Lasslo Extinction of Extive av 1: 9:399 mysdaloid regions. Facilitatory influences 4: 8:429 is possible causal facilitatory influences 2: 8:429 is corropin-releasing factor in depressive 1: 8:429 in other parameter facilitatory influences 2: 8:429 in other man releasing factor: implications for 1: 8:429 in other releasing factor: implications for 1: 8:429 in other releasing factor: implications for 1: 8:429 contropin releasing factor in the male releasing factor in the factor for model of 1: 8:429 contropin releasing factor in the factor for 1: 8:429 contropin releasing factor in the factor for 1: 8:429 contropin releasing factor in the factor for 1: 8:429 contropin releasing factor for model factor for 1:	sadorphin-like immunore
2: 11 mary corticosterone excretion, body tempera 6: 12. 229 le social contacte, exertisce and all-female 6: 10: 289 le rheaus monkeys. Experimental availables 4: 12. 229 le rheaus monkeys. Experimental availables 4: 12. 229 le social contacts, Experimental availables 4: 12. 287 slow. Clinical and experimental atudies on 1: 305 slow. Clinical and experimental atudies on 1: 328 and haloperidol on experimental atudies on 2: 18: 18: 18: 18: 18: 18: 18: 18: 18: 18	endorphin-like immunore
2: 59 leactal contacts exercise and all-female 6: 10: 289 le social contacts exercise and all-female 6: 10: 289 le rhesus monkeys. Experimental analysis. 9: 27 anorexia nervosa. Experimental analysis. 9: 287 view. Clinical and experimental atudies on 2: 288 manuel analysis. Parametri 7: 229 rat 4-10. Social and experimental atudies on 2: 229 rat behavior in an exploratory ocquiatory 10: 2: 229 ale preputial gland exploratory of developm 9: 235 ale preputial gland extracts on the male ra 1: 29 aloremones in the extracts on the male ra 1: 29 aloremones in the extracts on the male ra 1: 29 aloremones in the extracts on the male ra 1: 29 myddaloid regions. Pacilitation of Eds). Bo 10: 29: 375 myddaloid regions. Pacilitation of Eds avail 1: 19: 29 anormal facilitation of Eds avail 1: 29: 29: 20: 20: 20: 20: 20: 20: 20: 20: 20: 20	BL
17: 289 le receiue monkeye. Experiental analysis. B: 31 anoraxia nervosa. Experiental atudice on 2: 327 anorexia nervosa. Experimental atudice on 2: 287 view. Clinical and experimental atudice on 3: 2: 287 view. Clinical and experimental atudice of 3: 2: 287 repeated measures experiments. Parametri 7: 229 repeated measures experiments. Parametri 7: 229 repeated measures experiments. Parametri 7: 229 repeated measures experiments and devolopments of all proporticoids in expression and devolopments of a series of a preparation of extracts on the male rational and a proporticoids in extracts on the male rational active of a series. Progesterone facilitation of ESG syn 4: 175 de Research, Laszlo PA, Antoni P (Eds). Bo 10: 2: 29 myddaloid regions. Pacilitation of ESG syn 4: 429 is possible causal factor for mood changes 2: 2: 20; during early life. Pactors affecting the b 1:	100
B: 31  By overalectomy: an experimental analysis.  B: 527  anorexia nervosa. Experimental atudies on 1:  B: 527  sion. Clinical and experimental atudies on 1:  B: 81  And haloperidol on experimental atudies on 9:  Con trepeated measures experiments. Parametri 7:  Reconstruction of experiments of 1:  Reconstruction of experiments of 1:  Reconstruction of active av 1:  Reconstruction of active active active av 1:  Reconstruction of active	Dud.
8: 327 anorexia nervosa. Experimental studies on 1: 305 yiew. Clinical and experimental studies on 2: 287 view. Clinical and experimental studies on 9: 8: 81 frepeated measures experimental studies of 9: 8: 81 frepeated measures experiments. Parametri 7: 229 frat behavir in an exploratory behaviour i 8: 81 frepeated measures experiments on 1: 8: 81 frepeated measures experiments or parametri 8: 8: 81 frepeated measures experiments 8: 8: 81 frepeated measures of exploratory or 1: 8: 8: 8: 8: 8: 8: 8: 8: 8: 8: 8: 8: 8:	nd
1: 303 sion. Clinical and experimental studies on 2: 32 view. Clinical and experiments atudies on 9: 8: 81 and haloperidol on experiments tardive dy 9: 8: 81 TH-10. Social and experiments. Parametri 7: 229 rat-10. Social and experiments. Parametri 7: 229 rat-10. Prenatal and exploratory behaviour 1 8: 77 glucocorticoids in expension and developm 9: 235 ale preputial gland extracts on the male ra 1: 8: 405 de Research, Lasslo PA, Antoni F (Eds). Bo 10: 405 de Research, Lasslo PA, Antoni F (Eds). Bo 10: 405 mygdaloid regions. Pacilitation of Eds) and 4: 175 de Research formonal facilitation of Eds ayn 4: 175 de Research formonal facilitation of Eds ayn 4: 175 de Research formonal facilitation of facual 1: 1: 15: 1 sites of hormonal facilitation of facual 6: 105 icotropin-releasing factor for mood changes 2: 175 icotropin releasing factor: implications for 10: 1: 13: 0thalamat releasing factor: implicating the b 1:	ma
5: 287 view. Clinical and experimental studies on 9: 88 and haloperidol on experimental studies on 9: 81 frepented measures experiments. Parametri 7: 229 Trepented measures experiments. Parametri 7: 229 Trepented and experiments phenotouri 9: 77 glucocorticoids in experssion and developm 9: 77 glucocorticoids in expession and developm 9: 25; 255 ale preputial gland extracts on the male ra 1: 405 de Research, Laszlo FA, Antoni F (Eds). Bo 10: 3: 105 cats. Progesterone facilitation of Eds ayn 4: 175 de Research, Laszlo FA, Antoni F (Eds). Bo 10: 3: 105 cats. Progesterone facilitation of Eds ayn 4: 175 as Progesterone facilitation of Eds ayn 4: 175 is the of regions. Facilitatory influences 6: 19: 19: 19: 19: 19: 19: 19: 19: 19: 19	00
8: 81 and haloperidol on experiments is frequented and seasons of the control of	18
17. 229 TR4 Denavior in an exploratory behaviour in grid in girls. French an exploratory behaviour in grid in girls. French an exploratory copulatory in glacoorticoids in expension and developm grows all preputial gland extracts on the male ratio as all preputial gland extracts on the male ratio as a seleptoutial gland extracts on the male ratio as a seleptoutial gland extracts on the male ratio as a seleptoutial gland extracts on the male ratio as a seleptoutial gland extracts on the male ratio as a selection of sexual facilitation of sexual in graduloid regions. Facilitation of sexual in graduloid regions. Facilitatory influences as myddaloid regions. Facilitatory influences as in incorrogin. Facilitatory influences as incorrogin. Facilitatory influences as incorrogin. releasing factor in depressive in graduloid regions for incorrogin releasing factor? Does Liffit meet a section affecting the bits	0 4
7: 229 ret behavior in an exploratory, copulatory 10: 3: 187 in girls. Penatal exposure to androxyprog 2: 57 glucocorticoids in expension and developm 9: 25 ale preputial gland extracts on the male ra 1: 4: 52 de Research, Laszlo PA, Antoni P (Eds). Bo 10: 4: 175 de Research, Laszlo PA, Antoni P (Eds). Bo 10: 5: 105 cats. Progesterone facilitation of Eds) and 1: 15: 1 sites of hormonal facilitation of Eds ayn 4: 9: 375 myddalid regions. Pacilitation of excual 1: 9: 379 myddalid regions. Pacilitatory influences 4: 6: 105 inctropin releasing factor for mood changes 2: 175 icotropin releasing factor: implications for 9: 1: 131 other and releasing factor: implications for 10: 1: 131 other and releasing factor: maplications for 10: 1: 131 other and releasing factor? Does LHRH meet 8: 2: 203 during early life. Pactors affecting the b 1:	opu
3: 187 in girls. Frential exposure to medroxyprog 2: 235 cal hormones in the extracts on the male ra 1: 4: 29 ale preputial gland extracts on the male ra 1: 4: 175 de Research, Lasslo PA, Antoni F (Eds). Bo 10: 3: 105 cats. Progesterone facilitation of ESG ayn 4: 175 de Research formonal Facilitation of ESG ayn 4: 9: 599 mygdaloid regions. Facilitatory influences 4: 5: 91 ea. Inhibitory and facilitatory influences 6: 19: a possible causal factor for mood changes 6: 105 icotropin-releasing factor in depressive il 9: 1: 13: other same releasing factor: implications for 10: 1: 13: other same releasing factor: myllostions for 10: 1: 13: other same releasing factor? Boes LHRH meet 8: 2: 203 during early life. Factors affecting the b 1:	-110
9: 77 glucocorticoids in expension and developm 9: 25 cal hormones in the extinction and developm 9: 405 ale preputial gland extracts on the male ra 1: 9: 405 de Research, Laszlo PA, Antoni F (Eds). Bo 10: 2: 107 cats. Progesterone facilitation of BSG syn 4: 9: 575 l sites of hormonal facilitation of sexual 9: 575 mygaloid regions. Pacilitatory influences 4: 9: 99 ea. Inhibitory and facilitatory influences 6: 191 i a possible causal factor for mood changes 6: 105 icotrophn-releasing factor in perseave il 9: 173 icotropin releasing factor: implications fo 10: 2: 203 during early life. Pactors affecting the b 1:	83
4: 29 ale preputial gland extracts on the male ratio 4: 29 ale preputial gland extracts on the male ratio 4: 40 de Research, Jasslo FA, Antoni F (Eds). Bo 10: 4: 173 cats. Progesterone facilitation of ESG ayn 4: 5: 103 cats. Progesterone facilitation of sexual 4: 9: 375 laites of hormonal facilitation of sexual 1: 9: 379 mygdaloid regions. Pacilitatory influences 4: 6: 191 a. Inhibitory and facilitatory influences 4: 8: 429 i.a possible causal factor for mood changes 2: 173 icotropin-releasing factor: implications for 10: 2: 173 icotropin releasing factor: implications for 10: 2: 203 during early life. Pactors affecting the b 1:	ene
4: 405 de Research, Laszlo PA, Antoni F (Eds). Bo 10: 3: 405 de Research, Laszlo PA, Antoni F (Eds). Bo 10: 3: 4: 175 cate. Progesterone facilitation of Esti ayn 4: 19: 375 lastes of hormonal facilitation of saxual 1: 9: 379 mygdaloid regions. Pacilitatory influences 4: 9: 429 is possible causal factor for mod changes 2: 6: 105 icotropin-releasing factor in depressive 11 9: 175 othelmane releasing factor: implications for 9: 1: 131 othelmane releasing factor? Does LARM meet 8: 2: 203 during early life. Pactors affecting the b 1:	0 1
4: 175 de Research, Laszlo PA, Antoni F (Eds). Bo 10: 3: 103 cats. Progesterone facilitation of EST ayn 4: 9: 575 lastes of hormonal facilitation of EST ayn 4: 9: 599 ea. Inhibitory and facilitatory influences 4: 5: 991 ea. Inhibitory and facilitatory influences 4: 6: 105 in possible causal factor for mod changes 2: 175 icotropin-releasing factor in depressive il 9: 1: 175 othelmant releasing factor: implications for 10: 2: 203 during early life. Pactors affecting the b 1:	episonic secretion of p
3: 103 cats. Progesterone facilitation of EEG syn 4: 9: 375 lattes of hormonal facilitation of saxual 1: 9: 379 mygdaloid regions. Facilitatory influences 4: 5: 191 ea. Inhibitory and facilitatory influences 4: 8: 429 is a possible causal factor for mood changes 6: 105 icotropin-releasing factor in appleations 0: 173 icotropin releasing factor: implications 0: 10: 1: 131 othalamic releasing factor: Does LHRH meet 8: 2: 203 during early life. Pactors affecting the b 1:	OF
9: 375 l sites of hormonal facilitation of sexual 1: 399 mygdaloid regions. Facilitatory influences 4: 5: 191 ea. [Inhibitory and facilitatory influences 4: 6: 429 i a possible causal factor for mood changes 2: 175 icotropin releasing factor in depressive il 9: 2: 175 icotropin releasing factor: implications fo 10: 2: 203 during early life. Factors affecting the b 1:	n.t
9: 599 mygdaloid regions. Facilitatory influences 4: 5: 429 is possible causal factor for mod changes 2: 6: 105 icotropin-releasing factor in depressive il 9: 175 icotropin releasing factor; implications for 9: 1: 131 otheliamic releasing factor? Does LARM meet 8: 2: 203 during early life. Factors affecting the b 1:	1.4
5: 191 ea. Inhibitory and facilitatory influences 4: 8: 429 is possible causal factor for mod changes 2: 6: 105 icotropin-releasing factor in appressive il 9: 2: 173 icotropin releasing factor: implications fo 10: 1: 131 othalamic releasing factor? Does LHRH meet 8: 2: 203 during early life. Pactors affecting the b 1:	Pid
8: 429 : a possible causal factor for mood changes 2: 6: 105 icotropin releasing factor; in depressive il 9: 2: 175 icotropin releasing factor: implications fo 10: 1: 131 othalamic releasing factor? Does LHRH meet 8: 2: 203 during early life. Pactors affecting the b 1:	estradiol benzoate and
6: 105 icotropin-releasing factor in depressive il 9: 2: 175 icotropin releasing factor: implications to 10: 131 otheliamic releasing factor? Does LMRW meet 8: 2: 203 during early life. Pactors affecting the b 1:	to tardive dy
2: 173 icotropin releasing factor: implications fo 10: 1: 131 othelamic releasing factor? Does LHRH meet 8: 2: 203 during early life. Pactors affecting the b 1:	estradio1-17-beta uptak
1: 151 Otheramic releasing factory Does LHRH meet 8: 2: 203 during early life. Pactors affecting the b 1:	estradiol-17beta in bas
2: 203 during early life. Pactors affecting the b 1:	Setradiol: alterations
	estradiolbenzoate on lu

315	20 20 10 10 10 10 10 10 10 10 10 10 10 10 10	222 222 222 222	2542224 25422684 25426	20122222222
4400000000	90046 NONE	00044-00-0	401.8800000-0	66664066666
flight in nowices and tillid from patients wit fluid of cerizohrenic fluids sex-related association aspects of flutamide on naprotropin-rectous on thyrotropin-rectous on the thyrotropin-recto	follow-up behavioural a follow-up behavioural a food-class mounting and foreported reaction tim formation in the hypoth formation of the hypoth four-hour dexamethasine	four-hour dexamethasone four-hour melatonin sec free fatty acid changes free fatty acid changes frequency and menstrual Fontiors of Pineal Phy BSH to futefacing horm function and caloric ho function and caloric ho	function and stress in function in constal of function in normal adultunction in the nigro-s function: The effects functions alterations functions of dopasine. Functions of dopasine.	GABA and anterior pitui GABA receptor agoniation GABA receptors. Prolac GABA receptors. Prolac GABA upske into hippoc GABA) in the regulation GABA), a modulator of a GABA-c orgic system: role GABA-c orgic system: role GABA-c orgic system: role GABA-c orgic system: role
es during strenuous RH in cerebrospinal in la cerebrospinal of the antiandrogen rould antiandrogen in animals and and in the cerebrospen in animals and and in the cerebrospen in animals and animals and animals and animals and animals and animals and animals animals and animals animals and animals anim		mance of the thirty- hromatosia. Twenty- - endorphin and its nnel. Hormonal and n. Sexual behavior (Ed) Book Review: thalamic control of responses of IM and ty. Afrencortical tor of hypothalamic	olaconin, pituitary olaniamo- pituitary of tuitary-adrenal and neuroendoctine nergio activity and hium on human sperm arterior pituitary rimental analysis. Visual attentional and neuroendoctine: Past, Present and	is anatomical data.  dies on the role of  cts of progabide,  anterior pituitary  on of high affinity  aninobutric acid  is. Failure of the  Pharmacology of the  tubero-infundibular  pituitary action.
267 273 283 287 309 309	224 225 225 225 225 225 225 225 225 225	25 25 25 25 25 25 25 25 25 25 25 25 25 2	227 2203 319 371 129 409	2001 2001 2001 2001 2001 2001 2001 2001
		404500055-		000000000000000000000000000000000000000
and regeneration in Numen prolactin Kinefelter: in sex differentialinating pit influencing annual influencing seem and cattons seem	MH : 808	feeding. Neurohmacral female cats. Progester female cats. Progester female canspecifics. M female hamsters do not female hamsters donot female living condition female patients with en female patients with en female prients with en	female rat affected by female rat affected by female rat. Effects of female rat. Involvement female rat. Involvement female rat. Relationsh female rat. Relationsh female rat. Rolationsh female rats. Rolationsh female rats. Greets of female rats. Effects of female rats. Effects of female rats. Effects of female rats.	female rats. female rats. female resus female covus! female underg female underg female underg fitter pattern five years. flashes: stud
stem. Neurotrophic mine. Dopaming ic les using releasing enetic and hormonal se responsiveness ental and social the forting of intelligence:	offects in humans.  In schizophrenia.  Hormonal and free sand nonesterified cretions. Volatile sitive and negative techoismines in the Eatrogen postiive s the noradrenegic	e e e e e e e e e e e e e e e e e e e	es on marking in the development in the opin release in the the ovariectomized ivity in the diestrus ation in the cyclic ual behavior in the ual cast secretion in tation in the cyclic actin secretion in the tation in neonatal	and receptivity in n parental male and eagonse in male and d infant stimuli in oid interactions in using conditions in strual synchrony in tosexual status and sideration of reces. Editorial: The next on. Postmenopausal

	3:	8: 421			**	.9	2:	3:	7:		9:	7:	*	2:	3	7:		:6	000	10: 272				 V •		3:	3:	1: 389		::	000	7. 25	7:		4: 237		9: 173				6	,,,		46	20: 74	
(GH)		and	and	and	and	pue .	in a	in the	levels d	esponse e	_		-	-	-	-	-	42						y. Dextro				hypothalanic	of intelligence:	endocrinologica	Dynamics o	Thtake an	and congen		ne basolat	Book Re	menstrus	the prol	state ind	IN THE IN	on experime	nypopnys	or domperid		Errect or	INCETAGE FR
Growth hormone	th hormone		th hormone		th hormone	th hormone	th hormone	th hormone	th hormone	th hormone		th hormone	th hormone	-	-						-			th homeone	-	-					p16.	Digs.	astia		habenula or the basolat	g RL (Bd).	habits and the menstrus	Habituation of the prol	hallucinatory state ind					naloperidol tr	naloperidol. Sirect	rer repro-
_	f growth			60	**			_					_											d Growth							0.4						20		1							
carbonate.	Studies of	-	date serum levels.	roleptics on plasm	aloperidol therapy	ses of thyrotropin,	uced suppression of	corticosteroids and	44	en. Diurnal	s. Enhanced	rone replacement on	sleep-related human		ulsive treatment o	on diamepan-induced	Comparison of	ce of the clonidine	ne bromide on basal	d 24-hour rnythm of	ealthy volunteers.	eases plass	ts. Dose-dependen	in releasing numan	boardooringloon and	d increase in serum	hormones on neural	g with 3H-uridine.	of abuse dwarfism.	ine neuron damage.	e brain or the maie	and machatal	opathic adolescent		d by lesions of the	stry, and Behavior,	on alcohol drinking	chological stress.	e report. Paranoid	lactin responses to	of estradiol and	Brradiol an	release induced by	chizophrenics after	Lactin responses to	mediation
lithium	ervosa.	d plasm	date se	rolepti	aloperi	ses of	nced sa	cortico	lon of	sal women.	species.	rone re	sleep-r	and an	ulsive	on diam	man.	ce of t	ne brom	d 24-no	eal thy	T) incr	tB. DO	In rel	hoendoo	dincre	hormon	g with	of abus	ine neu	e brain	adult	topathi		d by le	stry, a	on alco	chologi	e repor	lactin	ct of e	er or e	releas	chizoph	Lactin	nearat
319	12	139	149	207	391	183	103	109	279	253	181	391	m	75	411	209	327	2	2	4.	469	381	122	107	170	277	327	251	351	213	500	27.0	25	245	359	203	201	481	251	23.1	512	600	177	0	164	211
3.5	7:	5:	10:	-	8:	8:	-	3	6	3	3	5	9	8	-	5			4		00		ni	00	000	9	8	8	8:	80 1		- α	3	7:	5	3	7:	10		:0:		- (		40	204	0
gamma-aminobutyric acid	gamma-aminobutyric acid	gamma-hydroxybutyrate n	gastric atress ulcers i	Gender identity confusi	genealogical descent of	Genetic and hormonal fa	Genetic aspects of the	Georges Ungar. In memo	OH and other responses	GH) release following t	GH), thyrotropin (TSH)	girls. Prenatal exposu	gland and its innervati	gland and the pituitary	gland extracts on the m	gland hormones in serum	gland respond to variat	gland: an intermediary	glands. Catecholamine	gilal cells. Actions o	glucocorticoid receptor	glucocorticoids in expr	glucocorticolds. Modul	glucose as a regulator	glacose, agino acida an	GM. Cleahorn JM. Grof P	Gmelin? How does the 1	GnRH): present status.	GnRH. Letter to the Ed	axis in the m	Conada dyskenesis. Ce	gonadal normontor level:	Ronadectomized adult an	gonadectomy and testost	gonadotrophin secretion				gonadotropin releasing		gonadotropin secretion.	gonadotropin secretion:	gonadotropin-releasing	Goods venicle driving t	Graves disease. Atten	Grot F (Eds) . Book hev
nt of serotonin and	Regulatory role of	one secretion under	neurotensin against	pe: a case report.	eth centuries. The	tion of the brain.	e adrenal medulla.	ngar. In memoriam:	rement of the	Growth hormone	of growth hormone (	se acetate (MPA) in	study of the pineal	between the pineal	of female preputial	ituitary and target	of the pineal	system. The pinesi	emoval of endocrine	in culture: role of	olemia. Lymphocyte	view. Hole of	par synaptosomes by	sence for a rote of	after monogodium I-	ndocrinology. Brown	. Testudo hermanni	releasing hormone (	ormone responses to	halamic- pituitary-	on in patients with	t the pituitary and	eripheral tissue of	e rat. Effects of	eurologic patients:	the timing of	leptic treatment on	in schizophrenia.			a in the control of	on testosterone and	tropin responses to	a real life heavy-	tion disturbance in	. orangaro .

261	141	189	253	235	391	237	101	249	161	303	147	245	11	481	349	339	135	16	3203	139	15	341	8	50	173	459	569	103	272	B3	261	399	205	37	379	399
9906	22	200	91		6	3			3	213		-	9	00	200	2	7:	6	200	5	7:	4:	-	n'i	6	8:	5		10	10:	9	1:	9:	9:	2	
before and after but not thyrotr elicits abnorma following low-d	in acromegaly.	in depressed, a		in man. Phobic	in rate. Diffe	in the cat. Ac	levels during t	receptors. Neu	relationships b		remember.	response	response to clo		responses to da	40	secretion and	secretion	secretion in th	secretion	secretion	secretion: 8		etimulation in	test on alco				projecting mela		-		Hormone-dependent brain	D.		. Hormone- rece
hormone hormone hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	Hormone	No February	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone	hormone.	hormone,	hormone.	hormone	hormone.	Hormone-	Hormone	hormone	hormone.	hormone
yrotropin-releasing ollicle-stimulating adotropin releasing yrotropin-releasing	ppression of growth adotropin-releasing	yrotropin releasing yrotropin-releasing	yrotropin-releasing	vrotronin-releasing	ollicle-stimulating	steroids and growth	cortisol and growth	rs. Neural steroid	eptivity (lordosis)	nd after recovery.	Thereoff of the batter	placement on growth	s. Enhanced growth	ne elicits abnormal	eurologic natients:	en. Diurnal growth	epan-induced growth	anterior pituitary	cate on luteinising	tagonists on growth	c acid in pituitary	5	ing doves. Gonadal	yrotropin-releasing	he clonidine growth	yrotropin-releasing			ur rhythm or growth	42			brain development.	PSH to luteinizing		cortisol and growth binding of thyroid
1917	222	185	177	107	321	47	327	359	339	311	155	365	363	281	200	121	225	371	183	405	1	53	235	103	181	251	253	29	421	261	391	279	37	165	329	253
3722	108	2.6	-:		8	*		-	7:	4		3	10:	9:		8:	2	**	œ ×		**	9:	7:	0		8	3:	7:	. a	9	6		9	3:	**	9
hamsters do not require hamsters of both sexes. handling and novelty on health theory: the eigh	health, endocrine and p	healthy individuals and healthy subjects. Mela	healthy volunteers. Gr	heavy-woods vehicle dri	hemochromatosis. Twent	85	hermanni Gmelin? How d		heterosexual status in	heterotypical sexual be	himponeral generations	history of childhood or	HOJ, Rance MJ, Tyers MC	homeostasis. Current e	Hormonal and free fatty	Hormonal and humoral in		**	hormonal factors in sex		-	-	7	hormone (beta- MSH). H	-	~	-	-	hormone (TKH): a useful	and	-	and	hormone and of prolacti	pue	and	hormone and prolactin s hormone and prolactin t
Mascullnised female jection in neonatal fects of isolation, nology from sex and	ry- adrenal axis in essive disorder and	ctive disorders and	ressed patients and	ra in a 'real life'	men with idiopathic	1 nervous system in	vertebrate, Testudo	. Acute offects of	pared. Homosexual/	The induction of	to dall netation of	nty patients with a	, Hughes J. Collier	unction and caloric	trained nermonnel.	brain development.	in man. Short-term	ble neural sites of	brain. Genetic and	al status and fetal	imorphic behavior.	ys. Behavioral and	ormal men. Diurnal	anocyte stimulating		adotropin releasing	yrotropin-releasing	yrotropin-releasing	grotropin releasing	lactin. lutainiaine	tion of luteinizing	yrotropin-releasing	& hormone-releasing	ca on plassa growth	••	thyrotropin, growth

211	03	32	121	21	39	23	61	83	131	115	105	43	0	55	209	61	24	00	60	27	8	3		66	20	287	181	67	68	311	16	279	65	2	212	7	222	620	20	127	193	37	613		202	230	121	90	6
0: 5																														3:	2:	3: 2	8:							4:	2:	4:	6		-	-	8:	5:	#:
•	-											-			•	-			-						-																								
_	_			humoral influences on b	hydroxybutyrate narco-	hydroxylase activity in	Hydroxytryptamine and t	hydroxytryptamine in th	hyperactive children: r	hyperactivity in newly	hyperplasis and 46.XY a	hyperplasia. The relat	unanderstion in prepar	Avnocal cluric affact of	henocortianlania. Lenn	vencel veeming in deprese	renoglaciants in normal	prophysicatomized rat b	Typophysectomy disturbs	nyposometotropiniam (pa	procthalamic and neuroh	venothalamic and pituit									hypothalamic oligopepti		hypothalamic releasing	hypothalamic ventromedi			=	0		hypothalamus or the pre	hypothalmic serotonin (		hypothesis. Behavioral		identity confusion, sch	Idiopathic adolescent &	idiopathic hemochromato	Illness. Neuroendocrin	Illness: a preliminary
beta- endorphin in	uced by naloxone in	morphine effects in	ction and stress in	ment. Hormonal and		-		-61					Tontino!	onfirmatory atudy.	samed matients with	ing ingulin-induced	to then the today	and haloperidol on	ntricular nucleus.	drome of reversible	e endorphing, novel	ormone mecretion by	me formation of the	view. Differential	in rata. Posterior	tinuous analysis of	e as a regulator of	ne in patients with	uridine. Growth in	obesity and central	ational behavior by	havioral effects of	the criteria for a	oal activity in the	Maturation of the	ence of pimogide on	locus coeruleus and	sensitivity in the	cholamines from the	-	(PMS). The role of	ited. The dopamine	ode of action and a		ase report. Gender	in boys at puberty:	pattern in men with	tudies in affective	pubertal depressive
131	552	187	19	237	29	231	-	33	25	167	135	500	210	203	203	45	47	245	17	171	285	463	215	321	273	219	500	617	13	13	13	363	301	311	522	241	579	289	282	569	285	19	373	177	359	83	361	153	173
3	:0	2	60	5:	4:	.9	5:	3		8	4:	15	:					. 60	.9							4:					.6	10:	9	:9		4	2	:01	2			10:	5:		:9	10:			10:
	•	Δ,	hormone? Is 5- methoxy			hormones and cortisol.	hormones and the brain:	hormones and the sexual.	during	10	1 m	In		9				Hormones. Collu R. Duch	Hormones, donamine rece			hour dexamethanone	hour dexamethanone	-		hours of sleep deprivat		-	-	-	_	-	human cortical evoked p	human cortical evoked p			human growth normone.		male be		Human memory and neuroh							human vaginal secretion	humans with special ref
rinology and growth	rotrophin releasing	age in serum growth	tryptamine a pineal	n systems. Peptide	retion of pituitary	eriden on pituitary	lasticity. Steroid	ces of men. Plasma	e brain: effects of	Eds). Book Review:	nd plasma levels of	ry and target gland	Part adressoretion	Effect of overlan	atal offerta of sex	of neurohypophyses]	Actions of staroid	urotransmitters and	and schizophrenia.	tives. Circulating	nd neurohypophyseal	saion. Thirty-four-	of the thirty-four-	tosis. Twenty-four-	ents on mood and 24-	e arousal during 64	ses under different	nic patients. A 24-	and simelidine (5-	ole of serotonin (5-	on of ketanserin (5-	Present and Puture,	n ACTH4-9 analog on	n ACTH4-9 analog on	of somstostatin in	d and sleep-related		uring the stress of	of sex hormones on	xual development in	ssin and oxytocin.	atment. Release of	minergic factors in	rgic stimulation on	mine and lithium on	of desimipramine in	opioid peptides in	ids, "copuline", in	isorder and healthy

222222222	24522 EVE 1436 EVE 1426 EVE 14	54.652.824.502.82.852.8 54.652.824.652.82.82.82.82.82.82.82.82.82.82.82.82.82	124444 12444 12444 1244 1244 1244 1244
4000000000			mmo-roman
limbic system and preop limitations. The prola lipotropin plasma level lithium carbonate. Gro lithium on human sperm lithium: a confirmatory liting on a condition lining on a forducation liands. Editorial: Le	loading in patients with localization of testost localization of testost localization of testost locus coeruleus and hyp lordosis) hormone relation low back pain. Prolact Low levels of somatosta lutesing hormone and luteinizing hormone and luteinizing hormone secluteinizing hormone secluteinized hormone secluteinized hormone secluteinized hormone secluteinized hormone secluteinized hormo	Macaca radiata induced macaques (Macaca radiat macaques Behavioral a major and minor depression. Premajor endicator female and female rats. Parale copulatory responsmale copulatory responsmale guina pig. Dynamale inab: a review. Male	male mouse. Reproducti male paychiatric patien male rat. Attractant e male rat. Effects of g male rat. Influence of male rats following ad- male rats following ad-
	es to 1.— tryptophan rat brain. Muclear sac activity in the sexual receptivity of a of patients with pressive esplaces. A hormone following hormone prolating the hormone prolating the hormone during the hormone, prolating the hormone, prolating the hormone action of a stradiolbensoate on a stradiolbensoate on the secretion of stradiolbensoate on the peripheral and FSH to hypocortisolemia.	of bonnet manages of anisation of bonnet of in infant rheaus in the diagnosis of est sensitivity for TH in patients with creion in parental x hormones on human male conspectives r activation of the gondal axis in the	The and
3444 344 34 447	44691. FBB F9B 0 B R F 646 F		
lamb: a review. Matura Lasslo FA. Antoni F (Ed Lean and obese. Compar learning in rate. Effe learning in rate. Feri length in mature premen Lespian lizards. Edito	lesions of the manerial lesions of the habenial lesions on estrous cycl lesions. L-Tryptophan Letter to the Editor an Letter to the Editor: Heter are after restraint levels after restraint levels during phenothia levels in the fay.	levels of hormones in a levels of hormones in a levels of sommatostatin levels of thyroid stimulevals of TRH in cerebrievals of youth hormone levels. Exfects of prolevals. Incompletely and PSH to luteinizing secretion in transseliARM action at the pituliARM action at the pituliARM given via differentialife, henvy-goods vehic	пананана
al axis in the male f Peptide Research, we anomalies in the e behavior and maze rogesterone affects and menstrual cycle is anotherny, cycle isards. Editorial: ale rat affected by	ale rat affected by all medial prophics with hypothalamic Baitor and Reply. Editor and Reply. Faponses to Graff. epinephrine, Metalineschion at the Gonadal receptor reased CSF cortisol and corticosterone and corticosterone sed serum prolactin and growth hormone yphenylacetic acid)  - lipotropin plasma nd plasma nd plasma polactin and corticosterone sed serum prolactin and plasma nd p	poness in protactin behavior and plasma sive episodes. Jow snot affect plasma reasion. Increased of endogenous ACTH tivol and protactin thylphenidate serum thylphenidate serum d TSH and protactin e: the responses of ositive feedback on The regulation of of the responses to asing factor? Does drivers in a 'real	ng early post-natal rannes during early eceptor-endegenue ocrine responses to ange of mothers and epildes with opiate- ain beta-endorphin- on beta-endorphin- l of the CNS. ACTH-

sand copulation in sale sexual behavior in sale	rate.	Pubertal de Relationshi	÷5,	17	ht. Central neural pathway. Molecular	mechanisms in diurnal r	- 6	265
	Thesaus	Bonkeys. A		-		mechanisms underlying n		-
	rheeus	monkeys. R	9	145		medial preoptic lesions	.6	-
Bale 80	Social	contacts, e	9 :	239		median eminence followi	4	-
7		of purious T		202	- 1	and interest innitiation of		
>	th a	males with antisocial a		165	um) mexual arounal:	mediation by visual oue		
:	Rffe	cts of nalt	3:	231	nization and neural	mediation of hanster re	2	
	Pren	atal femal	50	269	ytryptamine and the	medication of pituitary		
		Ammailan Vertebrate, T		327	uman male behavior:	medroxyprogesterone ace		
	Drogs	bide on pro		141	ines in the adrenal	medulla. Genetic aspec		-
ŏ	Se par	ison of gro	7:	141	of schizophrenia.	Meeting Report: Blochem		
I.	Su Cu	man. Influence of chlo		185	doorine processes.	Meeting Report: Cellula		-
÷,	hibi	tory effect	7:	25	euroendoorinology.	Meeting Report: Seventh		
č	orphi	ne innibite	5.6	625	uppression test for	melancholla. Compariso	,	
4 4	hobic	Phobic anxiety do		69	hormone, cortinol.	melanocyte stimulating		
	ineal	5-methoxy	4	117	sleep deprivation.	Melatonia excretion, bo		
æ	hythm	s of plasma	9	213	healthy subjects.	Melatonin in relation t		
62	hort-	term hormon	5:	225	. Twenty-four-hour	melatonin secretory pat		-
Ç	o ano	an: focus on thyrotrop	3	279		Melatonin, cortisol and		
-	ation	ts receivin	5.	253		Melatonin, pituitary fu		
-	atien	to. A 24-h	-	419		memoriam: Georges Ungar		
POL	1pt r	eviever. E	9	103	-	memory and neurohypophy		285
8	-	PRES TRO		197		memory consolidation.		5
	The	THH-induce	00	237	l cerebral atrophy.	memory defects and prol		95
	ni ned	female has	100	305		memory of nonttraining	-	165
Su L	1 eth	anol consum	7.	49		memory: Max Reiss.	•	2
20	behav	lour in the	*	237	ine in normal young	men and postmenopausal		339
8	in th	e female ra	*	127	rdive dyskinesis in	men and postmenopausal		429
	10m o	maturation of the brain		125	ecretory pattern in	men with idiopathic hem		321
	lon o	f the hypot	ď	213	TRH in normal adult	men. Differential prol		45
2	prese	mopausal wo	*	297	& hormone in normal	men. Diurnal hormonal		235
F	.88			2	prolactin in normal	men. Effect of dopanin		165
5	arnin	nate learning in rats.	3	271	oglycemin in normal	men. Effect of metergo	9	365
8	. B	look Review:	10:	363	xual preferences of	men. Plasma hormones a	2	33
2	Boo	k Review: P	-	321	olactin in impotent	men. Prolactin in impo		74
-	ment	of oxytocin	:9	347	ect in the surgical	menopause: a double-bli		325
1	Bent	of serum TS	8	455	s in studies of pre-	menstrual changes. Met	-	15
fe a	oment	Measurement of the GH a	6	279	ing the spontaneous	menstrual cycle and fol	7:	75
L	es exp	eriments.	7:	~	avior frequency and	menstrual cycle length		297
1	98. in	leasures, interventions	100	500		Menatrual cycle status	-	213
4		x, nge, nen	5.	192	g conditions on the	menstrum cycle. Influ	0 6	223
echanian		of centrosens		196	94	menactual chutha	'n	
1				-				

258228-382858888882-888388884-2188888	2555 B 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
5-xxxx-409xxxx5xxx2xxxxxxxxxxxxxxxx	000 0000000n-n
monkey. Social influentances: cortisol and gramonkeys to mother infa monkeys. Cortisol responses: Behavioral an monkeys. Gottinol responses: Relation between monkeys. Similar effections of social monkeys. Similar effections monkeys. The physiolog monkeys and neuroendocrine mood changes. Influence of and neuroendocrine morphine effects on pla morphine in facts. Site Morphine inhibits cortisorphine inhibits cortisorphine inhibits cortisorphine inhibits cortisorphine inhibits octima morphine inhibits octimate morphine and lighting extra mother and lighting extra mouse. Effects of isolumes. Effects of isolumes. Effects of isolumes. Typicalcutve or MRA). Prenatal effects millingin of sp	multiple sclerosis (MS) multisteroid responses multisteroid responses multisteroid responses naloxone in man. Short naloxone on genadotropi naloxone or beta-endor naloxone, and of the co naloxone. Influence on naltraxone on mood and naltraxone on testoster narco- analgesia in the
ion in the equirrel oning in the rhesus of ault squirrel captive male rhesus in female additrel ence in male rhesus riod in male rhesus or a delicin strer pressed patients on e canal ister pressed patients on e canal ister pressed patients on e canal ister on e canal ister on e canal ister on e canal ister on the patients of Acte and chronic artisl tolerance to secretion in man. brain paties and extend separation in secretion, sexual effects of change of change of change of change of change of change of sesterone acetate ogesterone acetate multiple solerosis	nt in patients with pression. ACTH and ss: relationship to n levels induced by hormonal effects of yndrome. Effect of the combination of humans. Pailure of e. beta-endorphin. Ir interaction with males. Effects of fects of heroin and mma-hydroxybutyrate
22122827252425245454 22122827252452454 2212282725524 22122827255 22122827255 22122827255 22122827255 22122827255 22122827255 22122827255 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 2212282725 22128272725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 221282725 22128272725 221282725 221282727 221282727 2212827 2212827 2212827 2212827 2212827 2212827 2212827 2212827 2212827 2212827 2212827 2212827 2212827 22128	4 * . 8 7 0 2 7 . U - 7 2 2
wwe-5	
Menetrual synchrony in menstruation; synchrony MRR-25 does not inhibit MRR-25 does not inhibit Met- enkephalin; periph Met- enkephalin; periph Met- heu, and des Tyrmetabolic, and affective metabolic, and affective metabolism. A possible metabolism. Role of the metabolism; a possible metabolism; a consider Methodological issues i methodological issues in mice. Alterations of buice. Alterations of buice. Mes-clamy. Editorial: Miscellany.	models for the study of models and fileation by neomata modification of sexuall Modulation of spinal sy modulation of saterior p. Molecular mechanisms of molecular structure of molecular structure of molecular structure of molecular of phospholipa monitoring of dexametha monitoring of the integ
ducational campus.  citad-Swiss mice.  Leu- and des-Tyr- beta- endorphin and ACTH. epinephrine, parative studies of a pigs. Uptake and a pigs. Uptake and a pigs. Uptake and a pigs. Uptake and a pigs. Effect of in normal subjects: ns for psychiatry. menatual changes. I man. Effect of in normal subjects: ns for psychiatry. premive patient by intentive patient by intenti	

F28852=	2==D8=8	2255 L 8628	245	2269226924	3454343454
					95958989556W
	NOT NEW	00000-NO	ō m ō w m w m	a a nua a nu o u a	endimeneuring
neuroendocrinology. Ba feurohumoral and endocr neurohypophyseal hormon neurohypophyseal peptid neurohypophyseal peptid neuroloptic druge: mech		neurologic patients: ho neuron damage. Growth, neuron systems. Poptid neurons and the regulat neurons as reflected by neurons of the arcust Reuropeptides: influenc	neurophysin I during in neurophysins and cortic neurotensin against gas neurotensin. Pharmaco- feurotensmitters and H Seurotrophic factors an Meurotrophic factors an	non-endogenous depressi non-mammalian vertebrat non-steroidal antiandro nonesterified fatty aci noredrensine in man. noradrenergic agonists noradrenergic feeding s noradrenergic feeding s	normal and accomegalic normal and accomegalic normal men. Bitest of normal men. Effect of normal mubjects. Bites normal subjects. Bites normal subjects. Bites normal subjects mestod normal twins and 'well- normal twins and 'well- normal twins and 'well-
al contributions to ontrol of feeding. endence. Effect of Human memory and el hypothalamic and cretory response to			. Release of human erum immunoreactive rotective effect of leasing hormone and Book Review: Brain al nervous system.		operator and and the herent patients and eleasing horacon in ne and prolacetin in ced hypoglycemia in extremphetamine in times of the day in a to amphetamine in a to amphetamine in a to amphetamine in extrements and extrements and extrements.
252 253	2×22225	248-448x-	265 243 265 265 265	E2513131	868 348 866 868 868 868 868 868 868 868
wwo-00	- 20000-0	F-WW40000	- 22 - 20 -	200000	##-K#0-444-F-
nated development in the natal development in the nature of the psycholog nature of the responses Neatness and spelling c	negative feed-back mech neonatal estrogen treat neonatal guinea pigs. neonatal hamsers of bo neonatal offapring. Ef neonatal rat: possible	nervosa folloving injec nervosa. Experimental nervosa and endocrine r nervous system in hepat nervous system in the c nervous system. Meurot nervous system: an appr	Neural and neuroendoori neural and peripheral t Neural Basis of Behavio Neural control of prola neural crest: a review- neural growth in cultur neural mechanisms in di	200	Neuroendoorine effects neuroendoorine function neuroendoorine function neuroendoorine integrat neuroendoorine marker. neuroendoorine regulati Neuroendoorine regulati Neuroendoorine regulati neuroendoorine regulati neuroendoorine regulati neuroendoorine regulati
onding based on the nucleus during post- y during early post- ntal studies on the n the age-dependent count. Editorial:	on the positive and its modification by differentiation in ectomized adult and longet injection in adrenal function in L. glutamate in the	release in anorexia isorder in anorexia oretion in anorexia onships between the Role of the central le of the sutonomic n in the peripheral tion in the central	tions of dopanie. sm of 3H-eastrone in accretion in man. ls derived from the steroid hormones on to light. Central	droganization and drogan Tutamide on trern coding in the rat. The possible hormone receptors and progesterone in affective illness to post-competative	oniarric parience. pamine. Neural and trexone on mood and oular mechanisms of attents: a possible nolecular bases of L-Tryptophan and ferive disordere. ythm regulation and al. blockere.

£2828282825282	282 282 282	£22.2001.2001.210.21002.22.22.22.22.22.22.22.22.22.22.22.22.
569-49544646	00 NOF-W0040	<u> </u>
outcome of the dexameth ovarian activity and ov ovariectomized ewe. Er ovariectomized female r ovariectomy; an experim ovulation in immature r ovulation in immature r ovulation in the cyclic ovulation and measurements.	oxytocin in the spinal oxytocin. Human memory pain-related stressful pain. Prolactin and companion urainus) sexual a Papic urainus). Erfect of an paradigm. Erfect of an Parallel changes in beharallel changes in beh	Paralla changes of the parameters by scute and parameters in women during the parameters in women during parameters and scans parameters and femal partial tolerance to me partial tolerance to me pathophysiology of deprehophysiology methylogs and healthy wo patients as abolished a patients with endogenou
al reference to the stroug receptivity, ehavior. Effect of ur responses of the radiata) induced by double-blind, cross-felationships. The ctonin (5HT) before varian activity and adocimentology of the adolmmunology of the	of vacopressin and recurrent postnatal fents with low back Male chacma baboon in chacma baboons eriod reaction time es in septal rate.	genous depression.  Jons of biochemical  G and paychological  Bates experiments.  pa: a case report.  eding system of the lactin secretion in  n of development of  holamine content in  ok Review: Opioids:  ntal studies on the  r the diagnosis and  rwking sympathetic  ced in a depressed  in of schincophrenic  release in depressed  in of schincophrenic  release in depressed  injection in manic  oral data on teenty  onal functioning in  rospinal fluid from  plasma cortisol in  methasone in female  sion test in female  sion test in female
212 E E E E E E E E E E E E E E E E E E	7-25-66-66-66-66-66-66-66-66-66-66-66-66-66	2525.85.85.85.85.85.85.85.85.85.84.8
9549-W@WW.00	- K0	- 54252444444488852
novel hypothalamic and novelty on the pituitar noviese and trained per Nuclear localization of nuclear size and labell nucleotid concentration uncleus during post-nat nucleus of fease on uncleus of fease of when the nucleus of fease of when the nucleus of fease of when the nucleus of fease of some nucleus of fease of cortisol time	obesity and central hypotocontral and contral hypotocontrol of the control of the	ontogeny and circadian optogeny and velocation optate antagonist actio optate antagonist actio optate receptor changes optate receptor endoge optate receptor. On the optate activity: e optates differ in receptolates differ in receptolates differ in receptolates differ in receptolates differ in receptolated peptides and optopoid peptides and optopoid peptides in huma optoidergic regulation optoidergic regulation optoidergic regulation optoider effects of was oral contraceptives. C RG276 and ACTH4-10.  Organization and neural organization of bonnet organization and neural organization of bonnet organization of sexual behaviourelives and our brain our brain
ation, handling and ation, handling and strenuous flight in n basal rat brain. one as reflected by entral hypothalamic opressin and cyclic ypothalamic arcasters of the arcaste alamic ventromedial the paraventricular major depression.		al rhythmatcity: its Brain peptides with stemato injection of al, behavioral, and attracted articles articutes of the ysial peptides and chronic effects of the ysial peptides and chronic effects of and brain. Poptor selectivity. Fects of and brain. Eds). Book Review: pophyseal hormones: pophyseal hormones: pophyseal hormones: pothyseal hormones: pothyseal administration of administration of administration of the sof chronological rhythms. Circalian see of chronological rhythms. Circalian stens in the social outer. Reproductive I behavior. On the Indoles of pines!

57588888	138553455532389	25222252525252555555555555555555555555
4-20000-D		
Personnel. Hormonal an Perspectives in peychon Paramaco-behavioral ef Pharamacology of the GAB phase in women with pre phenchianine and butyr phentolamine on diazepa	pheromones and other ch hobic anxiety does not phospholipase A?. Fros physical and paychistri physical and paychistri physicalogical response physicalogical status. physicalogical, EEG and Physicalogical, EEG and Physicalogical, EEG and physicalogical. EEG and physicalogical at a perfect physicalogical contractions of testo pig. Interactions bet	pigs. Uptake and metab pigs. Uptake and metab pilot atudy. Response pilot study. Response pilot study. Response pinoside on hypothalamo Pineal and associated no pineal gland and the pineal gland and the pineal gland respond to pineal gland: an interm pineal hormone? Is 5-pineal hormone? Is 5-pineal hormone? Is 5-pituitary and brain. O pituitary and brain. O pituitary and target glutiary and target glutiary dalamin. Opituitary dalamin. Opituitary dunction in chituitary function and pituitary function in chituitary hormone secreptuitary hormone sand stuitary hormones and
P		
6488258455 64885885 64895 64885 64895 64895 64895 64895 64895 64895 64895 64895 64895 64895 64895 64895 64895 64895 64895 64895 64895 64995 6490	5 8 4 8 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	
0,00000	9-r090044-8rrr	5400050000000000500-5000545005
patients with hypocorti patients with hypothals patients with low back patients with major aff patients with major dep patients with malor dep patients. After mont	patients. Differential patients. Effects of I patients. Flaces ortipatients. Places cortipatients. Serum addet patients: a possible ne patients: domadotrophin patients: homeor respontations. In men with idipattern in men with idipattern odding in the n patterns of depression patterns of rat anterio	
inding in depressed yptophan loading in characteristics of the use of drugs in ortisol and ACTH in tophan treatment in d cortisol in manic	diabetes insipidus diabetes insipidus in male psychiatric sone in psychiatric hagons in depensed onee in psychiatric ation in neurologic ation in neurologic tion of cross-fiber melatonin secretory copulatory response endocrine changes:	tides: the case for rail development of of picrotoxin— and in an assessment—of—ne neuron systems.  Cal Significance of and brain. Opicid the CNS. ACTH-like electivity. Opicid dependence. Brain and neurohypophysial injection of opisite e influence of ACTH uction of the brain dorous compounds on hormones, EEG, and nest. Diagnostic learning in rats. Folonged separation of crime status on rat ind mater enkephalin: regeneration in the for manetration in the status on rat ind mater enkephalin:

367		-					-		: 209	_				-	161 :	: 203	: 297	321	171	: 245	: 29	: 269	383	391	367			180	: 207	161 :	: 411	: 363	52	. 450	4115	13	121	11	107	: 303	301	181 :	381	315	: 173	: 195
80		0	r	N	0	-	9	9	r	10	0	S	5	10	7	•	4	N	n	9	61	5	N	N	0	20.	•	10	*	*	-	0	000	2 4	0	*	2	9	00	-	6	~	0	-	*	00
postmenopausal women. postmatal beta- endorph	postnatal pain-related	postoperative delirium:	postpartum vomen. Incr	Postsurgical IQ and beh	posttraining or pretest	potency in primates. E	potentials in a constan	potentials in a two-sti	power analysis. Circad	Pre- and post- dexameth	pre-menstrual changes.	preferences of men. Pl	pregnant mare serum (PM	preliminary report. Be	preliminary report. Co	preliminary study of ps	premenopausal women. S	premenstrual dysphoria:	premenstrual dysphoria:	premenstrual tension sy	premenstrual tension.	Prenatal 'female hormon	Prenatal effects of sex	Prenatal exposure to me	prenatal or postnatal b	prenatal stress syndrom	preoptic area. Effect	preoptic leafons on est	preparations. The effe	prepubertal depressive	preputial gland extract	Present and Puture, Hug	present strtue. Blosyn	pretest injections of A	prevelence course and	primary affective disor	primary affective disor	primate apecies. Enhan	primates. Behavioral.	primates. Environmenta	PRL responses to TRH in	PRL) secretion in snore		processes. Meeting Rep	prodrug of apomorphine.	production of the brain
skinesia in men and s after prenatal or	ffects of recurrent	rphin, cortisol and	ne treatment of six	craniopharyngioma.	luence on memory of	l changes in sexual	man cortical evoked	man cortical evoked	size by statistical	major depression.	saues in studies of	ones and the sexual	e rats treated with	erative delirium: a	pressive illness: a	genic impotence. A	le length in mature	he psychobiology of	he psychobiology of	phase in women with	rolactin and severe	nt in human males.	one acetate (MPA).	te (MPA) in girls.	eptor changes after	urrent status. The	e limbic system and	ota of amall medial	ent of brain tissue	1 hypersecretion in	nt effect of female	iew: Opioids: Past,	ing hormone (GnRR):	or posttraining or	dmitted alcoholica:	ses to carbidons in	onto achtaonhranta.	nyulaive shock in a	n mother and infant	n sexual potency in	pine on the diurnal	TSH) and prolactin (	raining and testing	s of neuroendocrine	in rat by an ester	ides. Emergence of
275	75	309	181	65	291	219	83	213	309	64	217	227	419	237	64	329	45	355	103	161	165	261	33	321	135	500	213	245	361	475	421	145	217		796	381	281	185	549	461	31	355	315	159	435	339
4.4	80	7:	5:	9	-	-	4:	8:	7:	7:	7:	3:	-	3	10:	7:	6		ř	6	ř	9:	2	9	41	-			7:	10:	8:	9	n		**	ď				10:	3	0	10:	10:	8:	5
nfluence	pituitary- adrenal axis	adrenal	pituitary- adrenal resp		pituitary- adrenal rhyt		pituitary- adrenocortic	pituitary- gonadal axis	pitultary- thyroid and	pituitary-adrenal funct	pituitary-adrenal respo	pituitary. Possible ro	plasma concentration of	plasma corticosteroids									Plasma hormones and the	plasma levels in chroni			plasma noradrenaline in					plasma testosterone and	plasma testosterone in	plasticity. Steroid ho	page to the role of burn	DANKET OF CALLES	notate and devementhenon	nositive and negative f	positive feedback on LH	post- dexamethasone sal	post-natal development	post-natal life. Estro	post-operative Neuroen	Posterior hypothelamic	Postmenopausal flashes:	postmenopausal women.
ior. Inhibition of	ines! gland and the	ultary- thyroid and	on. Behavioral and	es. Behavioral and	Factors influencing	d the medication of	tamethasone-induced	f the hypothalamic-	ession reflected in	basal and rhythmic	and novelty on the	tem in rat anterior	g of the integrated	morphine effects on	chiatric patients.	: determinations of	lia. Comparison of	t of amphetamine on	elationship between	rential response of	and neuroleptics on	apy (ECT) increases	references of men.	nd beta- lipotropin	ges in behavior and		in man. Hhythme of	tenation avadrons.	controllability and	te, to reduce basal	tary cyclic AMP and	nges in aggression,	s of aggression and	ural and benavioral	regreent mere cerum (	-methyltransferese	or of continol time	lornromagine on the	exuality. Estrogen	pression. Pre- and	uate nucleus during	tivity during early	riables relating to	ive shock in rats.	ical organisation.	ormal young men and

5.000	0000	₩		558454K4	W-F8-F0-	
prolactin secretory res prolactin to thyrotropi prolactin, growth horso	prolactin. Effect of 1 prolactin. Lack of eff prolactin. Lack proposed by properties the properties of	propionate injection in Prospects in Paychoneur Prostaglandine and cano	programmary provided carb provided carb FB (Ras) FB	paychistic patients: a paychistic patients: a paychisty. Nethodolog paychoactive drugs on t psychoactive aubstances paychobiology of premen paychobiology of premen paychomiocrine model o navchoandocrine audies	Paychogenic impotence, paychological and work paychological character paychological disorder paychological parameter paychological stress paychological attess.	paychological arreas. paychological tests of psychological variables psychoneuroendorine in psychoneuroendorine for psychoneuroendorinolog Psychoneuroendorinolog Psychoneuroendorinolog Psychoneuroendorinolog psychoneuroendorinolog psychoneuroendorinolog psychoneuroendorinolog psychoneuroendorinolog psychoneuroendorinolog
d limitations. The growth hormone and clic AMP and planma	timulation and timulation of phoria: the role of levels. Effects of	te and testosterone eview: Progress and anding and cancer. phospholipase A2.	hisophrenia, Brain vered depressives. rnadakia A, Timiran (Ed). Book Review: alth, endocrine and hip to physical and tio therapy in male	ng daxamernasone in ced fill response in H: implications for biogenic amines and c administration of nd treatments. The of prolactin. The del of depression.	hormone: a review.  ne relationships in  rw. II. Biological, a with clinical and n the nature of the silogical, EEG and testosterone after tical rescivity to	response in rate to and performance in Neurcendocrine and a useful tool for reliminary study of national Society of Review: Foogrees in Review: Foogrees in Foreview: Foogrees in F. Perspectives in F. Perspectives in F. F. Foogrees in
					255-48524 555-48524	egueegueegue ettiekveegueeu
production of the pines, profile. Effect of the progabide on prolactin	progesterone affects le Progesterone facilitati progesterone facilitati progesterone in neural	progesterone on progestin in the prognestic value frogress and Progress		Prolactin and TSH to the Prolactin control by the Prolactin in impotent and prolactin in rate by an prolactin levels during prolactin levels in the prolactin levels in the prolactin levels in the prolactin levels induced the prolactin levels induce	16.0 00 00 01 01 01 00 00	prolactin responses to prolactin responses to prolactin secretion in prolactin secretion.
p EEG and endocrine Effects in man of	in rate. Perinatal in rate. Perinatal in female cate. etween estrogen and	nges. Influence of havioral effects of active drugs on the Bds). Book Review:	review. Olfactory yrotropin (TSH) and ith low back pain. ent growth hormone, all tension. Plasma n syndrome. Plasma e Growth hormone.	and normone and or ry GABA receptors. n in impotent men. growth hormone and d decrease of serum n. Increased serum lability and plasma ential responses in	ic factors in human control of 73H and man of progablde on Habituation of the caubjects. Absent Growth hormone and men. Differential	pine on the diurnal Reural control of Corticosterone and Growth hormone and Growth hormone and Growth hormone and Sax differences in 1801 and stimulates 1801 and stimulates meduce based plasma memory defects and dithe regulation of

10:
9: 21
*
2
,
7:
-
0
C
0
1
-
0
77
_
,
-
-
•
•
•
•
α
21
31
-
-
91
-
•
•
-
N
ć

	unnanatathn==n	יייייייייייייייייייייייייייייייייייייי
202 L 20 20 20 L L B L L L B 20 20 20 20 20 20 20 20 20 20 20 20 20		248888888888888888888888888888888888888
90808222526600000000000000000000000000000		
Table of the control	and the section of th	the E
factor: factor: factor: factor: factor: horsone horsone horsone horsone horsone	de hormone on the ghormone attau de hormone attau de hormone attau de hormone; and of human growth of endocrine glocation amagantes exper managantes exper asparation in ve atteas aftas	Letter to the E Letter to the E Letter to the E Beta-endorphi Cortinal hyper Gender identit Francid-hallu Blochemical amp Callular and mo General Interna Cotive organs, ob Cotive rhythms. He syndrome is the syndrome h, Inmelo PA, An ne-pretracted ra in depression the land and the
Total to the control of the control	releasing hormone on the releasing hormone stimu releasing hormone stimu releasing hormone estate removal of endocrine given repeated mestures experepeated mestures and repeated mestures interpretative stress stimu repeated separation in tenest stimu seal separation in the sepa	Relly. Letter to the E Relly. Letter to the E Relly. Bets—endothl report. Cortiaol hyper report. Cortiaol hyper report. Paranoid-hallu Report: Seventh Interna Report: Seventh Interna Reproductive organs. ob reproductive reptans. ob reproductive reptans. ob reproductive reptans. ob reproductive reptans. ob reproductive reptans. ob reproductive reptans. ob responses to social dis resourch. Lamzlo PA. An reserthne-pretraated ra responding based on the response after thyrotro
	name to thyrotropin- onse to thyrotropin- ion and thyrotropin- ects. Thyrotropin e are equipotent in eminence following to clonidine after istical analysis of eeries analysis of ioni, adaptation to meters by soute and	osterone itor and itor and iliainary iliainary iliainary Mesting Mesti
	257 enected	
200-2202220010420		100E-WW-WLWLWWWWW
receptor- endogenous 11 receptors and schizophreceptors and schizophreceptors in the amenate ecceptors. Next and receptors. Follocitic of Recommendations for dependent of the courtest postatia paraceurent postatia paraceurent postatia paraceurent to the outcom reference to the reference to the outcom reference to the outcom reference to the refere	egularity Psychonoci regularity Psychonoci regularion and neuroend regularion in neurologi regularion of ACTM secr regularion of IRRM secr regularion of IRRM secr regularion of prolection regularion of prolection regularion of sexual be regularion of sexual be regularion of sexual be	a o memerorestrors
	olateral angedatord region of and attended regions and neuroendocrine role of GABA in the role of GABA in the role of a review. The role is review. The rough resident the rough and endocrine revous and endocrine revolution re	

2822222222		221
~0-000000	4×8×48¢58+85¢6+65+64¢+×64¢855+6+++68++	00
reticular whorls in neuroverse apomorphine effravership hypomator review of theories and review. Alrenal steeol review. Oliferential hereview. Maturation of review. Maturation of review. Maturation of review.		RI (Ed). Book Review: RNA and DNA synthesis i
Smooth endoplasmic lure of naloxone to in the syndrome of nine vasopressin: a enstrual dysphoria: sexual behavior: a f ACTH secretion: a of PSH secretion: a in the male lamb: a phuman subjects:	de and behaviour: a decoration: a the neural creat: a char Ed (Ed) Book toni F (Ed) F (Ed) Book toni F (Ed)	and Behavior, Rabig rmonal influences.
25211812824	21222222222222222222222222222222222222	447
# 00 L W W W W L C		000
response in male and feresponse in psychiatric response in rate to psy response in the mouse. Fresponse of mulpolar. b Fresponse of plasma gluc response pattern. Masc response to alpha-2 ad-		responsiveness. factor restraction on the timi
comparison of stress The TRH-induced TSH on of the prolatin re pituitary-adrenal s. TRH-induced TSH pituitary-adrenal sents. Differential the male copulatory ton growth hormone		terone levels after t. Effects of food

			255 1 25 1 25 1 25 2 2 2 2 2 2 2 2 2 2 2
now-one.	2452R24R4FF	-0040-0000	- 2000 - 200 200 -
secretion in secretion in secretion in secretion in secretion in secretion in	secretion in secretion in secretion in secretion in secretion in secretion in secretion of secretion of secretion.	44 4 4 5 5 C . E	self and self and the brain, senfinal endination of the senaltivity for major descriptivity for major descriptivity in the hyposeparation in mother an separation period in in separation of setting administration of setting administration of setting and behause and setting of the setting of the setting and behause and setting of the se
and prolactin (PRL) al planem prolactin ntrolling prolactin amepam on prolactin timulates prolactin ontrol of prolactin rences in prolactin	luteinizing hormone Juteinizing hormone Juteinizing hormone contiloned cortion IXI to a growth hormone convulsions on the nt and the episone ents: growth hormone ents: growth hormone ents: growth hormone fects and prolacting of the proposition of the propositi	ne and gondoroning regulation of ACTH and control of PSH uman growth hormone bition of prolanting, in human vaginal four-hour melatonings. The prolacting the marcotic cuetal force of the respective to the control of	factors influencing e concentrations in ne suppression in ne coeptor Dopanine receptor Dopanine receptor during a prolonged to mother—infant vels of hypothalmic at Involement of Involement Invole
131 139 187 187	22.48.88.4.2.5. 2.4.4.6.2.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5	255 885 388 255	ZER# - 2822 888 284 24 24 24 24 24 24 24 24 24 24 24 24 24
998666	25486944-95464	888 8000N-44	######################################
of the off	role of gamen aminobuty role of gammen-mainobuty role of galan calls. A Role of galucocorticoida role of galucoce as a re role of protactin. The Role of protaglanding role of serveronin (5-HT Role of the automomic n Role of the central ner role of the central ner	rotational behavior by routes. Studies on the Sachar EJ (Ed). Book R saliva and its applicat saliva testostecone aft saliva testostecone aft sample size by statistis schizophrenia and a 47 schizophrenia and	achizophrenia. Frain pachizophrenia. Failure achizophrenia. Gondact achizophrenia. Horeas achizophrenia. Hecras achizophrenia. Hecras achizophrenia. Hecras achizophrenia and norma achizophrenia and norma achizophrenic and or achizophrenic and a feecretion and lack of a secretion by hypothatan accretion in adults and accretion in adults and accretion in adults and
atosterone in adult A neuromodulatory ion: their possible r GABAergic system: ty and the possible h hormone: possible ntal studies on the	tultary. Possible retion. Regulatory growth in culture: I crest: a review. Fent evidence for a e serus (PMS). The rual dysphoria: the cutopin secretion. We inhibitory. The sulcers in rate maonia metabolism.	given via different given via different neuroendocrinology, saay of cortiaol in in men. Changes in post- dexamethasone of the appropriate identity confusion, amine hypothesis of	a levels in chronic creation in chronic ormone responses in amine receptors and leptic treatment in chemical aspects of rmone in depressed thalamus of chronic ients with multiple in a review of our measures sex age clation between the citye disorders and used growth hormone on any prolactin r pituitary hormone rmone and prolactin relations and sex and a prolactin relations and sex and a prolactin relations and sex and a prolactin relations and and prolactin relations and re

21898212144 2144 24828283	# 4 9 W 9 8 6 6 7 0 9 4 6 0 0 9 9 6 1 8 6 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	55.45
Site of action of develaties of horsonal facil Stuntional depression situations in aice. Al mix postpartum women. mixe and labelling with size by statistical pow eleep and endocrine rhy eleep and endocrine rhy eleep ferpivation. Nel	Sign and endocrine dial prooptic 1  a. Spdocrine ab and exploratory and exploratory and exploratory and exploratory and exploratory and exploratory and factors influence on confinements of Psychoneuroe anifers. Enhanced grow anifers anifers anifers anifers of count. The effect of Enhanced grow anifers of count. The effect of Enhanced for a depring in monkeys to mot be anifers ani	status. Biosynthesis o status. Indoles of pin status. The prenatal s sterecchemical studies
		one (GnRH): present l and physiological s syndrome: current and cancer: further
E 2 4 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8		5: 225 10: 221 9: 375
serum growth hormone: p serum lamunoreactive ne serum levels. Growth h serum prolactin in rat serum FRH: implications serum: determination of seven cases. Juvenile	severe prementrual ten sex and health theory:  Sex differences in dops.  Sex afteroids and affect sex.  Sex afteroids and differences.  Sex afteroids and differences.  Sexual behavior:  Sexual behavior in male sexual behavior in cast sexual behavior in male sexual behavior in the sexual behavior in the sexual behavior in the sexual behavior of guin sexual behavior of male sexual behavior of male sexual behavior of male sexual behavior. On the sexual behavior of male sexual behavior of male sexual preference in male sexual preference of male sexual motivation and receptivity (lor sexual receptivity (lor sexual receptivity (lor sexual receptivity in the shock and avoidance con shock in rate. Posteri	Short-term hormonal eff signalling of pheromone Significance of Peptide Similar effect of estra
induced increase in total to manages in total to methylphenidate olonged decrease of m women. Increased the measurement of t gland hormones in avioural studies in y. Meeting Report:	lamma prolactin and lamma prolactin and veloping rat brain: gratem of the rat. e and female rats. hormanil factors in prematal effects of cross-over atudy. n to body measures, n antisocial and/or erebroapinal fluid: al hamsters of both opplatory and socio-oon (Pagio ursinus) emenopausal women. ampects of crine regulation of an familiation of an of heterotypical lasses that mediate mounting and adult the emounting and adult the conjectores and the missis of the orgonial descent of Uncoupling of the orgonial descent of sponses to electric d electroconvulsive	f naloxone in man. oding in the neural Review: Biomedical inests in monkeys.

222222-22-222222		
448x5x24x-4265		######################################
studies in heroin addicatudies in seven cases. Studies of growth here studies of metabolic an studies of metabolic, estudies of pre-mentrus studies of pherty. Studies on the influence that is not the mature of studies on the pathogen studies using releasing tudies with corticotro	atudy of alcohol addict atudy of psychoneuroend study of the pineal gla atudy. Acute effects o study. Response to thy study. Sex steroids an subchornic administrationabjects as assessed by subjects. Absent prola subjects. Dose-depende subjects. Dose-depende subjects. Effect of a subjects. Measurement subjects. Measurement subjects. Measurement subjects. Measurement subjects. Measurement	aubjects: a review. Ne subjects: methodologica substance P. Rectroom suppression and brain y suppression response in suppression test in dep suppression test in fem suppression test in fem suppression test senait suppression test senait suppression test. Diag
addicts. Endocrine llow-up behavioural menopausal flashes: anorexia nervosa. obese. Comparative lation: comparative lation: comparative lation: comparative lation: depression: ther stereochemical vosa. Experimental al and experimental al and experimental fiter testosterone. fiter testosterone.	imal models for the need through the secretion: a pilot ium; a confirmatory c children: a pilot children: a coronegalic photomine in normal imipromine in normal informance to TRH in normal i the day in normal sorders and healthy sorders and healthy	d peptides in human TRH test in normal not thyrotropin or ion of perchaective ary adrencortical The dexamethasone of the dexamethasone or the dexamethasone or the dexamethasone on dexamethasone on dexamethasone on dexamethasone on dexamethasone on dexamethasone on dexamethasone of the dexamethasone dithe
44-47585515961584 44-47585515961584	F 2 2 4 F 2 F 2 E 2 E 2 E 2 E 2 E 2 E 2 E 2 E 2	74824 74824 74824 7482 7482 7482 7482 74
400000000000000000	0 L W L Q L W Q 4 - Q W 4 4 L 4	#0#4-@#0@00-Fw#-uwu
8 8 8 8 8 C - F	stimulation in men. Chatimulation in the male stimulation in the male stimulation in human praticulation on pituitar stimulation on pituitar stimulation test in end stimulation freeze recessimuli. Dopanne recessimuli. Theoretical catimular reaction time stimulus reaction time stimulus reaction time strengules for psychoen strengules for psychoen strengulating in now stress and endocrine stimulus stress controllability stress controllability.	atress in rats. Castress response in atress response of the stress response of the stress situations atress. Effects of the stress. Effects of the stress. Mantuation of the stress of the of the structure of fee structure of the
s system in hepatic receptors. Neural vioral placticity. cells. Actions of a review. Adrenal ters de not require effect of the non-sa-over study. Sax ann basal and TRH-by beta-melanosyte ormone and folicle-salewine of thyroid ormone and folicle-mal women. Thyroid lactin and cortaol esponses after ACTH	after psychological alpha-2 adrenergic n-releasing hormone n of growth hormone for beta-2 adrenergic ic value of the TRH supplies and infant olactin response to and other chemical potentials in a two-tudies of puberty ali changes during a. Interactions of livery function and ultery function and	

and affect in the	A consequence [ac)erum		trong.	term hormonal affacts o	5: 2	
one of the party of the			-	+00+	.0	100
Part de de la constante de la	Salas Bice. nan-23 doe			+884 48 844004448 44808	10.	10
and the innervating	symbacucate paruant.					N. 9.
strogen treatment.	Synapse formation of th			-	9:	0
pinephrine-mediated	synapses. Clonidine-in	3: 187	thasone suppression	test in depressive ilin	7: 2	100
odulation of spinal	synaptic transmission b		the TRH stimulation			
ke into hippocampal	synaptosomes by glucoco		0	=	7: 32	N
stical evaluation.	Synchronies between sle		derations. The TRH	test in normal subjects	7: 14	-
facilitation of EEG	synchronization in resp		epression. The TRH	test in the diagnosis o	6: 1	10
campus. Menstrual	synchrony in female und	5: 245	dine growth hormone	00	9: 17	-
es on menstruation:	synchrony, cycle length		thasone suppression	test sensitivity for ma	10: 28	ED.
rogen-insensitivity	syndrome compared. Adu	-	thasone suppression	test. Diagnostic perfo	10: 21	-
e and rescue in the	syndrome of abuse dwarf	-	cio-sexual approach		10: 4	-
of domicile, in the	syndrome of reversible	-	thasone suppression		10: 17	-
ne in Klinefelter's	syndrome. Effect of na	-	thasone suppression		8: 44	-
remenstrual tension		6: 245	ssessment-of-people		2: 1	200
The prenatal stress	current		ovocative endocrine	testing in recovered de	:6	10
rs in Klinefelter's	syndrome: the responses		vioral training and	testing procedures on b	9: 36	ar.
encem. RNA and DNA	synthesis in developing	3: 93	Changes in saliva	testosterone after payo	10:	-
etic aspects of the	Synthesis of catecholas	1: 103	n and naltrexone on	testosterone and gonado	1: 3	10
parts of the limbic	avatem and preoptic are	4: 75	receptor binding of		2:	-
the central nervous	avatem in heretic atero		agereasion nights	and	6: 14	1
reenletton of other			Jess project a sec	testosterone during the	6: 2	1
	9.5		THE WITS DESCRIPTION OF STREET		6.	200
and the merchant	-		on or aggregation of			
radrenergic teeding	or the parav		greenton and prasma			- 14
the nigro-stristal	OI	622 : 62	on beiore and arter	testosterone in Aineie		7.45
- endogenous Tigand			tro. the ellect of			0.6
peribueral nervous			radiol benzoate and	testosterone propionate	100	100
th the Berotonergic			or gonsdectomy and	tostosterone repracement	2	+ 1
the and the endocrine			ear localization of	tostosterone, dingrote		-6
the central nervous			a pig. Dynamics of	testosterone, ungurote		3 P
gy of the dabaergic			ne perore and arrest	testing testing		M
undibular GABAergic	system: role of anterlo	9: 125	n-releasing normone	tests in depressed bord		0.00
rates bilects of	systemic and intracered		ce in payencingient	THE WALL TO STREET TO STREET		
consession of motor	systemic injection of o		oboston vertebrate,	Theoretical considerati		u P
100+010 200-000	orations dance and habe		complete. sector	theories and treatments	2: 32	- 0
ral donamine nerron	negations, Dentide horse	2: 227	from sex and health	theory: the eighteenth		10
			Electroconvulsive	therapy (ECT) increases	6: 26	150
lating estradiol to	tardive dyskinesia in m		chronic neuroleptic	therapy in male psychia	3: 2/	-
dol on experimental	tardive dyskinesis in m	9: 375	avior: antiandrogen	therapy plus counseling		S
gen replacement and	tardive dyskinesia. Es		g electroconvulgive	therapy. Vasopressin r		0
erior pituitary and	target gland hormones 1		s after haloperidol	therapy: growth hormone	4: 32	O.
ods vehicle driving	task. Endocrine stress		est in depression.	Thirty-four-hour dexame	8: 4	S
modulatory role for	taurine in controlling		performance of the	thirty-four-hour dexame	10: 5	-
ssion by the male.	Telemetry and continuou		mone, prolactin and	thryotropin responses t	7: 1	-
nin excretion, body	temperature and subject		ergic regulation of		001	(E) 4
ement in ratings of	tension after TRH admin		ected in pituitary-	and pitui		0 4
n with premenstrual	tension syndrome. Plas	6: 245	take and binding of		-	an P
severe premenstrual	tension. Plasma prolac		and normal women.	Thyrold stimulating hor	2:	F11

| 345                     | 201  | 420  | 136   | -  | 302  | 9   | 31  | 321  | ORC   | 2000   | 177  | 45  | 20   | 131  
  | 147   | 150  | 200  | 200  | 200  | 60   | 147   
  | 237  | 413  | 349   | 359  | 196  | 240  
   | 413   | 20   | TRO  | 117  | ***  |   
  | 80   | 247  | 147   | 47   | 181   | 455   
  | 125  | *  | 391  | 365  | 321  | 163   
  | 159   | 311  | 363  | 229   | 367  |   | OV.   
   |
|-------------------------|--|--|---|--|--|---|---|--|---|--|--|---|--
---|---|--|--|--
--|--|--|--|--|---
--	--	--	---	--
--	---	--	---	--
--	--	--	--	--
--	--	---	--	---
5	7:	u.		
  | 7:  |  |  |  | -  | 2  | 2:  
  | 0  | 5:   | 5:  | 5:   | 5  | 2  
   |   |  |  |  |  |   
  |  |  |   | 9  |   | 8   
  | 6  | 9:   |  | 5  | 8  | -   
  | 5   | 9:   | 10:  | 7:  | 10:  | ,   | 0   
   |
| treatment of            | treatment on   | treatment on   | treetment on  | A HOME ON TO   | treatment when adult to  | treatment. Release of   | treatment. Synapse for  | treatments. The paycho   | TON administration in h   | White and the contract of the first of the f | IN THE CALADIDATE IT   | THE IN NOTHAL adult men   | TRH in normal subjects.  | TRH stimulation test in   | TRH test in normal sub-   | TRR test in the diagnos  
   | #DE 1 404404 (BE   | Sold for the ment of   | THE PARTE OF THE PARTE   | TREE . WHENTEL TOOL TOL  |  |  | TRH-stimulated  
  | Tryptophan  | Tryptophan   | tryptophan in normal an  | tryptophan loading in p  | tryptophan on hagal and   
   | Trentophen treatment an  | trentonhan treatment in  | trentonhol in man. Din   | THE PART THE PART LAND   | Total project a reject   | TOTAL CAR CA STOLEN  
   | THE TARBORRE IN BRUCKIA  | TSH response in unitedla  | TSH to thyrotropin-rele  | TSH) and prolactin (PRI   | TSH: implications for p  | tubero-infundibular GAB  
   | Tuberoinfundibular dopa  | twentieth centuries. T   | twenty patients with a   | Twenty-four-hour melato  | twins and 'well-state'   | two odorous compounds o  
  | two-stimulus reaction t  | Tyers MC (Eds). Book R   | Tyr-Met- enk  | Tyr-MIP-1. Development   |   | ulcers in rate. Role o  |
| e and butyrophenone     | chronic neuroleptic  | f alactroconvulativa   | rly heta- andorphin   | The second second second   | not require steroid  |   |   |  |   |  |  |   |  |  
  |   | - Pho  | -  | onoming money  | SHOPLOW SUITE TO LE  | Lerenging normone  | rential diagnosis.  
  | ocrine marker. The   | tophan on basal and  | alamic lesions. L-  | sclerosis (MS). L-   | ctin response to L-  | one responses to L-  
   | ck of affacts of L-   | s and cortinol. L-   | nativeness during L-   |  |  |   
  | One (TRH). Delayed   | r. The TRH-Induced   | nonia. TRH-induced  | nd of prolactin and  | (GH), thyrotropin (   | easurement of serum   
  | ctin control by the  | olactin secretion.   | e elghteenth to the  | behavioral data on   | c hemochromatosis.   | phetamine in normal   
  | est. The effect of  | ked potentials in a  | lier HoJ, Rance MJ,  |   | endorphin, CRF, or   |   | inst gastric stress   
   |
| 69                      | 275  | 225  | 263   | 100  | 181  | 261   | 63  | 137  | 100   | 200  | 623  | 195   | 279  | 253  
  | 47  | 180  | 2520   | 200  | 200  | 522  | 459   
  | 311  | 301  | 311   | 5  | 281  | 279  
   | 210   | 203  | 467  | 26   | 200  | 447   
  |  | 1.1  | 245   | 63   | 447   | 26  
  | 101  | 113  | 125  | 79   | 381  | 103   
  | 131   | 249  | 315  | 267   | 59   | 359   | 351   
   |
| 7:                      | 2  | -0   |   |  | 3  |   | 5:  | 2:   | , ,   |  | 01   | 3   | 3:   | 5:   
  | 2   | . 9  |  | 0 0  | - 1  |  |   
  | 3:   | 9  | .9  | 10:  | 10:  | 0  
   |   |  | ď  | , i  |  |   
  |  |  |   |  | 8   | 7:  
  | 7:   | 7:   | 7:   | *  | .6   | 10:   
  | -   | 6  | 5:   | 5:  | 4  | 5   | 0:  
   |
| thyroid stimulating hor | •  | Thurstroubin releasing   | thurst and a section  | Surprise Landous Landous Line  | thyrotropin (TSH) and p  | thyrotropin or substanc   | Thyrotropin releasing h   | thyrotropin releasing h  |   | thyrotropin response to  | thyrotropin, growth nor  | thyrotropin-releasing h   | thyrotropin-releasing h  | thyrotropin-releasing h  
  | thyrotropin-releasing h   | therotronia-releasing h  | The state of the s | thyrotropin-reteating n  | tuyrotropin-releasing n  | thyrotropin-releasing h  | thyrotropin-releasing h  | thyrotropin-releasing h  | time paradigm. Effect   
  | time paradigm. Effect   | time series analysis.  | time-noints and dexamet  | times of the day in nor  | timing of entrops recen   
   | timing of somedotronin   | Pinters Did (BAs) Hook   | tions of sonodertoning   |  | tionnes that modiate as  |  
   |  |   |  | -   | -  | traffic controllers at   
   | traffic controllers at   | traffic controllers at   | trained personnel. Hor   | training and testing pr  | transmission by beta- m  | transport. Estradiol:  
  | transsexuality. Estrog   | treated male rate. Dif   | treated with pregnant m   | treatment and the episo  | treatment in patients w   | treatment in schizophre   |
| ot plasma levels of     | baylor of male rats  | A control offerto  | and the Breat of  | protite. Bilect of   | rowth hormone (GH),  | ing hormone but not   | ine investigation.  |  | out of the same of the  | de depression. The   | or the responses or  |   | s and man: focus on  | release following  
  | rolactin and TSH to   | ot semones to  | 200  | ne and protactin to  | TOWING INJUCTION OF  | rmonal responses to  | one suppression and   
  | avioral response to  | foreperiod reaction  | o-stimulus reaction   | . interventions and  | Number of cortinol   | nidine at different  
   | butterio acid in the  | restriction on the   | of no Vernadakia A   | ure   and northbere  | the southern of heart  | To concept of the state of  
  | The section of the section of  | aloneant of nartial  | area .IR. Barbana A.  | one (TRH): a uneful  | n rate. Changes in  | ine activity in air   
  | ine activity in air  | ine activity in air  | ine activity in air  | ight in novices and  | various behavioral   | of spinal synaptic  
  | sm of intracellular   | on LH secretion in   | castrated, androgen  | on in immature rate   | sol. L- Tryptophan   | uring L- tryptophan   | s after neuroleptic   
   |
|                         | levels of thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: thyroidestomiaed prior 2: 275 chronic neuroleptic treatment on gondotrop 7: | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: 64 formic neuroleptic treatment on gondotrop 7: 64 formic neuroleptic treatment on gondotrop 7: 64 formic neuroleptic treatment on grandotrop 7: | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: thyroidectomized prior 2: 275 chronic neuroleptic treatment on gonadotrop 7: Thyrotrophin releasing 10: 225 f electroconvulsive treatment on growth hor 5: the first confirmation for growth hor 5: | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: 6 chronic neuroleptic treatment on gondotrop 7: Thyrotrophin releasing 6: 255 felectrocorvilsive treatment on growth hor 5: thyrotrophin releasing 4: 363 rly beta- endorphin treatment on the behavi 10: | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: thyroidectomized prior 2: 275 chronic neuroleptic treatment on gondotrop 7: Thyrotrophin releasing 4: 363 riy beta- endorphin treatment on the behavi 10: thyrotrophin (TSH) and p 3: 181 not require steroid treatment when adult to 5: | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: thyroidectomized prior 2: 275 chronic neuroleptic treatment on gonadotrop 7: Thyrotrophin releasing 4: 25 f electroconvulsive treatment on growth hor 5: thyrotrophin (1981) and p 3: 181 not require stroid treatment when adult fo 5: thyrotropin (1981) and p 3: 181 not require stroid treatment. Release of 10: | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: 75 chronic neuroleptic treatment on gondotrop 7: 73 chronic neuroleptic treatment on groundstrop 7: 74 peter on control for six postpa 7: 75 riy beta-endorphin releasing 4: 563 riy beta-endorphin treatment on the behavi 10: 74 thyrotropin of substance 6: 26; 7 with clossing treatment when adult fo 5: 7 neoning results treatment. Release of 10: 7 neoning results treatment. Sprange for 3: 7 neoning estate treatment. Sprange for 3: 7 neoning 11: 7 neoning 12: 7 neoning 12: 7 neoning 13: 7 neoning 13: 7 neoning 13: 7 neoning 13: 7 neoning 14: 7 neoning 15: 7 neoning 1 | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: thyroidectomized prior 2: 275 chronic neuroleptic treatment on gonadotrop 7: thyrotrophin releasing 4: 363 ribeta-endorphin treatment on the behavi 10: thyrotrophin (TSH) and p 3: 181 not require steroid treatment when adult to 5: thyrotropin or substance 6: 261 y with clomipramine treatment. Release of 10: thyrotropin releasing h 5: 63 y neonatal entropes treatment. Sprages for 3: thyrotropin releasing h 5: 177 lev of theories and treatment. The provedor 2: | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: 75 enfonts neuroleptic treatment of six postpa 7: 75 enfonts neuroleptic treatment on groundstrop 7: 7 electroconvisive treatment on grouth hor 5: 7 thyrotrophin releasing 4: 363 riy beta—endorphin treatment on the behavi 10: 10: 10: 10: 10: 10: 10: 10: 10: 10:  | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: 275 chronic neuroleptic treatment on gondotrop 7: Thyrotrophin releasing 4: 563 riy beta- endorphin treatment on mgrowth hor 5: thyrotrophin releasing 4: 563 riy beta- endorphin treatment on the behavi 10: thyrotrophin or substance 6: 261 y with clomipromine treatment when adult fo 5: Thyrotrophin releasing h 5: 63 y neonatal estroid treatment. Synapse for 5: thyrotrophin releasing h 2: 137 lew of theories and treatments. The payoho 2: thyrotrophin response to 6: 189 gs of tension after TRH administration in h 7: | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: Thyroidectomised prior 2: 275 chronic neuroleptic treatment on gondotrop 7: Thyrotrophin releasing 4: 363 rly beta—endorphin treatment on growth hor 5: thyrotrophin (781) and p 3: 181 not require steroid treatment when adult to 5: thyrotropin or substance 6: 261 y with alomipment treatment. Release of 7: Thyrotropin releasing h 5: 63 y neonatal entrogen treatment. Synapse for 7: thyrotropin releasing h 2: 177 lew of theories and treatment. The psycho 2: thyrotropin response to 6: 189 ga of tension after 781 administration in h 7: thyrotropin, growth hor 6: 253 Increased levels of 781 in cerebrospinal file. | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: 275 chronic neuroleptic treatment on gondotrop 7: Thyroirophin releasing 4: 363 riy beta- endorphin treatment on growth hor 5: thyrotropin or substance 6: 261 y with clomapramine treatment when adult fo 5: thyrotropin releasing h 5: 63 y neonital settogen treatment. Spanse of 10: thyrotropin releasing h 2: 137 lew of theories and treatment. Synapse for 5: thyrotropin releasing h 2: 137 lew of theories and treatments. The psycho 2: thyrotropin growth hor 6: 253 Increased levels of TRH in orrestorable 11 4: | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: Thyroidectomised prior 2: 275 chronic neuroleptic treatment on genedorop 7: Thyrotrophin releasing 4: 363 rly beta-endorphin treatment on my growth hor 5: 181 not require stroid treatment on the behavi 10: thyrotrophin releasing h 5: 261 y with alomipramine treatment. Helease of 10: Thyrotrophin releasing h 5: 63 y neonatal estrogen treatments. Release of 10: thyrotrophin reasons to 137 lew of theories and treatments. The psycho 2: thyrotrophin reasons 6: 189 gs of tension after TRR administration in h 7: thyrotrophin-releasing h 5: 279 along the stone of TRR in cerebrosphinal fl 4: thyrotrophin-releasing h 5: 279 along the stone of TRR in normal adult men 6: thyrotrophin-releasing h 5: 279 along the stone of TRR in normal adult men 6: thyrotrophin-releasing h 5: 179 along the stone of TRR in normal adult men 6: thyrotrophin-releasing h 5: 179 along the stone of TRR in normal adult men 6: thyrotrophin-releasing h 5: 179 along the stone of TRR in normal adult men 6: thyrotrophin-releasing h 5: 179 along the stone of TRR in normal subjects 9: 180 and | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: Thyroidectomised prior 2:275 chronic neuroleptic treatment on gondotrop 7: Thyrotrophin releasing 4: 563 rly beta-endorphin treatment on grouth hor 5: thyrotropin or substance 6: 261 y with clomipramine treatment, when adult fo 5: Thyrotropin releasing h 2: 137 lew of theories and treatment. Synapse for thyrotropin releasing h 2: 137 lew of theories and treatment. Synapse for 5: thyrotropin releasing h 2: 253 loreased levels of TRH in normal adult men 6: 253 thyrotropin-releasing h 3: 195 to haloperidol and TRH in normal adult men 6: 253 thyrotropin-releasing h 3: 279 al RN response to TRH in normal adult men 6: 253 thyrotropin-releasing h 3: 253 nostic value of the TRH stimulation test in 2: | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: Thyroidectonised prior 2: 275 chronic neuroleptic treatment on genedotrop 7: thyrotrophin releasing 4: 363 rly beta—endorphin treatment on growth hor 5: thyrotrophin (781) and p 3: 191 not require steroid treatment on the behavi 10: thyrotropin releasing h 5: 261 y with elomipramine treatment. Synapse for 5: 5 y neomatil entrogen treatment. Synapse for 5: 5 thyrotropin releasing h 2: 177 des of theories and treatment. Synapse for 5: thyrotropin releasing h 2: 177 des of themsion after 7RH in cerebrospinal fl 4: thyrotropin-releasing h 5: 279 al PKL response to 5: 279 al PKL response to 5: 279 noisite thyrotropin-releasing h 5: 279 noisite thyrotropin releasing h 5: 279 noisite thyrotropin releasing h 5: 279 noisite value of the 7RH in normal subjects thyrotropin-releasing h 5: 279 noisite value of the 7RH statulation test in 2: | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: Thyroidectomized prior 2: 275 chronic neuroleptic treatment on gondotrop 7: Thyrotrophin releasing 4: 363 rly beta—endorphin treatment on growth hor 5: thyrotrophin (*281) and p 3: 181 not require steroid
treatment on the behavi 10: thyrotrophin releasing h 5: 261 y with clomipramine treatment. Release of 10: Thyrotrophin releasing h 5: 47 neontal entrogen treatment. Synapse for 5: thyrotrophin releasing h 2: 177 lew of theories and treatment. The propho 2: thyrotrophin releasing h 5: 253 increased levels of TRH administration in h 7: thyrotrophin-releasing h 3: 279 in RH. Treatments and it men 6: thyrotrophin-releasing h 5: 253 nostic value of the TRH stimulation test in 2: thyrotrophin-releasing h 5: 253 nostic value of the TRH stimulation test in 2: thyrotrophin-releasing h 5: 253 nostic value of the TRH stimulation test in 2: thyrotrophin-releasing h 6: 253 references to 2: The TRH stimulation test in 2: thyrotrophin-releasing h 6: 253 references to 2: The TRH stimulation test in 2: 279 on stimulations. The TRH steat in normal subjects and 2: 279 on stimulations. The TRH stimulation test in 2: 279 on stimulations. The TRH stat in normal subjects and 2: 279 on stimulations. The TRH stat in the 2: 279 on stimulation and 2: 279 on stimulations. The TRH stat in normal subjects and 2: 279 on stimulations. The TRH stat in normal subjects and 2: 279 on stimulations. The TRH stat in normal subjects and 2: 279 on stimulations. The TRH stat in subjects and 2: 279 on stimulations. The TRH stat in subjects and 2: 279 on stimulations. The TRH stat in subjects and 2: 279 on stimulations. The TRH stat in subjects and 2: 279 on stimulations. The TRH stat in subjects and 2: 279 on stimulations. The TRH stat in subjects and 2: 279 on stimulations. The TRH stat in subjects and 2: 279 on stimulations. The TRH stat in subjects and 2: 279 on stimulations. The TRH stat in subjects and 2: 279 on stimulation stat states and 2: 279 on stimulation states and  | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: Thyroidectomised prior 2: 275 chronic neuroleptic treatment on gondotrop 7: Thyrotrophin releasing 4: 563 rly beta-endorphin treatment on growth hor 5: 14 thyrotrophin or substance 6: 261 y with clompramine treatment when adult fo 5: Thyrotrophin releasing h 2: 137 lew of theories and treatment. Sprapes of 10: 14 thyrotrophin-growth hor 6: 253 lew of theories and treatment. The psycho 2: 14 thyrotrophin-growth hor 6: 253 lew of theories and treatments. The psycho 2: 14 thyrotrophin-releasing h 3: 195 to haloperidol and TRH in normal adult men thyrotrophin-releasing h 5: 279 al PRI responses to TRH in normal subjects. Thyrotrophin-releasing h 5: 279 and PRI responses to TRH in normal subjects thyrotrophin-releasing h 5: 279 and PRI responses to TRH in normal subjects thyrotrophin-releasing h 6: 37 onsiderations. The TRH stimulation test in thyrotrophin-releasing h 6: 37 onsiderations. The TRH test in normal subjects of thyrotrophin-releasing h 6: 37 onsiderations. The TRH test in normal subjects of thyrotrophin-releasing h 6: 37 onsiderations. The TRH test in normal subjects or 189 or depression. The TRH test in normal subjects or 189 or depression. The TRH test in normal subjects or 189 or depression. The TRH test in normal subjects or 189 or depression the test in normal subjects or 189 or depression to the TRH test in normal subjects or 189 or depression. The TRH test in normal subjects or 189 or depression to the TRH test in normal subjects or 189 or depression to the TRH test in normal subjects or 189 or depression to the TRH test in normal subjects or 189 or depression to the TRH test in normal subjects or 189 or depression to the TRH test in normal subjects or 189 or depression to the TRH test in normal subjects or 189 or depression to the TRH test in the diagnostic test in normal subjects or 189 or depression to the test in normal subjects or 189 or depression to the TRH test in the | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: Thyroidectomised prior 2: 275 chronic neuroleptic treatment on genedorop 7: Thyrotrophin releasing 4: 363 rly beta-endorphin treatment on growth hor 5: 181 not require steroid treatment on the behavi 10: thyrotrophin releasing h 5: 261 y with clomipramine treatment when adult for 5: Thyrotrophin releasing h 2: 177 we of theories and treatment. Synapse for 5: 187 thyrotrophin reasons for 6: 283 increased levels of TRH administration in h thyrotrophin-releasing h 5: 279 increased levels of TRH administration in h 5: 279 nostlo value of the TRH in normal adult men 6: thyrotrophin-releasing h 5: 279 nostlo value of the TRH in normal adult men 6: thyrotrophin-releasing h 5: 279 nostlo value of the TRH in normal adult men 6: thyrotrophin-releasing h 6: 283 releasing h 2 | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: thyroidestomised prior 2: 275 chronic neuroleptic treatment on genadotrop 7: thyrotrophin releasing 4: 367 rly beta- endorphin treatment on growth hor 5: thyrotrophin releasing 4: 367 rly beta- endorphin treatment on the behavi 10: thyrotropin releasing 6: 261 y with clossipramine treatment. Myname adult fo 5: thyrotropin releasing h 2: 137 gas of theories and treatment. Myname for 5: thyrotropin releasing h 2: 137 gas of theories and treatments. The peycho 2: thyrotropin-releasing h 3: 195 inchemed lavels of TRH in normal adult men thyrotropin-releasing h 3: 195 al RM, responses to TRH in normal adult men thyrotropin-releasing h 5: 279 al RM, released the mormal adult men thyrotropin-releasing h 6: 37 nostic value of the TRH test in normal subj 7: thyrotropin-releasing h 6: 37 onsiderations. The TRH test in normal subj 7: thyrotropin-releasing h 6: 253 - releasing hormone (TRH) injection in manic 5: thyrotropin-releasing h 7: 59 - releasing hormone (TRH). Delayed TSH releasing h 7: 59 - releasing hormone (TRH). | thyroid stimulating hor 7: 69 e and butprophenone treatment of six postpa 5: Thyroidectomised prior 2: 275 chronic neuroleptic treatment on geneditor p 7: Thyrotrophin releasing 4: 363 rly beta-endorphin treatment on Roveth hor 5: thyrotrophin releasing 6: 261 rly beta-endorphin treatment when adult fo 5: thyrotrophin releasing h 5: 261 y with closipramine treatment. Release of 10: Thyrotrophin releasing h 2: 177 lew of theories and treatment. Release of 10: 14 thyrotrophin-releasing h 2: 177 lew of theories and treatment. The psycho 2: thyrotrophin-releasing h 5: 293 increased levels of TRH administration in h 7: thyrotrophin-releasing h 5: 279 nosite of the TRH administration in thyrotrophin-releasing h 5: 279 nosite of the TRH stimulation test in 2: thyrotrophin-releasing h 6: 37 nonsiderations. The TRH stimulation test in 2: thyrotrophin-releasing h 6: 189 or depression. The TRH statin normal subjects thyrotrophin-releasing h 6: 189 or depression. The TRH statin normal subjects thyrotrophin-releasing h 6: 253 releasing hormone (TRH) injection in manic 5: thyrotrophin-releasing h 7: 235 releasing hormone (TRH): Delayed TSH rele | thyroid stimulating hor 7: 69 e and butprophenone treatment of six postpa 5: Thyroidectomized prior 2: 275 chronic neuroleptic treatment on genedotrop 7: Thyrotrophin releasing 4: 363 rly beta—endorphin treatment on growth hor 5: thyrotrophin (TSH) and p 3: 181 not require steroid treatment on the behavi 10: thyrotrophin releasing h 5: 63 y neonatal entrogen treatment. Sprapse for 5: Thyrotrophin releasing h 2: 177 lew of theories and treatment. Sprapse for 5: thyrotrophin releasing h 2: 177 lew of theories and treatment. The psycho 2: thyrotrophin-releasing h 3: 279 increased levels of TSH in normal adult men 6: 253 increased levels of TSH in normal adult men 6: 254 thyrotrophin-releasing h 3: 279 nostic value of the TSH test in normal adulects. The thyrotrophin-releasing h 5: 259 nostic value of the TSH test in normal aubjects. thyrotrophin-releasing h 6: 251 releasing hormone (TSH). Delasting h 7: 255 releasing hormone (TSH). Delasting h 2: 259 thyrotrophin-releasing h 7: 259 releasing hormone (TSH). Delasting hormone thyrotrophin-releasing h 7: 259 releasing hormone (TSH): suseful tool for 5: 59 thyrotrophin-releasing h 7: 259 releasing hormone (TSH): suseful tool for 5: 59 tential diagnosis. THR! response 5: 59 tential diagnosis. TSH: TSH: response 5: 59 tential diagnosis. | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: Thyroidectomised prior 2: 275 chronic neuroleptic treatment on genedictory 7: thyroicophin releasing 4: 363 rly beta—endorphin treatment on growth hor 5: thyrotrophin releasing 4: 363 rly beta—endorphin treatment on the behavi 10: thyrotrophin releasing h 3: 191 not require stroid treatment. Release of 5: thyrotrophin releasing h 2: 177 leve of theories and treatment. Shapes for 3: thyrotrophin releasing h 2: 177 leve of theories and treatment. Shapes of 5: thyrotrophin-releasing h 3: 279 increased levels of 7RH in cerebrospinal fl 4: thyrotrophin-releasing h 5: 279 nosite ratios of 7RH in normal adult men 5: thyrotrophin-releasing h 6: 189 or depression. The TRH test in normal and 17: thyrotrophin-releasing h 6: 189 or depression. The final point of 18H releasing h 6: 189 or depression. The TRH test in normal and 17: thyrotrophin-releasing h 6: 189 or depression. The 7RH test in normal and 17: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 235 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 295 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing
hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing h 7: 59 releasing hormone (7RH): museful tool for 5: thyrotrophin-releasing hormone (7RH): mus | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: Thyroidectomized prior 2: 275 electrocorbil treatment on according 5: Thyroidectomized prior 7: 69 e and butyrophen treatment to according 6: 265 rly beta—endorphin treatment on the behavi 10: thyrotrophin releasing 6: 261 y with closipramine treatment. Release of 10: Thyrotrophin releasing 6: 261 y with closipramine treatment. Release of 10: Thyrotrophin releasing 6: 261 y with closipramine treatment. Release of 10: Thyrotrophin reasonale 6: 197 ga of themsion after TRH administration in h 7: thyrotrophin-releasing h 5: 279 nostic value of the TRH in normal adult men 6: 197 thyrotrophin-releasing h 5: 279 nostic value of the TRH stimulation test in 2: thyrotrophin-releasing h 5: 279 nostic value of the TRH stimulation test in 2: thyrotrophin-releasing h 6: 189 or depression. The TRH test in normal and 5: thyrotrophin-releasing h 6: 259 releasing hormone (TRH) injection in manic 5: thyrotrophin-releasing h 7: 259 releasing hormone (TRH) injection in manic 5: thyrotrophin-releasing h 7: 259 releasing hormone (TRH) injection in manic 5: thyrotrophin-releasing h 7: 259 releasing hormone (TRH) injection in manic 5: thyrotrophin-releasing h 7: 259 releasing hormone (TRH) injection in manic 5: thyrotrophin-releasing h 7: 259 releasing hormone (TRH) injection in manic 5: thyrotrophin-releasing h 7: 259 releasing hormone (TRH) induced TSH reapons 10: tophan paradigm. Effect 6: 301 tophan on bassi and TSH stimulated TSH and | thyroid stimulating hor 7: 69 e and butprophenone treatment of six postpa 5: Thyroidectomized prior 2: 275 chronic neuroleptic treatment on genedotrop 7: thyrotrophin releasing 4: 563 rly beta—endorphin treatment on growth hor 5: thyrotroph (TSH) and p 3: 181 not require storoid treatment on the behavi 10: thyrotroph releasing h 5: 261 y with clomipramine treatment, when adult fo 5: thyrotroph releasing h 2: 177 lew of theories and treatment. Symapse for thyrotroph releasing h 2: 177 lew of theories and treatment. Symapse for thyrotroph releasing h 5: 253 increased levels of TRH administration in h 7: thyrotroph-releasing h 5: 253 increased levels of TRH in normal adult men 6: 189 thyrotroph-releasing h 5: 253 onsiderations. The TRH test in normal aubjects. thyrotroph-releasing h 6: 253 -releasing hormone (TRH): injection in manic 5: thyrotroph-releasing h 7: 255 releasing hormone (TRH): injection in manic 5: thyrotroph-releasing h 7: 255 releasing hormone (TRH): injection in manic 5: thyrotroph-releasing h 3: 279 created hormone (TRH): injection in manic 6: 253 releasing hormone (TRH): injection in manic 6: 254 releasing hormone (TRH): injection in manic 7: thyrotroph-releasing h 3: 279 created hormone (TRH): museful fool for 5: thyrotroph-releasing h 3: 279 created hormone (TRH): injection in manic 6: 253 releasing hormone (TRH): museful fool for 6: 301 tophan on basal and TRH-releacing hormone 7: TRH-releacing hormone 7 | thyroid stimulating hor 7: 69 e and butprophenone treatment of six postpa 5: thyroidectomized prior 2: 275 chronic neuroleptic treatment on according 6: 275 chronic neuroleptic treatment on magnetic property thyrotrophin releasing 4: 363 rly beta—endorphin treatment when adult for 5: thyrotrophin releasing h 3: 181 not require stroid treatment on the behavi 10: thyrotrophin releasing h 5: 261 y with closipramine treatment. Release of 10: 18 protrophin releasing h 2: 177 lew of theories and treatment. Release of 10: 18 protrophin-releasing h 2: 177 lew of theories and treatment. The psycho 2: thyrotrophin-releasing h 3: 195 increased levels of TRH in ormal adult men 6: 187 thyrotrophin-releasing h 5: 279 nosite the TRH stimulation that in thyrotrophin-releasing h 5: 279 nosite the TRH stimulation that in thyrotrophin-releasing h 6: 189 or depression. The TRH stimulation that in thyrotrophin-releasing h 7: 295 releasing hormone (TRH) injection in manic thyrotrophin-releasing h 7: 295 releasing hormone (TRH) injection in sanic thyrotrophin-releasing h 3: 299 or depression. The TRH stimulation that 10: 17: 290 releasing hormone (TRH) injection in sanic thyrotrophin-releasing h 7: 295 releasing hormone (TRH) injection in the first thyrotrophin-releasing h 3: 459 releasing hormone (TRH) injection in the first thing paraligm. Effect 6: 301 tophan on basal and TRH-induced TRH response 10: 11 thing paraligm. Effect 6: 301 tophan on basal and TRH-estmulated TSH and 2: 11 thing paraligm. Effect 6: 301 tophan on basal and TRH-estmulated TSH and 2: 11 thing paraligm. Sefect 6: 301 tophan on basal and a trypophan and neuroend 2: 11 thing paraligm. Sefect 6: 301 tophan on basal and releasing hereone 12: 12: 13: 13: 13: 13: 13: 13: 13: 13: 13: 13 | thyroid stimulating hor 7: 69 e and butprophenone treatment of six postpa 5: thyroidectomized prior 2: 275 chronic neuroleptic treatment on genedotrop 7: thyrotrophin releasing 4: 563 rly beta—endorphin treatment on growth hor 5: 261 rly beta—endorphin treatment on the behavi 10: thyrotrophin releasing h 3: 181 not require steroid treatment on the behavi 10: thyrotrophin releasing h 5: 277 gu of theories and treatment. Release of 10: 19 reprotrophin releasing h 2: 177 gu of theories and treatment. Release of 10: 197 gu of theories and treatment. Release of 10: 197 gu of theories and treatment. Release of 10: 197 gu of tension after TRH administration in h 7: thyrotrophin-releasing h 3: 279 increased levels of TRH in normal adult men 6: 187 nostic value of the TRH test in normal aubjects. The protrophin-releasing h 5: 259 nostic value of the TRH est in normal aubjects thyrotrophin-releasing h 6: 259 releasing hormone (TRH) injection in manic thyrotrophin-releasing h 7: 259 releasing hormone (TRH): Delased TSH releasing thyrotrophin-releasing h 7: 259 releasing hormone (TRH): Linduced TSH respons 10: thyrotrophin-releasing h 7: 259 rential diagnosis. The TRH test in the diagnos 5: thyrotrophin-releasing h 7: 259 rential diagnosis. TRH-induced TSH respons 10: thyrotrophin-releasing h 7: 259 rential diagnosis. TRH-induced TSH respons time paradigm. Effect 6: 311 alamic leasions. L- TTRH-induced TSH respons time paradigm. Effect 6: 311 alamic leasions L- TTRH-induced TSH respons time paradigm. Effect 6: 311 alamic leasions L- TTRH-induced TSH releasing time paradigm. Line paradigm. L- TTRH-induced TSH releasing time paradigm. Line Li | thyroid stimulating hor 7: 69 eand butyrophenone treatment of six postpa 5: Thyroidectomised prior 2: 275 chronic neuroleptic treatment on growth hor 5: Thyrotrophin releasing 4: 363 rly beta—endorphin treatment on growth hor 5: 181 not require steroid treatment on the behavi 10: thyrotrophin releasing 6: 26; y with elomipramine treatment. Release of 7: Thyrotrophin releasing h 2: 197 gu of theories and treatment. Synapse for thyrotrophin releasing h 2: 197 gu of theories and treatment. Synapse for thyrotrophin-releasing h 3: 279 included levels of 7RH in cerebrosphinal fit 4: thyrotrophin-releasing h 3: 279 al Ph. responses to TRH in cerebrosphinal fit thyrotrophin-releasing h 5: 279 nosite will be 7: THH staulation test in 7: thyrotrophin-releasing h 6: 37 nosite will be 7: THH test in normal subjects. thyrotrophin-releasing h 6: 39 or depression. The TRH test in normal subjects thyrotrophin-releasing h 7: 59 releasing hormone (TRH): a useful for 5: thyrotrophin-releasing h 7: 59 releasing hormone (TRH): a useful for 5: thyrotrophin-releasing h 7: 59 releasing hormone (TRH): a useful for 5: thyrotrophin-releasing h 7: 59 releasing hormone (TRH): a useful for 5: thyrotrophin-releasing hormone (TRH): a useful for 5: thyrotrophin-releasing hormone (TRH): a useful for 5: thyrotrophin-releasing hormone (TRH): a useful for 5: time paradigm. Effect 6: 31: tophan on beasi and TRH-induced TSH respons time paradigm. Effect 6: 31: and and neuroend 2: time paradigm. Effect 6: 31: and and neuroend 2: time paradigm. Effect 6: 31: and and neuroend 2: time paradigm. The day in normal and parament in normal and neuroend 2: time paradigm. In frame paradigm. In frame parament and neuroend 2: time paradigm. In normal and neuroend 3: time paradigm. In normal and neuroend 3: time parament | thyroid stimulating hor 7: 69 e and butprophenone treatment of six postpa 5: thyroid stimulating hor 2: 275 chronic neuroleptic treatment on according thyrotrophin releasing 4: 563 rly beta—endorphin treatment on the behavi 10: thyrotrophin releasing 6: 261 y with closipramine treatment. Release of 7: thyrotrophin releasing h 2: 177 lew of theories and treatment. Release of 10: 187 thyrotrophin releasing h 2: 177 ga of themsion after TRH administration in thyrotrophin-releasing h 2: 177 ga of themsion after TRH administration in thyrotrophin-releasing h 3: 179 nostic value of the TRH in ormal adult men 6: 187 thyrotrophin-releasing h 5: 279 nostic value of the TRH in normal and thyrotrophin-releasing h 5: 279 nostic value of the TRH stimulation test in 2: thyrotrophin-releasing h 6: 189 or depression. The TRH test in normal and thyrotrophin-releasing h 6: 189 releasing hormone (TRH) injection in manic thyrotrophin-releasing h 7: 279 releasing hormone (TRH) injection in manic thyrotrophin-releasing h 7: 279 releasing hormone (TRH) injection in manic thyrotrophin-releasing h 7: 279 releasing hormone (TRH) injection in manic time paradigm. Effect 6: 301 tophan on basal and TRH eighned TSH and their copening time paradigm. Effect 6: 301 tophan on basal and tryptophan and neuroend 2: time paradigm. Effect 6: 301 cerime marker. The TRH-eighned TSH and time principle of the day in nor 5: 10: 281 celleasing hormone of tryptophan and neuroend 2: time series analysis. | thyroid stimulating hor 7: 69 e and butprophenone treatment of six postpa 5: thyroid
stimulating hor 2: 275 chronic neuroleptic treatment on genedator 7: thyroicophin releasing 4: 363 rly beta—endorphin treatment on growth hor 5: 261 rly beta—endorphin treatment on the behavi 10: thyrotrophin releasing h 5: 261 y with clomipramine treatment. Sprapse for 5: 177 dew of theories and treatment. Release of 10: 178 revorthopin releasing h 2: 177 dew of theories and treatment. Release of 10: 178 dew of theories and treatment. Sprapse for 5: 177 dew of theories and treatment. Sprapse for 5: 177 dew of theories and treatment. Sprapse for 5: 177 dew of theories and treatment. Sprapse for 5: 177 dew of theories and treatment. Sprapse for 5: 177 dew of theories and treatment. Sprapse for 5: 177 dew of theories and treatment. Sprapse for 5: 177 dew of theories and treatment. Sprapse for 5: 177 dew of theories and treatment. Sprapse for 5: 177 dew of theories and treatment. Sprapse for 5: 177 dew of theories and TRH in normal adult men 6: 278 devices of 178 dew of theories and 188 dem 188 de | thyroid stimulating hor 7: 69 e and butprophenone treatment of aix postpa 5: thyroidectomized prior 2: 275 chronic neuroleptic treatment on according 6: 275 chronic neuroleptic treatment on according 6: 265 rly beta—endorphin treatment on the behavi 105 thyrotrophin releasing 6: 261 y with closipramine treatment. Release of 5: 261 y with closipramine treatment. Release of 5: 261 y with closipramine treatment. Release of 5: 261 y with closipramine treatment. Release of 6: 189 gs of tension and treatment. Release of 7: 189 increased levels of 7: 181 in cerebrospinal fl 4: 4: 4: 4: 4: 4: 4: 4: 4: 4: 4: 4: 4: | thyroid stimulating hor 7: 69 e and butprophenone treatment of six postpa 5: thyroid stimulating hor 2: 275 chronic neuroleptic treatment on genedity 7: thyroitophin releasing 4: 563 rly beta—endorphin treatment on the behavi 10: thyrotrophin releasing 6: 261 y with closification treatment. Release of 7: thyrotrophin releasing h 2: 177 lew of theories and treatment. Release of 197 ga of themsing h 2: 177 ga of themsing and treatment. Release of 197 ga of themsing and the thyrotrophin-releasing h 3: 279 nostic value of the TRH animistration in h thyrotrophin-releasing h 5: 259 nostic value of the TRH stimulation test in 2: thyrotrophin-releasing h 6: 189 or depression. The TRH test in normal subjects thyrotrophin-releasing h 6: 259 releasing hormone (TRH) injection in manic thyrotrophin-releasing h 7: 259 releasing hormone (TRH) injection in manic thyrotrophin-releasing h 7: 259 releasing hormone (TRH) injection in manic thyrotrophin-releasing h 7: 259 releasing hormone (TRH) injection in manic time paradigm. Effect 6: 301 alamic leasing hormone (TRH) induced TSH respons time paradigm. Effect 6: 301 alamic leasons to I—Tryptophan and neuroend 2: time paradigm. Effect 6: 301 alamic leasons to I—Tryptophan and neuroend 2: time series analysis. Persons of I—Tryptophan in normal and time of the day in nor 9: 279 one response to I—Tryptophan in normal and time of sentence recep 5: 319 one response to I—Tryptophan in normal and time of sentence recep 5: 319 one response to I—Tryptophan no basal and time of sentence recep 5: 319 one response to I—Tryptophan normal and time of sentence of sentence recep 5: 310 and occision in the sentence of sentence recep 5: 310 and occision in the sentence of sentence recep 5 | thyroid stimulating hor 7: 69 e and butyrophenone treatment of aix postpa 5: Thyroidectomized prior 2: 275 chronic neuroleptic treatment on according 6: 275 chronic neuroleptic treatment on according 6: 275 riy beta—endorphin treatment on the behavi 105 thyrotrophin releasing 6: 261 riy beta—endorphin treatment on the behavi 105 thyrotrophin releasing h 2: 197 received levels of treatment. Shapse for 5: 197 revort horder control of 199 ga of tension after TRH administration in h Tripyrotrophin-releasing h 3: 279 nonsiderations and treatment. Shapse for 199 revort phin-releasing h 3: 279 al FRI response to thyrotrophin-releasing h 5: 279 nonsiderations. The TRH in orreal adult men thyrotrophin-releasing h 5: 279 nonsiderations. The TRH test in normal adult activation in h 199 releasing h 6: 189 or depression. The TRH test in normal and 199 thyrotrophin-releasing h 6: 189 or depression. The TRH test in normal and 199 thyrotrophin-releasing h 6: 189 or depression. The TRH test in normal and 199 thyrotrophin-releasing h 7: 59 releasing hormone (TRH): mestil tool for 50 thyrotrophin-releasing h 7: 59 rential diagnosis. TRH-induced TSH releasing thyrotrophin-releasing h 6: 301 tophs on basal and TRH-induced TSH response time paradigm. Effect 6: 301 tophs on basal and TRH-induced TSH and 199 contine and dexamet in normal and neuroend time paradigm. Effect 6: 301 tophs on basal and TRH-induced TSH and 199 contine and dexamet no 9: 279 one feetcase of 1- tryptophan and neuroend times are seen analysis.  **Limerpoints and dexamet for 200 one response to 1- tryptophan in normal and 200 one response to 1- tryptophan in normal and 200 one response to 1- tryptophan in normal and 200 one response to 1- tryptophan in normal and 200 one response to 1- tryptophan in normal and 200 one response to 1- tryptophan in normal and 200 one response to 1- tryptophan in normal 200 one response to 1- tryptophan release to 1- tryptophan relea | thyrotid stimulating hor 7: 69 chonic mearologuic treatment of six postpa 5: thyrotrophin releasing 4: 55 rly beta-endorphin treatment on geneditor 5; thyrotrophin releasing 4: 55 rly beta-endorphin treatment on the behavi 10: thyrotrophin releasing 6: 26; y with clomipramine treatment. Release of 5: 67 y neonatal estrogen treatment. Synapse for thyrotropin releasing h 2: 137 lev of theories and treatment. Release of 5: 67 y neonatal estrogen treatment. The payono 2: thyrotropin releasing h 2: 137 lev of theories and treatments. The payono 2: thyrotropin releasing h 3: 279 to haloperidol and TRH in normal analyses for thyrotropin-releasing h 5: 257 to haloperidol and TRH in normal analyses thyrotropin-releasing h 5: 257 nosiderations. The TRH test in normal analyses thyrotropin-releasing h 6: 37 nosiderations. The TRH test in normal and 17: 59 releasing hormone (TRH) injection in part in the diagnos thyrotropin-releasing h 7: 259 releasing hormone (TRH) injection in sanic 5: thyrotropin-releasing h 7: 259 releasing hormone (TRH); a useful tool for 5: thyrotropin-releasing h 7: 259 releasing hormone (TRH); a useful tool for 5: time paradigm. Effect 6: 30: tophan on basal and TRH-stimulated TSH and time eries analysis. Effect 6: 30: tophan on basal and TRH-stimulated TSH and time eries analysis. Effect 6: 30: tophan on basal and TRH-stimulated TSH and time eries analysis of estrous recep 5: 31: and releasing of genedectopin section in any eries of the day in nor 9: 279 cone responses to 1- Tryptophan and neuroend time eries analysis of estrous recep 5: 319 cone responses to 1- Tryptophan release to 1- Tryptophan present in 2: timing of estrous recep 5: 329 cone responses to 1- Tryptophan release in all and TRH-stimulated TSH and timing of estrous recep 5: 329 cone responses to 1- Tryptophan release in 10: 227 cone responses to 1- Tryptophan release in 10: 227 cone responses to 1- Tryptophan release in 10: 227 cone responses to 1- Tryptophan release in 10: 227 cone responses to 1- Tryptophan release in 10: 227 con | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 7: Thyrotroghin releasing 4: 355 rly beta—endorphin treatment on gondotrop 7: Thyrotrophin releasing 4: 355 rly beta—endorphin treatment on groundstating thyrotrophin releasing 4: 355 rly beta—endorphin treatment on the behavi 10: Thyrotrophin releasing 6: 255 rly beta—endorphin treatment. Science 6: 257 releasing 6: 258 releasing 6: 258 releasing 7: 197 lev of theories and treatment. Spanse for 5: 197 locesed levels of TH administration in h 7: 197 locesed levels of TH administration in h 7: 197 locesed levels of TH in normal adult men 6: 259 locesed levels of TH in normal subjects thyrotropin-releasing 6: 259 nostic wale of TH in normal subjects 1. Thyrotropin-releasing 6: 259 nostic wale of TH in normal subjects thyrotropin-releasing 6: 259 nostic wale of TH in normal subjects 1. Thyrotropin-releasing 6: 259 nostic wale of TH in normal subjects thyrotropin-releasing 6: 259 nostic wale of TH in normal subjects 1. Thyrotropin-releasing 6: 259 nostic wale of TH in normal subjects 1. 259 releasing hormone 7. THH test in normal subjects 1. 259 releasing hormone 7. THH test in normal subjects 1. 259 releasing hormone 7. THH test in normal subjects 1. 259 releasing hormone 7. THH test in normal subjects 1. 259 releasing hormone 7. THH test in normal subjects 1. 259 releasing hormone 7. THH-induced 72H respons 1. 259 releasing hormone 7. THH-induced 72H respons 1. 259 releasing hormone 7. THH-induced 72H respons 1. 259 releasing hormone 7. 27H test in normal and surroend 2. 27H time series manaysis. 1. 259 releasing hormone 7. THH-induced 72H respons 1. 27H time series manaysis. 2. 27H test in normal and surroend 2. 27H test in subjects 2. 27H test in 1. 27H tryptophan in normal and 2. 27H times of the day in nor 2. 27H times 2. 27H test in 1. 27H tryptophan in normal and 2. 27H times 2. 27 | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 7: Thyrotroghin releasing 4: 275 chools neurolaptic treatment on genedotory 7: Thyrotrophin releasing 4: 365 rly beta-endorphin treatment on the behavi 10: 275 thyrotrophin releasing 4: 365 rly beta-endorphin treatment on the behavi 10: thyrotrophin releasing 6: 26: 31 with clomipramine treatment. Release of 10: 27: 17 beta-endorphin treatment on the behavi 10: Thyrotrophin releasing 6: 26: 37 neonatal entrope treatment. Shapes for 7: thyrotrophin releasing 6: 27: 31 nereased levels of THH administration in h 7: thyrotrophin-releasing 6: 27: 3279 and FRI response to THH in normal subjects. Thyrotrophin-releasing 6: 27: 31 pressed levels of THH administration in h
7: thyrotrophin-releasing 6: 37: 37: 37: 37: 37: 37: 37: 37: 37: 37 | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: 275 cheonic neurolepic treatment on genedotop 7: 18 postpa 10: 22 7 cheonic neurolepic treatment on genedotop 7: 18 postpa 10: 22 7 cheonic neurolepic treatment on genedotop 7: 18 postpa 10: 22 7 cheonic neurolepic treatment on the behavi 10: 18 18: 18: 18: 18: 18: 18: 18: 18: 18: | thyroid stimulating hor 7: 69 e and butyrophenone treatment of six postpa 5: 1875 cheonic meurolepito treatment on genedotop 7: 1875 cheonic meurolepito treatment on genedotop 7: 184 petrotophin releasing 4: 365 riy beta endotophin treatment on the behavi 10: 255 thyrotrophin releasing 6: 26; y with clomipramile treatment when adult fo 5: 4 y neonatal entrogen treatment. Belease of 10: 255 thyrotrophin releasing h 2: 177 is with clomipramile treatment. Belease of 10: 255 thyrotrophin releasing h 2: 177 is with clomipramile treatment. Belease of 10: 257 increased lawels of 78H in correlogation in thyrotrophin-releasing h 3: 279 increased lawels of 78H in correlogation in thyrotrophin-releasing h 5: 279 increased lawels of 78H in correlogation in thyrotrophin-releasing h 5: 279 increased lawels of 78H in correlogation in thyrotrophin-releasing h 5: 279 increased lawels of 78H in correlogation in thyrotrophin-releasing h 7: 279 increased lawels of 78H in correlogation in thyrotrophin-releasing h 7: 279 increasing hormone TRH in the diagnos thyrotrophin-releasing h 7: 259 remital diagnosms of 78H; a useful tool for 5: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 78H; a useful tool for 5: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin-releasing h 7: 259 remital diagnosms of 2: 4 thyrotrophin of 2: 4 thyrotrophin releasing h 7: 250 remital diagnosms of 2: | thyrotid stimulating hor 7: 69 cand butyrophenone treatment of six postpa 5: thyrotrophin releasing 4: 563 rip beta- endorphin treatment on the behavi 10: thyrotrophin releasing 4: 563 rip beta- endorphin treatment on the behavi 10: thyrotrophin releasing 6: 261 y with clompramine treatment. Heleas of 10: thyrotrophin releasing h 2: 73 lew of theories and treatment. Heleas of 10: 14 thyrotrophin releasing h 2: 73 lew of theories and treatment. Heleas of 10: 14 thyrotrophin releasing h 2: 73 lew of theories and treatment. Heleas of 10: 14 thyrotrophin releasing h 2: 73 lew of theories and treatment. Heleas of 10: 14 thyrotrophin-releasing h 2: 253 londerstone. The THH aministration in h 2: 14 thyrotrophin-releasing h 5: 253 londerstone. The THH animation test in the diagnost thyrotrophin-releasing h 5: 253 londerstone. The THH test in normal subjects thyrotrophin-releasing h 5: 253 londerstone. The THH test in normal subjects thyrotrophin-releasing h 5: 253 londerstone. The THH test in normal subjects thyrotrophin-releasing h 5: 253 londerstone. The THH test in normal subjects thyrotrophin-releasing h 7: 255 rential diagnosis. THH test in the diagnosis thyrotrophin-releasing h 7: 255 rential diagnosis. THH test in normal subjects thyrotrophin-releasing h 7: 255 rential diagnosis. THH test in the diagnosis thyrotrophin-releasing h 9: 459 rential diagnosis. THH test in the diagnosis time paradigm. Effect 6: 301 tophin on basel and first in normal and time paradigm. Effect 6: 301 tophin on basel and time paradigm of estous response to 10: 55 solderstone and dexamet in 2: 10: 5 solderstone and dexamet in 2: 10: 5 solderstone and dexamet in 10: 5 solderstone and dexamet in 10: 5 solderstone and dependence 2: 11 one (THH) thyrotrophin release in anorexia rilance that sedates as 2: 11 one (THH) thyrotrophin testing 10: 10: 10: 10: 10: 10: 10: 10: 10: 10: | thyrotod stimulating hor 7: 69 cand butyrophenone treatment of six postpa 5: thyrotocharchailed prior 2: 275 chonton ceurolepito treatment on growth hor 5: thyrotochain releasing 4: 363 rip beta- endorphin treatment on the about 10: thyrotochain releasing 5: 65 not require steroid treatment when adult for thyrotochain releasing h 2: 71 lev of theories and treatment. Release of 10: thyrotochain-releasing h 2: 71 lev of theories and treatment. Release of 10: thyrotochain-releasing h 2: 72 lev of theories and treatment. The propose for thyrotochain-releasing h 2: 279 longiderations. The THH administration in h 2: 14 thyrotochain-releasing h 5: 279 notice value of the THH in normal adult men thyrotochain-releasing h 5: 279 notice value of the THH in normal adult men thyrotochain-releasing h 5: 279 notice value of the THH in normal adult men 6: 279 notice value of the THH in normal adult men 6: 279 notice value of the THH in normal adult men 6: 279 notice value of the THH in normal adult men 6: 279 notice value of the THH in normal and 20: 14 hyrotochain-releasing h 5: 279 notice value of the THH in normal and 20: 14 hyrotochain-releasing h 5: 279 notice value of the THH in normal and 20: 14 hyrotochain-releasing h 5: 279 notice merker. The THH test in normal and 20: 14 hyrotochain-releasing h 5: 279 restial diagnosis. THH test in normal and 20: 14 hyrotochain-releasing h 5: 279 restial diagnosis. THH test in normal and 20: 14 hyrotochain-releasing h 5: 279 restial diagnosis. THH test in normal and 20: 14 hyrotochain-releasing h 5: 279 normal and 20: | thyrotid stimulating hor 7: 69 cand butyrophenone treatment of six postpa 5: thyrotrophin releasing 4: 563 riy beta- endorphin releasing 4: 563 riy beta- endorphin teamment on the behavi 10: thyrotrophin releasing 6: 261 y with clompramine treatment. Helease of 10: thyrotrophin releasing 6: 261 y with clompramine treatment. Helease of 10: thyrotrophin releasing h 2: 137 lew of theories and treatment. Helease of 10: thyrotrophin releasing h 2: 137 lew of theories and treatment. Helease of 10: thyrotrophin releasing h 2: 137 lew of theories and treatment. Helease of 10: thyrotrophin-releasing h 2: 139 lonesed levels of 7HH in hormal aubjects 14 thyrotrophin-releasing h 5: 253 nostic value of 7HH in hormal aubjects 14 thyrotrophin-releasing h 5: 253 nostic value of 7HH in hormal aubjects 14 thyrotrophin-releasing h 5: 253 nostic value of 7HH in hormal aubjects 15 thyrotrophin-releasing h 5: 253 nostic value of 7HH in hormal aubjects 15 thyrotrophin-releasing h 5: 253 nostic value of 7HH is at in hormal aubjects 14 thyrotrophin-releasing h 5: 253 nostic value of 7HH is at in hormal aubjects 14 thyrotrophin-releasing h 7: 255 releasing hormone f 7HH; a use of 10: 10: 10: 10: 10: 10: 10: 10: 10: 10: | thyroid stisulating hor 7: 69 e and butyrophenone treatment of aix postpa thyroid stisulating hor 2: 275 chould school for the convolutive treatment on the behavi 10: 10 petch-rotophin releasing 4: 565 rly beta-endorphin treatment on the behavi 10: 10 petch-rotophin (281) and p 2: 19: 7 petch-rotophin treatment on the behavi 10: 10: 10: 25: 7 percental treatment on the behavi 10: 10: 10: 10: 10: 10: 10: 10: 10: 10: | thyroid stiaulating hor 7: 69 eand butyrophenone treatment of six postpa thyroid stiaulating hor 7: 275 choroid substance prior 2: 275 choroid stiaulating hor 7: 227 choroid substance by 2: 275 choroid streatment on the behavi 10: 14 choroid streatment on the behavi 10: 14 choroid streatment on the behavi 10: 14 choroid streatment. Release of 10: 14 choroid streatment. Re | thyroid stiaulating hor 7: 69 e and butyrophenone treatment of gix postpa provided considering 4: 567 relevant controlled treatment on growth hor 7: 181 relevant controlled treatment on growth hor 7: 181 relevant controlled treatment on the behavi 10: 252 relevant controlled treatment on the behavi 10: 252 relevant controlled treatment on the behavi 10: 252 relevant controlled treatment. Release of 10: 252 relevant controlled treatment. Release of 10: 252 relevant controlled treatment. Release of 10: 252 relevant controlled remained by 2: 273 relevant controlled remained by 2: 273 relevant controlled remained by 2: 274 relevant controlled remained by 2: 275 relevant | thyroid stiaulating hor 7: 69 e and butyrophenone treatment of grawth of provided pr | thyroid stiaulating hor 7: 69 e and butyrophenone treatment of six postpa provided constant files in the provided constant of 12.275 falestronowulster treatment on growth hor thyrotropin releasing 4: 565 rules treatment on the behavi for thyrotropin releasing 4: 565 rules treatment on the behavi for thyrotropin releasing 5: 57 lev of theories and treatment on the behavi for thyrotropin releasing 6: 57 lev of theories and treatment. Release of 10: 197 lev of theories and treatment in the psychologin releasing 6: 57 lev of theories and treatment. Release of 10: 197 lev of theories and treatment in the psychologin releasing 6: 57 lev of theories and treatment. Release of 10: 197 lev of theories and treatment in the psychologin releasing 6: 57 lev hilloperidol and 7HH in normal adult men of thyrotropin releasing 6: 57 nortic value of the 7HH tent in normal and 10: 197 lev phyrotropin releasing 6: 57 nortic value of the 7HH tent in normal and 10: 197 lev phyrotropin releasing 6: 57 nortic value of 10: 199 lev of derecasion. The THH tent in normal and 10: 199 lev phyrotropin releasing 6: 57 nortic value of 7HH tent in normal and 10: 199 lev phyrotropin releasing 6: 57 nortic value of 7HH tent in normal and 10: 199 lev phyrotropin releasing 6: 57 nortic value of 7HH lev
transmisting 7HH lev and 10: 10: 57 normal and 2: 11 | thyroid stimulating hor 7: 69 o and butyrophenone treatment of six postpa filthyroid stimulating hor 7: 2275 function the reatment on gonadotopo 7: 1 thy beta endorphin testment on growth hor 7: 1 thy beta endorphin testment on the shawing thyrotrophin releasing h 2: 1 the reatment on the shawing 10: 1 thyrotrophin releasing h 2: 1 thy beta endorphin testment on the shawing 10: 1 thyrotrophin releasing h 2: 1 thy beta endorphin treatment on the shawing 10: 1 thyrotrophin releasing h 2: 1 thyrotrophin-releasing h 2: 2 thyrotrophin mann pin 4: 2 | thyroid attaulating hor 7: 69 o and butyropleanon treatment of six postpa filthyroid attaulating his 7: 69 o and butyropleanon treatment of six postpa hyrotropin releasing 4: 55 rivers and print teatment on growth hor phyrotropin releasing 5: 65 y with closippeaning treatment on the behavior thyrotropin releasing 6: 61 y with closippeaning treatment on the behavior in thyrotropin releasing 6: 62 y incomatal sevinogen treatment. Release of 70 thyrotropin releasing 6: 177 the worth thoroise and treatment. Release of 70 thyrotropin releasing 6: 177 the worth thoroise and treatment. Release of 70 thyrotropin releasing 6: 177 the worth thoroise and treatment. Release of 70 thyrotropin-releasing 6: 177 thyrotropin-releasing 7: 177 thyrotropin-releasing 8: 177 thyrotropin 8: 177 thyrotropi | thyroid establishing her 7: 69 e and butyrophenone treatment of six postpa filthyroid established by 10: 2275 felestroomvilstve treatment on gonadotop filthyroid paints of 15: 15: 15: 15: 15: 15: 15: 15: 15: 15: | thyroide canalating hor 7: 69 on and bytrophenon treatment of gray postpa 5 thyroide canalating hor 7: 69 on and bytrophenon treatment of gray horse and gray or analysis of 25 the control of treatment of gray of the control of the physics of the control o | thyroid staulating hor 7: 69 e and bytrophenon treatment of six postpa full protection and prior 6: 255 rispect endophin treatment on gondstrop 7: 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, | thyroid estaulating hor 7: 69 on and bytrophenon treatment of aix posts 5 thyroid estaulating hor 7: 69 on and bytrophenon treatment on granding 5 thyroid estaulating hor 7: 625 thyroid estaulating horse of 8: 627 |

ers of both sexes.	Uncoupling of the sexua		191	d paychopathology.	Weekly monitoring of de	10:	261
synchrony in female	undergraduates living o		245	p to change of body	weight and psychopathol		192
cellular mechanisms	underlying neural and b	2	-	n normal twing and	well-state bipolar pat		63
n memorian: Georges	Ungar. In memorian: Ge		109	doplasmic reticular	whorls in neurons of th		65
TSH response in			147	la P, Racagni G, de	Wied D (Eds). Book Rev		5
n'a disease: follow-	up behavioural studies		149	ovulatory cycle of	woman: a review. The p		89
na in brain:			300	gical parameters in	women during the sponts		75
uines nies.			25	chological tests of	women with and without		-
d patradiol-17-bets	untake and		105	the lutes! phase in	women with premenatrual		576
4 PA / E-11 P. P. P.			**	and nontemenonement	women. Diurnal growth	-	CE
-01	appeared timit of the				1		10
nigh arrinity daba			200	Brration in nearthy			0
ling with 3H-			269	t or six postpartum			747
an rhythm of	-		421	ature premenopausal	women. Sexual behavior		29
aboon (Papio			31	and postmenopausal	women. The relationshi	-	129
boons (Papio	urainus). Environments		287	ophrenic and normal	Thyroid s		3
age. sesson and the	use of drugs in patient		192	. paychological and	-		-
property none (h)	utility in aliminal ago		147	ffic controllers at			8
aratana . mie				ffic controllers at	-		5
conuline" in human	vasinal secretions. Vo		153				
Acres America Acres	and accorded to the total	.0	475		Work, III. Belationshin	-	126
TOTAL PROPERTY AND INC.	value of the TRH atimul		131				1
Money Benericantial	variables influencing n			manculinization: 46.			105
TWING TO THE	d Guitallou Till Gotton In		2 . 2				1
e and psychological	variables relating to p			the same and	1		2
urse and associated	variables. Adrenocorti		412		TY		50
ogeny and circadian	variations in stress re		291	lus counseling. 47,	XXX	-	69
al gland respond to	variations of the envir		327				201
ulation. Effect of	various behavioral trai		381				
	vasopressin and ACTH an		261	rial: The next five	years. Editorial: The	9	-
	vanoprantin and evelie		171	tion: the effect of	vohimbine. Purther evi		253
The contract of last as			185	Thetamine in normal	Tours men and nostanon		E
es of Tystne-	Vasopressin and 1-desai		200	The committee of the state of t	John Bell and posterior		16
opposite ellects of	Vasopressin and oxytoci		202	mone strattanton and	young payenotic entitate		5
Sirect of Lysine			612				
amino-8-D-arginine-	vasopressin on memory 1		185	T-2 antagonist) and	simelidine (5-HT re-upt		2
ive therapy.	Vasopressin release dur		505				
injections of ACTH,	vasopressin, epinephrin		165				
d controls.	Vasopressin- oxytocin i		187				
central effects of	vasopressin. Purther e		439				
of arginine	. sopressin: & review o		319				
life' heavy-goods	vehicle driving task.		107				
in the hynothalamic	ventromedial nucleus of		13				
of company and Andrea	Vernedahte A finance		167				
o and Agains	vernadants Ap timited :		101				
In a non-manmarian	wind to the party hand		AOR				
A congenital	Viritizing adrena nype		200				
stis and congenital	Virilizing adrenocortic	- 1	223				
onsal: mediation by	visual cues from female		2				
nous ACTH levels to	visual- attentional fun		22				
of the cockerel in	vitro. The effect of t		60				
aginal secretions.	Volatile fatty acids, "	-	153				
and healthy	volunteers. Growth hor	7:	177				